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- 
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Resumo 
Os canabinóides, agonistas dos receptores do sistema endocanabinóide (SEC), são as drogas ilegais 
mais consumidas no mundo, sendo os adolescentes um dos grupos etários em que o consumo destas 
substâncias é mais prevalente.  
A adolescência representa um período crítico do neurodesenvolvimento, no qual o sistema nervoso 
central é extensamente reorganizado – sendo, também, um período de vulnerabilidade aumentada aos 
efeitos de influências externas, como por exemplo drogas de abuso. Criticamente, grande parte destas 
alterações neuronais são mediadas e/ou moduladas pelo SEC sendo, portanto, expectável que o uso de 
drogas que interagem com esse sistema cause alterações profundas, e possivelmente persistentes, no 
funcionamento do sistema nervoso. Congruentemente, dados obtidos quer com humanos, quer com 
roedores, sugerem que a exposição crónica adolescente a canabinóides tem efeitos deletérios quer ao nível 
da função neurocognitiva, quer ao nível do funcionamento afectivo. 
Assim, estudos epidemiológicos em populações humanas têm demonstrado que indivíduos adultos, que 
enquanto adolescentes foram consumidores crónicos de canabinóides, apresentam um risco aumentado de 
serem diagnosticados com perturbações de ansiedade e/ou perturbações depressivas. Mais ainda, devido a 
um conjunto ainda não totalmente estudado de factores, este aumento de risco é mais marcado na população 
do sexo feminino. 
Em linha com estas observações, estudos experimentais com roedores têm consistentemente 
demonstrado que a exposição crónica adolescente a canabinóides induz um conjunto profundo e 
diversificado de alterações a nível molecular, morfológico, estrutural, funcional e comportamental. Em 
relação ao último, estudos comportamentais têm repetidamente demonstrado que animais adultos expostos 
a canabinóides durante a adolescência apresentam défices não só em tarefas de função cognitiva, como em 
testes de função afectiva – apresentando alterações comportamentais que sugerem um efeito prodepressivo 
desta exposição, que, replicando os dados humanos, é mais marcado em fêmeas.  
Uma limitação da literatura até agora é, no entanto, o uso de um conjunto limitado de canabinóides. De 
facto, praticamente todos os estudos usaram apenas uma de três substâncias, o que levanta a possibilidade 
de existirem outros canabinóides cujos efeitos diferem dos até agora observados, o que – a ser verdade – 
representaria um problema importante na literatura.  
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O presente trabalho pretende averiguar essa possibilidade, ao estudar o HU-210, um potente agonista 
total e não-selectivo dos receptores canabinóides 1 (CB1R) e 2 (CB2R). Apesar de este fármaco ser 
amplamente usado em investigação sobre o SEC, e já ter sido encontrado em substitutos sintéticos de 
canábis, não existe – à data – nenhum relato publicado acerca do impacto que a exposição crónica 
adolescente a HU-210 possa ter no funcionamento afectivo. Assim, o presente trabalho consiste num 
conjunto de quatro experiências desenhadas para caracterizar esses efeitos. 
Na primeira experiência ratos, Wistar fêmea com 35 dias de idade (PND 35) foram administrados HU-
210 diariamente, durante 15 dias, num plano de doses ascendentes (PND 35-39: 25μg/kg; PND 42-46: 
50μg/kg; PND 49-53: 100μg/kg, ou solução veiculo equivalente). Após o fim da administração, os animais 
foram deixados durante 27 dias – de modo a que efeitos residuais, ou resultantes de abstinência, pudessem 
ser minimizados e permitindo que os animais atingissem a idade adulta – ao fim dos quais foram testados 
numa bateria de testes comportamentais. Especificamente, para medir alterações ao nível do 
comportamento ansioso, os animais foram testados no Elevated Plus Maze (EPM; PND 80), Open Field 
Test (OFT; PND 80 e 81) e Marble Burying Test (MBT; PND 91). Para determinar os efeitos do tratamento 
no comportamento social foi utilizado o Social Interaction Test (SIT; PND 82). Finalmente, para avaliar 
os efeitos da exposição a HU-210 nas dimensões de stress-coping e de resposta à recompensa, do 
comportamento depressivo, os animais foram testados no Modified Forced Swim Test (mFST; PND 85) e 
no Sucrose Preference Test (SPT; PND 88-91), respectivamente. Adicionalmente, o peso dos animais foi 
registado ao longo da duração da experiência.  
Análise dos resultados obtidos revelou que, tal como descrito previamente para outros canabinóides, a 
exposição a HU-210 não induziu alterações persistentes ao nível do comportamento ansioso, em nenhum 
dos três testes. Contrariamente ao anteriormente descrito, não foi observada qualquer alteração no SIT, 
indicando a ausência de efeitos persistentes. No que diz respeito ao comportamento depressivo, foi 
registado um decréscimo ligeiro no comportamento de trepar, no mFST – sugerindo a possibilidade de 
alterações de stress-coping – sem qualquer diferença nos outros comportamentos. No SPT não foram 
encontradas diferenças quer na quantidade de sacarose consumida, quer na preferência relativa por 
sacarose, indicando que a resposta à recompensa não está alterada. Finalmente, em linha com estudos 
anteriores, a exposição a HU-210 induziu decréscimos marcados no ganho de peso, que persistiram durante  
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15 dias após o fim da administração. 
Dado que os resultados da experiência 1 não foram os esperados, e que várias limitações foram 
identificadas no protocolo, a experiência 2 foi desenhada para – de novo – testar os efeitos a longo-termo 
da exposição crónica adolescente a HU-210. Assim, ratos Sprague-Dawley fêmea receberam duas 
injecções diárias de HU-210 durante 11 dias, seguindo um padrão de doses ascendentes (PND 35-37: 
25μg/kg; PND 38-41: 50μg/kg; PND 42-45: 100μg/kg ou veículo equivalente). Após o término da 
administração, os animais foram deixados em repouso durante 30 dias, ao fim dos quais lhes foi aplicada 
a mesma bateria de testes comportamentais usada na experiência anterior. Adicionalmente, de modo a 
determinar os efeitos da exposição adolescente nos níveis de proteína CB1R, amostras de tecido do 
hipocampo, estriado e córtex pré-frontal, foram recolhidas após o fim da bateria comportamental (PND 
88), tendo os níveis de CB1R sido avaliados através de western blotting. 
Tal como na experiência 1, não foram encontradas quaisquer alterações no comportamento ansioso, ou 
no comportamento social, e foi observado um decréscimo marcado no ganho de peso que – mais uma vez 
– persistiu durante 15 dias pós-última administração. No entanto, em contraste quer com a experiência 
anterior, quer com a literatura, no mFST também não foram observadas alterações. Semelhantemente, no 
SPT, o desempenho foi igual entre grupos. Em linha com a ausência de alterações comportamentais, não 
se detectaram alterações nos níveis de proteína CB1R em nenhuma das três regiões estudadas. 
Dada a discordância entre os resultados obtidos na experiência 2 e o descrito na literatura, a experiência 
3 consistiu em avaliar se a administração adolescente de HU-210 tinha de facto algum efeito mensurável 
a curto-prazo que poderia ter desaparecido, durante o interregno de 30 dias entre a última administração e 
o início dos testes. Para isso uma nova série de ratos Sprague-Dawley fêmea foi manipulada como descrito 
na experiência 2, e testada no OFT e mFST, nos dois dias após a última administração de HU-210 (PND 
46-47). Adicionalmente, amostras de tecido para western blot foram recolhidas no dia após o fim dos testes 
comportamentais (PND 48).  
Surpreendentemente, apesar de nenhuma alteração ter sido encontrada no OFT, no mFST os animais 
mostraram um padrão comportamental marcado e sugestivo de um efeito antidepressivo do tratamento, 
com decréscimos no tempo passado em imobilidade e aumentos no tempo passado a trepar. Mais ainda, 
análise do western blot revelou um decréscimo de cerca de 50% nos níveis de proteína CB1R, na região  
4 
 
hipocampal, sem alterações nas restantes.  
Uma vez que os resultados na experiência 3, no que respeita aos parâmetros do mFST, foram 
inteiramente inesperados, e as alterações moleculares encontradas foram incongruentes com um efeito 
antidepressivo, a experiência 4 foi desenhada para mais uma vez avaliar os efeitos imediatos da exposição 
adolescente a HU-210, recorrendo a outros dois testes, frequentemente usados para testar ansiedade e 
depressão, o EPM e o SPT, respectivamente. Assim, uma nova série de ratos Sprague-Dawley fêmea foi 
manipulada como descrito nas experiências 2 e 3, e testada no EPM (PND 46) e SPT (PND 46-49) nos 
dias que se seguiram à última administração de HU-210.  
Em linha com o encontrado na experiência 3, não foram observadas alterações no comportamento 
ansioso no EPM. No entanto, em contraste marcado, no SPT, o grupo tratado com HU-210 consumiu 
significativamente menos sacarose que os controlos e mostrou, igualmente, um decréscimo acentuado na 
preferência pela mesma – alterações sugestivas de um efeito prodepressivo. 
No geral os resultados obtidos ao longo das quatro experiências sugerem que, apesar de o HU-210 ser 
capaz de induzir alterações marcadas no funcionamento afectivo, estas alterações desaparecem após algum 
tempo. Mais ainda, o facto deste fármaco não induzir efeitos a longo termo sugere a possibilidade de que 
diferenças nas características farmacológicas dos vários canabinóides possam ter influência importante e 
imprevisível, nos resultados observados na literatura. Especificamente, é possível que a ausência de efeitos 
duradouros após exposição crónica adolescente a HU-210, derive de diferenças farmacodinâmicas deste 
canabinóide quer ao nível da sua interacção com o SEC, quer ao nível de possíveis interacções com outros 
sistemas de neurotransmissão/neuromodulação. Assim, a principal conclusão derivada deste trabalho 
prende-se com a noção de que, ao usar apenas um conjunto limitado de agonistas dos receptores 
canabinóides, se está a incorrer dois riscos: por um lado, o risco de ignorar a totalidade dos possíveis efeitos 
da modulação do SEC, e por outro, se formarem conclusões extrapoladas a partir de dados obtidos com 
vários fármacos diferentes, cuja farmacologia e efeitos podem não ser totalmente comparáveis. Ambos 
estes riscos têm fortes implicações para a interpretabilidade e utilidade da investigação feita usando 
canabinóides e acerca do potencial benéfico e/ou deletério da manipulação farmacológica do SEC.  
 
Palavras Chave: canabinóides, adolescência, HU-210, depressão, ansiedade. 
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Abstract 
Cannabinoids, drugs acting as agonists at the cannabinoid receptors comprising the endocannabinoid 
system (ECS), are the most widely used illegal drug class in the world, with adolescents being one of the 
age group where the use of such drugs is most prevalent. Adolescence represents a critical 
neurodevelopmental period, during which the central nervous system undergoes extensive reorganization, 
with this development being heavily mediated by the ECS. Thus, it is expectable that the adolescent use of 
drugs targeting that system will lead to profound, and possibly permanent, alterations in nervous system 
functioning. Accordingly, both human and rodent studies suggests that chronic adolescent exposure to 
cannabinoids induces deleterious effects at both the cognitive and affective functioning levels: 
Epidemiological studies of human populations have shown adults, who were chronic cannabinoid users 
as adolescents, to be at an increased risk of being diagnosed with both anxiety and/or depressive disorders, 
with risk being even greater for females. Similarly, rodent experimental studies have consistently 
demonstrated that chronic adolescent cannabinoid exposure leads to lasting deficits not just in tasks of 
cognitive function, but in tests of affective functioning, as well – with behavioral alterations suggesting a 
prodepressant-like effect of cannabinoid treatment which, as in humans, is more marked in females. 
One limitation of the literature is, however, the overreliance on a limited set of cannabinoids, raising 
the possibility that other, yet unstudied cannabinoids, may have differing effects from those reported thus 
far – a significant problem for the field, if true. As such the present work aimed, through four experiments, 
to test that possibility, by characterizing the affective impact of chronic adolescent exposure to HU-210 – 
a potent non-selective full-agonist at both cannabinoid receptors 1 (CB1R) and 2 (CB2R) – that, despite 
being widely used in ECS research, has yet to be studied in this regard.  
In the first experiment, female Wistar rats aged 35 days (PND 35) were administered HU-210 daily, for 
a 15-day, in an escalating dosing schedule (PND 35-39: 25μg/kg; PND 42-46: 50μg/kg; PND 49-53: 
100μg/kg, or equivalent vehicle solution). Following a 27-day washout period animals were put through a 
battery of behavioral tests: to assess anxiety-like behavior the Elevated Plus Maze (EPM; PND 80), Open 
Field Test (OFT; PND 80-81) and Marble Burying Test (MBT; PND 91) were used; to assess social 
behavior, the Social Interaction Test (SIT; PND 82) was employed; to assess the stress-coping and reward 
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functioning dimensions of depressive-like behavior the Modified Forced Swim (mFST; PND 85) and the 
Sucrose Preference Tests (SPT; PND 88-91) were used, respectively.  
Data showed that, as previously described for other cannabinoids, adolescent exposure to HU-210 did 
not lead to persistent alterations at the level of anxiety-like behavior. However, contrarily to what had been 
previously described, in the SIT no alteration was observed, suggesting no lasting treatment-induced 
impairments. With regards to depressive-like behavior, a slight decrease in climbing behavior was 
observed in the mFST – suggesting the possibility of altered stress-coping – but no changes were found in 
any of the other behaviors scored. Moreover, no changes were found in the SPT, pointing towards reward 
functioning being intact.  
Experiment 2 was designed to again test the long-term effects of chronic adolescent HU-210 exposure, 
controlling for confounds that may have biased the results of experiment 1. As such, female Sprague 
Dawley rats, received twice-daily intraperitoneal injections of HU-210 for a period 11-days, following an 
escalating dosing schedule (PND 35-37: 25μg/kg; PND 38-41: 50μg/kg; PND 42-45: 100μg/kg or 
equivalent vehicle solution). After a 30-day washout period, animals were tested using the same behavioral 
testing battery used in the previous experiment. Additionally, so as to determine the effects of exposure on 
CB1R protein levels, through western blotting, tissue samples were collected from the hippocampus, 
striatum and prefrontal cortex (PND 88). 
As was the case in experiment 1, no changes were found in anxiety-like or social behaviors. However, 
in contrast with both the previous experiment and the literature, no changes were observed in any of the 
mFST parameters, nor in the SPT. Furthermore, in line with the absence of behavioral alterations, CB1R 
protein levels were found to be unaltered in all the three brain regions studied. 
Given the discrepancy between the results obtained in experiment 2 and those described in the literature, 
experiment 3 was performed so as to determine whether adolescent HU-210 administration did, in fact, 
have any measurable short-term effect, that might be normalized during washout. To that end a new set of 
female Sprague-Dawley rats, was manipulated as described in experiment 2, and tested in both the OFT 
and the mFST, in the two days following the last drug injection (PND 46-47). Additionally, tissue samples 
for western blotting were collected from the same brain regions (PND 48).  
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Surprisingly, in the mFST animals presented a behavioral pattern suggestive of an antidepressant-like 
effect of treatment – with decreased in the time spent in immobility and increased time spent climbing. 
Critically, this effect occurred in the absence of any alterations in the OFT. Moreover, a decrease of 
approximately 50% in hippocampal CB1R protein levels was observed, with no changes in the remaining 
regions studied. 
Since the results of experiment 3 were unexpected, and the molecular alterations observed were 
incongruous with an antidepressant-like effect, experiment 4 was performed to complement them, by using 
two other tests: the EPM and the SPT. As such, a new set of female Sprague-Dawley rats was manipulated 
as described in experiments 2 and 3, and tested in the EPM (PND 46) and SPT (PND 46-49) on the days 
following the last drug administration. 
In line with the previous experiment, no alterations were observed in anxiety-like behavior. However, 
contrastingly, the HU-210-treated group presented markedly decreased sucrose intake and relative sucrose 
preference, in the SPT – suggesting a prodepressant treatment effect. 
In general, the results obtained across the four experiments suggest that, despite HU-210 being able to 
alter affective functioning, these alterations are normalized after sufficient washout time. Moreover, the 
fact that this drug did not induce long-term effects suggests the possibility that differences in the 
pharmacological properties of cannabinoids – either in terms of ECS or non-ECS interactions – may 
influence results observed in the literature, in important and unpredictable ways. As such, the primary 
conclusion derived from the present work pertains to the notion that, by relying on a limited set of 
cannabinoid receptor agonists, one may be at risk of ignoring the totality of the possible effects of ECS 
modulation and of forming possibly erroneous conclusions, extrapolated from data obtained with different 
drugs, whose pharmacology and effects may not be totally comparable. Both of these risks have strong 
implications for the interpretability and usefulness of cannabinoid research, and into the beneficial and/or 
deleterious potential of pharmacological manipulation of the ECS. 
 
Keywords: cannabinoids, adolescence, HU-210, depression, anxiety. 
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Chapter 1 – Introduction 
1 – Cannabinoid Use and Abuse Worldwide  
Cannabis sativa (along with its many derivative preparations, such as hashish) is the most widely 
consumed illegal drug in the world, having been used at least once in the last 12 months by an estimated 
2.7-4.9% of the global population (183±55 million people)1, and is used daily by an estimated 1% of the 
European population2. Indeed, the use of this substance is so prevalent that it is only surpassed by the, more 
widely available, legal psychoactive substances, such as alcohol, tobacco, and caffeine1.  Critically, a large 
segment of cannabis consumers are adolescents: the 2015 European School Survey Project on Alcohol and 
Other Drugs, found that, in a sample of 96046 students aged 15-16, from 35 European nations, 16% 
reported having used cannabis at least once in their lives, 7% reported using it in the last 30 days, and 3% 
reported having first used cannabis at ≤ 13 years of age3.  These figures, which represent increases from 
previous years1,3, are likely  to grow in the future, given the increasing support for the 
decriminalization/legalization of cannabis across the American and European continents4, and the 
simultaneous decrease in the perceived harmfulness of cannabis use amongst teenagers5. 
Concomitantly with the increase in cannabis use in recent years, there have been reports, starting in 
2008, of the use of synthetic cannabinoids (SCs)6, as legal alternatives to cannabis. Indeed, between 2008 
and 2016 more than 240 different new cannabinoid compounds, spanning multiple chemical classes, were 
identified in commercially available products1. These products – sold in highly branded packaging, under 
the guise of being incense or potpourri, and “not for human consumption”, in an attempt to skirt drug laws6 
– are often attractive to adolescents due to their perceived legality, as well as their lower cost and greater 
ease of access7,8, relative to cannabis. However, despite this, there is a dearth of global epidemiological 
data regarding, the prevalence and patterns of SC adolescent use: a recent study found that 3.5% of 
American high school seniors reported having used SCs in the past year9, whereas studies done in Spain, 
Sweden and Germany have estimated adolescent use of SCs to have a prevalence of 0.8%, 3.2% and 6%, 
respectively6. 
Despite being sold as legal alternatives to it, SCs possess characteristics that make them markedly 
different from and, indeed, likely more dangerous than cannabis. Unlike Δ9-tetrahydrocannabinol (THC), 
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the main psychoactive compound in cannabis – which is responsible for the majority of both its pleasant 
(e.g., euphoria, increased appetite, heightened sense perception, relaxation and pain reduction) and 
unpleasant effects (e.g., short-term memory deficits, xerostomia, increased anxiety and motor impairment), 
by acting as a partial agonist at the human cannabinoid receptor type 1 (CB1R)10 – the overwhelming 
majority of SCs are high potency, high affinity, full agonists at this receptor. Furthermore, given the well-
established biphasic dose-effect relationship that characterizes THC – whereby at low doses users report 
mainly pleasant effects, whereas unpleasant effects become more prevalent at higher doses11 – these 
pharmacological differences are likely to underlie the more severe effects and adverse psychological 
reactions reported by SC users, such as extreme anxiety, hallucinatory phenomena, as well as psychotic 
and suicidal episodes12. Moreover, there is increasing evidence that SCs may also be more physically toxic 
than cannabis, with reports detailing cases of hyperemesis, hyperthermia, cardiovascular problems, acute 
kidney injury, seizures, and loss of consciousness, following SC use, which have in some cases led to 
fatalities12. Importantly, at least a few of these physical symptoms (e.g., seizures13) have been directly tied 
to activity of SCs at the CB1R. 
Given both the increases in access to, and use of, both cannabis (especially higher potency 
strains/preparations14–16) and SCs, it is unsurprising that concomitant increases in the prevalence of, and 
search of treatment for, cannabinoid use disorders (CUD) have been reported. Importantly, not only do the 
majority of treatment entrants report having begun cannabis use during adolescence17,18, but there has also 
been a steady decrease in the age at which individuals first seek treatment for these disorders1. Moreover, 
despite increasing access to treatment19, it is estimated that only 15-37% of individuals treated for CUD 
will maintain abstinence20, with one of the main reasons for this being the manifestations of cannabinoid 
withdrawal syndrome21. This  well characterized syndrome presents mostly in heavy chronic users, and 
consists of muscle weakness, restlessness, sweating, dysphoria, insomnia, anxiety and craving22. 
Furthermore, as is the case with their acute effects, this syndrome seems to be much more pronounced in 
consumers of SCs23,24, often requiring hospitalization25, and is reported to begin as early as 15 minutes 
after the last use24.  
Given this picture of widespread cannabinoid use and abuse, it is quite interesting that there is also a 
parallel, and increasingly higher, interest in the medicinal use of cannabinoid-based therapeutics26. Indeed, 
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cannabinoids and other drugs targeting the endogenous cannabinoid system (endocannabinoid system; 
ECS) are being investigated as possible therapeutics for numerous conditions such as chronic and 
neuropathic pain27,28, chemotherapy induced nausea and vomiting29,30, obesity31–33, AIDS and cancer 
induced cachexia/anorexia34–36, glaucoma37, cancer38,39, epilepsy40, neurodegenerative diseases such as 
Huntington’s disease and multiple sclerosis41–45 and neuropsychiatric diseases such as post-traumatic stress 
disorder46–48, schizophrenia49,50, anxiety disorders51,52 and depressive disorders53.  However, despite being 
a highly promising field for experimental therapeutics, development and introduction of new drugs 
targeting the ECS has been hindered by two main concerns: the psychoactive “on target” side-effects of 
many of the experimental substances tested54, and the concerns regarding the consequences of long-term 
use of these drugs, especially in more vulnerable populations such as children and adolescents55,56. 
As such, a better understanding of the consequences of, and mechanisms behind, the consequences of 
prolonged treatment with cannabinoids – whether recreational or therapeutic – is key to facilitate the 
development of strategies to mitigate or revert any lasting effect that this type of exposure may entail, and, 
thus, both unlock the full therapeutic potential of cannabinoid-based therapeutics, as well as lift the 
increasing burden imposed on national health systems57. 
2 – The Endocannabinoid System 
Cannabinoids exert their actions through interactions with the ECS. This highly conserved 
neuromodulatory system58 is known to be expressed at very early stages of embryonic development, being 
involved in the specification and development of neuronal tissue59. Moreover, the ECS has been found to 
be critically involved in numerous relevant physiological processes, such as neurogenesis60, the shaping of 
neuronal connectivity61, neuroplasticity and the regulation of synaptic activity (see section 2.2), thus 
explaining the its involvement in processes such as memory and learning62,63, pain perception64,65, stress 
responses66–68, motor control69,70, homeostatic regulation71–73, reproductive functioning71, reward 
processing68,74 and, critically for the present work, affective functioning75,76. 
To more deeply understand how the ECS is involved in this last process (section 2.3) and how the 
chronic use of cannabinoids during adolescence may impact affective functioning (section 3), the ECS 
must first be described. 
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2.1 – Endocannabinoid System Structure 
The extensive and diverse processes in which the ECS is known to be involved, derive from the 
widespread distribution of its constituting elements. Thus, the ECS is comprised of endogenous ligands 
(endocannabinoids, eCBs), the enzymes responsible for the synthesis and degradation of those ligands, 
protein transporters, and cannabinoid receptors (fig. 1.1). 
 
Fig 1.1 – Schematic representation of the endocannabinoid system. The ECS is comprised of receptors, eCBs, the enzymes responsible for the 
synthesis and inactivation of these ligands, and of the EMT (not pictured). The CB1R is primarily located on the presynaptic membrane, being 
activated by AEA and 2-AG released from the postsynaptic neuron. Synthesis occurs in an “on demand” fashion, in response to a number of 
stimuli, such as the activation of metabotropic glutamate receptors, 2-AG being primarily synthetized postsynaptically, by the DAGLα pathway. 
AEA synthesis also occurs at the presynaptic neuron, by activation of the NAPE-PLD pathway, and can be released to activate postsynaptic 
TRPV1R. Fittingly, the primary degradative enzyme for 2-AG, MAGL, is predominantly located in the presynaptic neuron, whereas FAAH – 
primarily responsible for AEA inactivation – is located postsynaptically. In addition, a number of other enzymes are known to have a role in 2-
AG inactivation, such as ABHD6. Moreover, the ECS is also expressed in both astrocytical and microglial cells. In the former, CB1R couples to a 
different G-protein than in neurons (Gq and Gi/o, respectively), and is thought to mediate the release of gliotransmitters, In the former, CB2R and 
possibly CB1R are involved in immune responses mediated by these cells. Figure taken and adapted from Lutz et al.66 
2.1.1 – Endocannabinoid Synthesis and Release 
There are at least seven recognized eCBs77, of which the most studied are N-arachidonoyl-ethanolamine 
(anandamide, AEA; fig. 1.2a)78 and 2-Arachidonoyl-glycerol (2-AG; fig. 1.2b)79. Unlike most 
neurotransmitters and neuromodulators, which are synthetized and stored in vesicles for posterior use, 
eCBs are primarily synthetized in the postsynaptic neuron, in an “on demand” fashiona, in response to 
depolarization-induced calcium (Ca2+) increases and/or the activation of Gq/11 coupled receptors77. 
                                                     
a It should be noted that, in recent years, evidence has emerged that there may non-on demand production of eCBS, whereby these 
neuromodulators are stored, and released only when necessary80. 
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Anandamide, which acts as a partial agonist at both the CB1R and CB2R10, is synthetized by several 
pathways81, the most well characterized of which is the canonical pathway – in which membrane-lipid 
derived phosphatidylethanolamine is transacylated by an N-acyltransferase, to form N-
acylphosphatidylethanolamine (NAPE), which is then hydrolyzed to AEA by the Ca2+-sensitive 
phospholipase D (NAPE-PLD)81.  
2-AG, which, unlike AEA, is a full agonist at both the CB1R and CB2R82, is synthetized by several 
different pathways, the most widely studied of which is the PLCβ-DAGα pathway. This pathways seems 
to be triggered by Gq/11 activation, leading to phosphatidylinositol (PI) being hydrolyzed by phospholipase 
C β (PLCβ) to form diacylglycerol (DAG), which is then hydrolyzed by DAG lipase α (DGLα) to form 2-
AG81,83. Interestingly there is evidence to support the idea that different 2-AG synthesis pathways (some 
which are PLCβ-independent), started by different stimuli, have distinct physiological roles84,85. Once 
synthetized, these endogenous compounds diffuse across the cellular membrane and into the synaptic cleft 
where they activate cannabinoid receptors.  
 
Fig 1.2 - Molecular structures of anandamide and 2-arachidonoyl-glycerol. AEA (a) and 2-AG (b) are the primary eCBs present in the brain, 
being responsible for the majority of ECS actions. While AEA acts as a partial agonist at both the CB1R and CB2R, 2-AG is a full agonist at both 
receptors. 
2.1.2 – Cannabinoid Receptors 
All known cannabinoid receptors belong to the A-class of the G-protein coupled receptor (GPCR) 
superfamily86, with two – the CB1R and CB2R – having been amply characterized. In addition, there are 
several other previously orphan GPCRs (e.g., GPR18, GPR55, and GPR119), whose belonging to the ECS 
is still disputed – with the most prominent of these being the GPR5586. Moreover, in recent years the 
transient receptor potential cation channel subfamily V member 1 (TRPV1), has also been recognized to 
be an important element in the ECS77. 
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2.1.2.1 – Cannabinoid Receptor Type 1 (CB1R) 
The CB1R is one of the most abundant receptors in the human central nervous system87 and is also 
found in peripheral nervous system87, as well as in non-nervous tissue such as the liver and adipose tissue88. 
In the brain it is found in high levels in the inner layers of the hippocampus and the olfactory bulb, in the 
striatum, and in the molecular layer of the cerebellum, with intermediate levels having been found in the 
frontal, parietal and cingulate cortexes, the amygdala, the hypothalamus, and in some brainstem nuclei77,87. 
At the cellular level, this receptor is predominantly located on the presynaptic terminals of both γ-
aminobutyric acid (GABA) releasing neurons (GABAergic neurons), and, to a lesser extent, in 
glutamatergic neurons77, where it modulates presynaptic activity. In addition, it also expressed in the 
postsynaptic membrane – where it has been shown to work as an auto-receptor89,90 –  as well as in 
astrocytes91,92, microglia93 and oligodendrocytes94.  
The CB1R is typically coupled to Gi/o protein, whereby its activation results in the inhibition of adenylyl 
cyclase (AC) and, therefore, in a decrease of 3',5'-cyclic adenosine monophosphate (cAMP) 
accumulation95. However, it has been shown that this effect is dependent on the specific isoform of AC 
being expressed, with the opposite effect (i.e., stimulation of AC and cAMP accumulation) occurring in 
cells expressing AC isoforms 2, 4 and 7, likely through the action of the dissociated Gβγ heterodimer96.  
Moreover, several studies have found that, in some conditions, CB1Rs are capable of signaling through 
other G-proteins: CB1R activation has been demonstrated to lead to increases in AC activity, through Gs 
protein, in cells where Gi/o activation is limited – such as in cells previously treated with pertussis toxin 
(PTX)97, or in which other Gi/o coupled receptors, such as the dopamine (DA) receptor type 2 (D2R), are 
simultaneously activated98. Furthermore, some reports have found that CB1R are capable of signaling 
through Gq protein, leading to intracellular Ca2+ increases99, most notably doing so in hippocampal 
astrocytes92. 
Gi/o protein activation is also the key component in CB1R-mediated modulation of ion channels. Indeed, 
CB1R activation is known to both increase potassium (K+) conductance, via activation of A-type and G-
protein coupled inwardly rectifying K+ channels (GIRK)88,100, and to decrease Ca2+ conductance, via 
inhibition of L-, N- and P/Q-type voltage gated Ca2+ channels (VGCC) – through Gβγ mediated 
interactions88,100. 
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Furthermore, in addition to modulating the AC-cAMP pathway and ion channel activity, CB1R 
activation also leads to the stimulation of several mitogen activated protein kinase (MAPK) family kinases: 
depending on the cell type, CB1R activation has been demonstrated to lead to stimulation of extracellular 
signal-regulated kinase 1/2 (ERK; alternatively named p42/44 MAPK)88,  through Gi/o protein activation, 
phosphatidylinositol-3-kinase (PI3K) activity via protein kinase B (PKB, also known as Akt kinase)101, 
inhibition of  AC and protein kinase A (PKA)102, vascular endothelial growth factor (VEGF) receptor 
transactivation103, Src tyrosine kinase FYN activation104, and activation of Raf MAP kinase through the 
synthesis of the lipid second messenger ceramide105. Finally, CB1R activation, has also been shown to lead 
to increased activity of both p38 MAPK and c-Jun N-terminal kinase (JNK), in a cell-type dependent 
manner88,100. 
2.1.2.2 – Cannabinoid Receptor Type 2 (CB2R) 
The CB2R was, for a long time, thought to be a peripheral cannabinoid receptor, with no significant 
expression in the nervous system106. Indeed, this receptor is found in high levels in peripheral and immune 
tissues, such as the spleen, bone, as well as in the gastrointestinal and reproductive systems106. However, 
in the last 15 years, reports have increasingly – but not without significant controversy106,107 – found CB2R 
expression in the nervous system, albeit in much smaller numbers, in comparison with CB1R. The highest 
levels of CB2R have been reported in pyramidal neurons of layers III and V of the orbital, visual, auditory, 
motor and piriform cortexes, in pyramidal neurons of the CA2 and CA3 regions of the hippocampus, in 
the striatum, amygdala, and in Purkinje and granular cells of the cerebellum, and more moderate expression 
levels are found in several brainstem nuclei, such as the substantia nigra pars reticulata and periaqueductal 
gray108,109. At the synaptic level, this receptor, unlike the CB1R, is found primarily in the postsynaptic 
membrane110, and has been demonstrated to act as an auto-receptor via 2-AG signaling, in the CA2 and 
CA3 regions of the hippocampus111. Moreover, CB2R is also expressed in both microglia and astrocytes, 
in an activation state-dependent manner106,112,113 . 
CB2R activation is tied to many of the same intracellular cascades as CB1R activation: by coupling to 
Gi/o protein, CB2R activation leads to inhibition of the cAMP-PKA pathway86,95, and to both increased K+ 
conductance and decreased Ca2+ conductance, through Gβγ interactions with GIRK114 and VGCCs115, 
respectively. Additionally, CB2R activation leads to stimulation of the Raf-MAPK cascade, leading to 
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increased ERK1/2 activity, in four possible ways: through Gi/o-dependent activation of PLC116, through 
decreased PKA activity117, through stimulation of the PI3K/PKB pathway94, and through the synthesis of 
ceramide118. Furthermore, CB2R mediated activation of both the p38 MAPK119,120 and JNK120 pathways 
has also been reported. Finally, CB2R activation has been shown to lead to an increase in intracellular Ca2+ 
concentration, through PLC mediated Ca2+ release from IP3 controlled calcium stores121. 
However, two important distinctions have to be made between these two receptors: first, unlike CB1R, 
CB2R has not yet been shown to be capable of coupling to G proteins other than Gi/o, and, secondly, the 
inhibitory effect that CB2R activation has over AC is strongly modulated by both expression levels and 
cell environment, such that in some cells CB2R activation leads to little or no inhibition of AC activity, 
whereas in others it fully inhibits it117.  
2.1.3 – Endocannabinoid Uptake 
Once eCBs have activated the cannabinoid receptors, they are removed from the synaptic cleft so as to 
be intracellularly degraded81. However, the mechanism through which eCB uptake occurs is highly 
debated, and not yet fully elucidated122,123. Indeed, there is a long standing idea of an eCB membrane 
transporter (EMT)124, which posits the existence of a (yet to be characterized) membrane transporter which 
would transport eCBs (especially AEA) to the intracellular space122,123. This transporter is purported to be 
saturable, to work in a time and temperature-dependent manner, and to be capable of being selectively 
inhibited123. Accordingly, drugs have been developed that greatly decrease the rate at which AEA is 
removed from the extracellular space125. Moreover, experiments have demonstrated AEA uptake to be 
ATP- and ion gradient-independent, thus excluding the possibility of EMT working like other transporters 
(such as the DA transporter)125–127. However, several aspects of this hypothesis have been questioned, 
giving rise to alternative models: 
Based on the findings that the original drugs used to inhibit the putative EMT have shown to also inhibit 
the activity of the AEA degradative enzyme fatty acid amide hydrolase (FAAH)128, that selective inhibition 
of FAAH greatly reduces AEA uptake129, and that inhibition of EMT does not, on a short time scale (<40s), 
inhibit AEA uptake130,131, a passive diffusion model was proposed130. In this model it is suggested that it is 
FAAH  – by creating a concentration gradient – that drives AEA uptake, such that AEA passively diffuses 
across the cellular membrane, and is hydrolyzed intracellularly130,131. However, this model has been put 
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into question, due to the fact that AEA uptake still occurs (albeit in a reduced manner) in cells derived 
from FAAH-/- knockout mice132,133, and that newer, more selective, inhibitors of EMT, that do not inhibit 
FAHH, have shown to still be effective in blocking AEA uptake132. 
Another proposed model for how AEA is uptaken proposes that, instead of entering the cell through the 
EMT or passive diffusion, AEA might instead do so via endocytosis134–136. Specifically, it is suggested that 
AEA binds to proteins in cholesterol rich domains of the cell membrane (lipid rafts), undergoes rapid 
endocytosis, and is then transported in vesicles, to be hydrolyzed by FAAH134–136. This model is supported 
by the fact that depletion of cholesterol reduces AEA uptake135, whereas increased cholesterol augments 
it137, that exogenously administered AEA and 2-AG were shown to congregate towards lipid rafts138, and 
that AEA has been shown to be accumulated intracellularly in adiposomes139. Despite the fact that this 
model has yet to be fully refuted, it cannot explain why FAAH inhibitors also reduce AEA efflux140, given 
it only posits a mechanism for uptake.  
A third model posits that AEA is indeed uptaken via passive diffusion, but that, once inside the cell, 
AEA binds to carrier proteins which take it to be enzymatically degraded141,142. Of these carrier proteins 
the most widely studied are fatty acid binding proteins 5 and 7 (FABP5/7), as well as albumin and heat-
shock protein 70, which have already been demonstrated to transport eCBs intracellularly143,144. Supporting 
this model, there are reports that FABP overexpression increased both AEA uptake and hydrolysis, 
whereas FABP inhibition had the opposite effects143, and that FABP5-/- knockout mice had a 50% increase 
in whole-brain AEA levels145. However, contrary to this model, there is conflicting data regarding the 
levels of FABP expression in adult neurons146, and there is yet no concluding data that excludes the 
possibility of the existence of an EMT. Additionally, much like is the case with the endocytosis model134–
136, this model cannot explain the inhibitory effects of AEA uptake inhibitors on AEA efflux140. 
Finally, a more recent model, combines the previous model with the idea of the EMT, by suggesting 
that AEA does indeed bind to a membrane located transporter, which facilitates its diffusion to the 
cytoplasm123. Once in the intracellular space, AEA is suggested to bind to carrier proteins, which then take 
it to be degraded by FAAH123. By suggesting the existence of an EMT, this model allows for the inhibitory 
effects of AEA uptake inhibitors on AEA efflux. 
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It should be noted that comparatively little research as yet been done on the mechanism by which 2-
AG is removed from the extracellular space, although there is some suggestive evidence that this eCB 
might be uptaken by the same EMT as AEA, as shown by the fact that 2-AG inhibits AEA uptake147 and 
vice versa148, and that AEA uptake inhibitors also inhibit the uptake of 2-AG140. 
2.1.4 – Endocannabinoid Inactivation 
Once eCBs have been removed from the synaptic cleft they are then targeted by several degradative 
enzymes, which inactivate them. There are distinct enzymatic pathways for AEA and 2-AG metabolism81. 
However, it should be noted that, in addition to these eCB specific pathways, other enzymes, such as 
ciclooxigenase-2 (COX-2), lipoxygenases (LOXs) and cytochrome P450, have been demonstrated to 
interact with both 2-AG and AEA, leading to their metabolism or modification into other bioactive 
compounds. These non-specific pathways will not be covered in the present work, but have been 
extensively reviewed by Rouzer & Marnett149. 
AEA is hydrolyzed to arachidonic acid (AA) and ethanolamine by one of three enzymes, with 
complementary distribution. AEA hydrolysis in the central nervous system is mainly mediated by the 
previously mentioned FAAH81, as shown by the fact that FAAH-/- knock out mice had greatly increased 
levels of AEA in the brain150. This membrane bound enzyme is located in the endoplasmatic reticulum 
(ER) of postsynaptic neurons151. Despite the shared name, FAAH-2 – the second enzyme responsible for 
AEA inactivation – has little in common with FAAH, underlining the reduced homology between them152: 
it is located not on the ER, but on adiposomes153, it is known to be less efficacious in hydrolyzing AEA 
than FAAH153, its expression is greater in peripheral tissues152, such as the liver, and is found in humans 
but not rodents152. Finally, N-acylethanolamine hydrolyzing acid amidase (NAAA) is also known to 
inactivate AEA, being found primarily in immune cells154, including microglia155, where it thought to be 
involved in the control of inflammatory processes.  
Like AEA, 2-AG is also metabolized into AA by several different enzymes81,156. The primary hydrolytic 
enzyme involved in 2-AG inactivation is monoacylglycerol lipase (MAGL)156, as shown by the marked 
increases in 2-AG concentration that are observed in MAGL-/- animals157. Unlike FAAH, MAGL is located 
in presynaptic neurons, close to cannabinoid receptors151, highlighting its role in controlling eCB mediated 
retrograde signaling158. More recently two other enzymes have been discovered to play lesser, but still 
18 
 
significant, roles in 2-AG inactivation: Alpha/beta-hydrolase domain-containing 6 (ABHD6), located 
postsynaptically159, is responsible for the hydrolysis of approximately 5% of 2-AG in the mouse brain160. 
Due to the fact that its active site is located intracellularly159,160 it is thought that the role of this enzyme is 
to limit the intracellular concentrations of 2-AG159. On the other hand, Alpha/beta-hydrolase domain 
containing 12 (ABHD12) is a postsynaptic integral membrane protein, whose active site is located on the 
extracellular domain159,160. This enzyme is responsible for the hydrolysis of approximately 9% of 2-AG, 
and is thought to be important in the control of 2-AG levels in situations where MAGL is not available, or 
when 2-AG concentrations reach high levels161. 
2.2 – Endocannabinoid System Functioning 
The ECS is involved in diverse physiological roles, primarily through its modulatory effect on synaptic 
function. This modulatory effect, which can be either short- or long-lasting, is achieved through three 
separate types of eCB signaling: retrograde signaling, non-retrograde signaling and neuron-astrocyte 
signaling. In addition, there is a persistent, activity-independent, eCB tone162,163. 
2.2.1 – Retrograde Signaling 
The first described method of action of the ECS was that of retrograde signaling164. Indeed, even after 
the discovery of other types of ECS signaling, this is still the most researched, with eCBs being, by and 
large, the most well characterized retrograde messengers. This type of ECS signaling is involved in both 
short- and long-term synaptic plasticity, by inducing short- and long-term depression, respectively.  
2.2.1.1 – Endocannabinoid Mediated Short-Term Depression (eCB-STD) 
Endocannabinoid mediated short-term depression (eCB-STD) is a group of phenomena whereby 
postsynaptically synthetized eCBs are released into the synaptic cleft, to diffuse backwards and activate 
presynaptic CB1R, leading to the transient inhibition of either the excitatory or the adjacent inhibitory 
inputs, through the inhibition of presynaptic VGCC165. This group of phenomena can be broadly divided 
into three groups as a function of the stimuli triggering eCB synthesis: 1) Ca2+ increases; 2) receptor 
activation or; 3) a combination of both:  
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Firstly, eCB-STD depending on Ca2+ driven eCB release, includes depolarization induced suppression 
of inhibition (DSI) and excitation (DSE), as well as presynaptic suppression caused by N-methyl-D-
aspartate receptor (NMDAR) mediated Ca2+ influx165. In DSI166 and DSE167 postsynaptic depolarization 
leads to Ca2+ influx through VGCC, triggering the synthesis of DAG, through a yet unknown enzyme, 
which will then be converted to 2-AG via DLGα165. NMDAR dependent eCB-STD168 is thought to work 
in a mechanistically similar way to DSI/E, with the difference being that the increase in postsynaptic Ca2+ 
influx is thought to be mediated by NMDAR, instead of VGCC165. 
Secondly, eCB-STD dependent on receptor driven eCB release165 – also known as metabotropic-
induced suppression of inhibition/excitation (MSI/MSE)169 – occurs independently of changes in 
postsynaptic intracellular Ca2+ concentration165,170. In this type of short-term depression, strong activation 
of Gq/11-coupled postsynaptic receptors (e.g., group I mGluRs)171 leads to the activation of the PLCβ-DLGα 
pathway, culminating in the synthesis and retrograde release of 2-AG165,170. 
Finally, eCB-STD depending on Ca2+ assisted receptor-driven eCB release165 occurs when subthreshold 
activation of postsynaptic Gq/11 coupled receptors (i.e., not strong enough to trigger MSI/MSE) is 
simultaneously combined with subthreshold increases in intracellular Ca2+ concentrations, leading to 2-
AG synthesis through the PLCβ-DLGα pathway84,172,173. 
2.2.1.2 – Endocannabinoid Mediated Long-Term Depression (eCB-LTD) 
eCB-LTD is a widespread phenomenon, having been described in numerous brain regions and on both 
inhibitory and excitatory synapses165,174. 
Like eCB-STD, eCB-LTD requires the postsynaptic synthesis and release of eCBs. Indeed, it is thought 
that the molecular processes for eCB synthesis are similar between short- and long-term forms of eCB 
mediated plasticity, with eCB-LTD having been found to occur after Ca2+ driven, receptor driven, and Ca2+ 
assisted receptor driven eCB synthesis165,174. 
However, eCB-STD and eCB-LTD differ in two critical aspects: while eCB-STD is induced with brief 
CB1R activation, induction of eCB-LTD requires several minutes of persistent receptor activation174,175. 
Moreover, CB1R activation by eCBs, even if prolonged, is not – by itself - enough to induce eCB-LTD, 
instead requiring simultaneous presynaptic depolarization and increased intracellular Ca2+ 
concentration176. The combination of these two events is thought to lead to a shift of the presynaptic 
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phosphorylation/dephosphorylation equilibrium, towards the latter170: on the one hand, CB1R activation 
leads to decreased cAMP-PKA activity, resulting in diminished phosphorylation of a yet unknown protein 
target170,174, that is thought to result in a reduction in the activity of the active zone protein RIM1α177 and 
– at least in inhibitory synapses – the vesicular protein Rab3B178. On the other hand, the simultaneous 
presynaptic firing results in increased presynaptic Ca2+ concentrations – through VGCC or NMDAR 
mediated influx, or release from internal stores174 – which further reduce the phosphorylation of the 
aforementioned protein target, by activating the Ca2+-sensitive phosphatase calineurin176. Additionally, 
some authors have proposed that reduced expression of presynaptic P/Q type VGCC, might be an 
alternative or complementary mechanism for eCB-LTD179. 
2.2.2 – Non-Retrograde Signaling 
Although retrograde signaling is the primary mode of eCB action, it is not the only one. Indeed, eCB 
non-retrograde signaling also exists, with two main forms known – TRPV1-LTD and Slow Self-Inhibition 
(SSI). 
TRPV1-LTD is a type of eCB mediated LTD that is independent of both CB1R and CB2R, resulting, 
instead, of the activation of  TRPV1180–182 by AEA, which acts as a full agonist at this receptor86. In this 
type of LTD, postsynaptic activation of mGluR5 leads to AEA synthesis, through PLC activation, and 
release180–182. AEA then activates postsynaptic TRPV1, leading to Ca2+ influx that will – via the activation 
of calcineurin/dynamin180 – lead to the endocytosis of postsynaptic AMPAR. It should be noted that, in 
some brain regions, there is also evidence of a presynaptic component, whereby released AEA also 
activates presynaptic CB1R resulting in inhibition183. 
On the other hand, SSI  is a type of eCB non-retrograde signaling – found in cortical interneurons89, 
pyramidal neurons90, and in cerebellar basket cells184 – that relies on activation of postsynaptic CB1R. In 
this type of signaling high postsynaptic stimulation leads to increased Ca2+ concentrations, that trigger 2-
AG synthesis89. Once released, 2-AG activates somatic CB1R which, through Gβγ interactions with GIRK, 
lead to increased K+ conductance and neuronal hyperpolarization89. 
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2.2.3 -  Neuron-Astrocyte Signaling 
Neuron-astrocyte eCB signaling has recently become a topic of heavy interest, due to the fact that 
through this type of signaling, eCBs have been found to be able not only of inducing long-term depression 
of synaptic activity, but also to be able of inducing short- and long-term potentiation at heteroneuronal 
synapses (i.e., synapses of adjacent neurons with which there is no direct communication)185. Thus, the 
canonical conception of eCBs as retrograde negative modulators of synaptic activity has, through these 
findings, come into doubt. Furthermore, it is worth noting that, while traditional eCB signaling is spatially 
constrained, neuron-astrocyte signaling has been demonstrated to have a much greater reach185, such that 
it might be able to influence activity of a broader number of synapses. 
2.2.3.1 –Neuron-Astrocyte Mediated Short-Term Potentiation 
Neuron-astrocyte mediated short-term potentiation (also known has lateral potentiation)185 at 
heteroneuronal synapses has been demonstrated to often co-occur with DSE at homoneuronal synapses 
(i.e., synapses with which there is direct communication). In short, 2-AG synthetized and released by the 
homoneuronal postsynaptic neuron will not only activate homoneuronal presynaptic CB1R (thus inducing 
DSE), but also astrocytic CB1R92. Unlike neuronal CB1R, the astrocytic variant of this receptor is coupled 
to Gq/11 protein92,186, such that its activation leads to increased intracellular Ca2+ concentrations and 
subsequent release of glutamate at heteroneuronal synapses187. At this synapse, glutamate will 
simultaneously activate presynaptic mGluR1 – leading to enhanced glutamate release, via increased Ca2+ 
concentrations – and postsynaptic NMDAR – increasing Na+ and Ca2+ conductance, depolarizing the 
postsynaptic neuron. This combination of events results in a transient potentiation of synaptic activity187.  
2.2.3.2 – Neuron-Astrocyte Mediated Long-term Plasticity 
Neuron-astrocyte signaling has also been shown to be involved in some forms of both long-term 
depression and long-term potentiation185.  
In terms of LTD, this type of signaling has been implicated in a form of spike-timing dependent LTD 
(t-LTD) whereby back-propagating action potentials trigger the synthesis and release of eCBs, which 
activate astrocytic CB1R, leading to astrocytic release of glutamate at the homoneuronal synapse188. 
Activation of presynaptic NMDAR leads to depolarization of the presynaptic neuron188, and fulfills the 
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requirements for t-LTD (i.e., that presynaptic firing succeeds, rather than precedes, postsynaptic firing)189. 
Additionally, neuron-astrocyte signaling has also been proposed to play a role in LTD induced by 
exogenous cannabinoids, whereby CB1R mediated astrocytic glutamate release activates postsynaptic 
NMDAR, consequently leading to the internalization of postsynaptic AMPAR91. Furthermore, this type of 
signaling seems to be critically involved in the adverse effects of exogenous cannabinoids on memory – 
given that, while knockout of neuronal CB1R had no impact on the severity of these effects, knockout of 
astrocytic CB1R effectively abolished them91. 
More recently, neuron-astrocyte signaling has also been found to play a role in a form of eCB mediated 
LTP at heteroneuronal hippocampal synapses190. For this phenomenon to occur, three conditions have to 
simultaneously be met: eCB activation of astrocytic CB1R, leading to glutamate release at the 
heteroneuronal synapse, synthesis and retrograde release of nitric oxide (NO) from the heteroneuronal 
postsynaptic neuron and, finally, activation of presynaptic mGluR1 and, subsequently, of PKC190. 
2.3 – The Endocannabinoid System in Affective Functioning 
Ever since it was first described, and taking into account the fact that cannabis is used recreationally 
for its mood elevating effects, the ECS has been investigated as to the role it plays in affective functioning. 
Indeed, not only is the ECS highly expressed in areas classically related to affective and reward processes 
– such as the hippocampus and the pre-frontal cortex (PFC)191 – but there are two other complementary 
lines of evidence supporting the assertion of a role for the ECS in these processes: 
On one hand, there is significant evidence that impaired eCB signaling is tied to negative changes in 
affect191. Indeed, animal studies have reported that the selective inactivation of CB1R (through CB1R 
antagonism or deletion) leads to changes at both the behavioral (e.g., anhedonic-like behavior192, increased 
anxiety193, and decreased appetitive behavior194) and biological levels (e.g. diminished brain derived 
neurotrophic factor [BDNF] signaling, and increased hypothalamic-pituitary-adrenal axis [HPA] 
activity195–197) which are typically associated with depressive and anxiety disorders. In addition, studies 
analyzing animals exposed to manipulations that induce depressive/anxious-like phenotypes (e.g. chronic 
mild stress [CMS]) have found reduced expression of CB1R in brain regions known to play roles in 
affective functioning, such as the hippocampus, hypothalamus and the striatum198,199, and overall decreased 
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concentrations of AEA199–201. Furthermore, there is human evidence of association between disrupted eCB 
signaling and affective disorders. The most notable of these pieces of evidence is the fact that the CB1R 
antagonist/inverse agonist rimonabant – originally marketed as an anti-obesity drug – had to be removed 
from the market, after patients with no previous history of psychiatric illness, began reporting anxiety and 
depressive/suicidal ideation as side effects31,202. Accordingly, not only have reduced levels of eCBs been 
reported in women diagnosed with major depressive disorders203,204, but there is evidence that certain single 
nucleotide polymorphisms, which are more prevalent among individuals with mood disorders205, in the 
Cnr1 gene (which encodes CB1R) are tied to increased risk of stress-precipitated depressive episodes206 
and resistance to antidepressant drug treatment207. 
Secondly, and complementarily to the deleterious effects of ECS impairment, there is evidence that 
restoring or improving eCB signaling leads to the opposite effect – i.e., improvement of affective state191. 
Indeed, animal studies have found that both exogenous and endogenous cannabinoids, as well as inhibitors 
of FAAH (which lead to increased AEA levels) reliably lead to both improved outcomes in behavioral 
assays of depression/anxiety-like behavior208–212, and to biological changes typically associated with 
antidepressant effects, such as suppression of stress induced HPA axis activation196, increased hippocampal 
neurogenesis213, and augmented BDNF levels104. Moreover, both exogenous and endogenous cannabinoids 
have been demonstrated to be able of exerting inhibitory effects over monoamine uptake214 and to be able 
to directly affect the activity of serotonin (5-HT) and noradrenaline (NA) releasing neurons209,210,212 – thus 
providing a possible mechanism for their reported antidepressant effects. 
As such, and despite the fact that there is still much to be fully understood about the subject, there seems 
to be reasonable evidence to assert that the ECS plays a significant role in the control of affective 
functioning in both animals and human beings. 
3 – Adolescence and Chronic Cannabinoid Abuse 
3.1 – Adolescence 
Adolescence is a critical developmental period, during which mammals transition from childhood into 
adulthood, occurring between the ages of 12 and 18 years of age in humans, and postnatal days (PND) 28-
42 in rats215. This period is characterized by extensive biological changes (such as puberty), one of the 
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most prominent of which is the widespread remodeling that occurs in brain, including increased neuronal 
plasticity, synaptic sprouting and pruning, extensive myelination (resulting in increased white matter and 
decreased grey matter volumes), as well as changes in the receptor expression profiles and in 
neurotransmitter concentrations216. These changes are paralleled at the behavioral level, with reported 
increases in social activity, novelty seeking, and risk-taking behaviors (such as drug use) occurring during 
this period215.  
Given the heightened plasticity of the brain at this developmental stage, adolescence is also a period of 
extreme vulnerability, during which external influences (e.g. cannabinoid use) can not only leave lasting 
impacts, but do so in a much faster and profound manner217. Indeed, there is evidence that not only do 
adolescents become addicted faster than adults218, but that these addictions are more persistent219.  
With the ECS being known to play important roles in the development of the brain, and adolescence 
being one such period, it is not at all surprising that the ECS has been found to be involved in the some of 
the changes that take place during adolescence, such as those observed in HPA activity220. Indeed, there is 
suggestive evidence that ECS functioning may underpin for some of the behavioral changes that 
characterize adolescence: manipulation of the Cnr1 gene, meant to induce an increase in receptor-
functionality, led to adult rats exhibiting an adolescent-like behavioral profile that was reversed by low-
doses of the CB1R antagonist/inverse agonist rimonabant221. In accordance, it has also been demonstrated 
that wild-type (WT) adolescent mice, pre-treated with the CB1R antagonist/inverse agonist AM251, do not 
show the adolescent-typical increased consumption of both alcohol and sucrose, behaving similarly to 
adults222.  
In addition, the ECS itself has been shown to undergo substantial changes during adolescence: levels 
of AEA increase from early to late adolescence (although with some region specific fluctuations) in brain 
areas tied to mood, reward and cognition – such as the PFC, the amygdala and the nucleus accumbens 
(NAc)223,224 – with these increases being paralleled by decreased FAAH activity in many of these same 
regions224. Moreover, in the NAc and the PFC there is a decrease in the levels of 2-AG, from early to mid-
adolescence, that in the PFC is reversed during late-adolescence223. Furthermore, the expression of CB1R 
also changes over time, such that receptor density increases gradually from the early post-natal period, 
peaking at the onset of adolescence, and then gradually decreases towards adulthood223,225, with some 
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differences between male and female rats225. In addition, the changes at the molecular level might have 
some parallel in functional terms in the hippocampus, such that both eCB-LTD and the inhibitory effect of 
THC over synaptic transmission, are increased in adolescent rats in comparison to adult rats226. 
3.2 – Effects of Chronic Adolescent Cannabinoid Abuse 
Given that there seems to be a strong relationship between eCB signaling and the modifications 
occurring in the CNS during adolescence, it is reasonable to expect that cannabinoid use within this period, 
during which it typically begins215, might interfere with the changes taking place, leading to lasting 
alterations. Accordingly, there is significant evidence to support this idea, with respect to both cognitive 
and affective functioning, obtained from both human and rodent studies. 
3.2.1 – Human Studies of Chronic Adolescent Cannabinoid Abuse 
Most human data regarding the lasting effects of chronic adolescent exposure to cannabinoids have 
been obtained by observational studies. While these studies do find some significant associations between 
adolescent cannabinoid use and negative outcomes – in both the cognitive and affective domains – the 
interpretability of the results is necessarily hindered by the problem of inverse causality: that is, there is a 
possibility that cannabinoid abuse might be the result, and not the cause, of the changes found. Moreover, 
cannabinoid abuse and these negative outcomes may not be causally related, but – instead – be symptoms 
of higher level causes, such as socioeconomic disadvantages or poor family relationships227. 
The fact that, in epidemiological studies, adolescent cannabis use has been consistently associated with 
poorer school performance and earlier school abandonment228–231 has led some researchers to propose a 
causal relationship between the two. One often cited mechanism for this is the so-called amotivational 
syndrome, which is purported to be characterized by “apathy and diminished ability to concentrate, follow 
routines, or successfully master new material”232, and whose neurobiological basis has been proposed as 
being related to cannabis-induced impairments in motivation and reward circuitry233. The existence of this 
syndrome is, however, subject to wide discussion, with no conclusive evidence having emerged thus far232. 
Another such suggested causal mechanism relates to the proposed intelligence quotient (IQ) lowering 
effects of cannabis use, whereby lack of educational achievement would be propitiated by reductions in 
intelligence234. This proposal, however, seems to not be supported by data, as other studies have found no 
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effect of cannabis use on IQ235, especially when adequate adjustments are made for socioeconomic 
factors236. Indeed, a more likely explanation for this apparent deleterious effect of cannabis on educational 
performance, is the existence of the aforementioned common psychosocial factors, namely socioeconomic 
disadvantage and lack of parental educational achievement227,229,231. 
Despite this, there is significant evidence suggesting that individuals, who regularly used cannabis as 
adolescents, present alterations at the structural, functional and neurocognitive levels. Structurally, it seems 
that adolescent cannabis use leads to decreases and increases in gray and white matter237,238, respectively, 
as well as to changes in cortical thickness, in a number of brain regions (including the PFC)239, and to 
decreases in both hippocampal240 and orbitofrontal cortex (OFC) volumes241. Moreover, it has been 
reported that adolescent cannabis use leads to decreased white matter integrity, with age of regular drug 
use onset being a key predictor of white-matter tract microstructural anomaly severity242. 
In accordance with these structural abnormalities, research looking at functional activity, has found it 
to be altered in the brains of individuals who used cannabis as adolescents238. Specifically, abnormal 
activation patterns have been found in the limbic and parietal regions, as well as in the cerebellum and PFC 
of these individuals243–247. Likewise, reductions in blood flow have been observed not only in prefrontal 
brain regions, but in temporal and insular regions as well248. Furthermore, one interesting study found that, 
despite showing normal performance in a cognitive task, participants who had used cannabis as adolescents 
showed abnormally high prefrontal activation, suggesting a need for compensatory recruitment of neuronal 
resources to achieve normal performance247. In addition, resting-state activity patterns have also been 
shown to be significantly different between adolescent cannabis users and control participants238. 
In line with the structural and functional abnormalities described above, cognitive studies have found 
adolescent users to present impaired performances in tasks relating to working memory and executive 
functioning243,244,249,250, attentional control251,252, cognitive inhibition and impulsivity249,252, decision-
making245,252, and to both visuospatial253 and verbal memory240. Furthermore, the severity of these 
impairments is related to both the age at use onset, as well as to the frequency of use and to the doses 
used243,249. 
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While the lasting cognitive effects of adolescent cannabis use have been relatively extensively 
investigated through several approaches, almost all studies on the affective consequencesb of such drug 
exposure have been epidemiological in nature, although many of the functional and structural alterations 
reported above238 also impact brain regions heavily involved in affective functioning. 
With regard to anxiety, a number of studies have found adolescent cannabis use to be a risk factor for 
the later development of anxiety disorders, with some studies reporting these individuals to be more than 
twice as likely to be diagnosed with an anxiety disorder as adults, and to be at even greater risk if cannabis 
use began before age 15, and if consumers are female254–256. It should, however, be noted, that a recent 
meta-analysis257 of several epidemiological studies concluded that, depending on whether all studies or 
only high-quality ones were included in the analysis, adolescent cannabis use either represented a 
negligible risk factor for, or had no influence on, adult likelihood of anxiety disorder diagnosis, 
respectively.  
Concerning depressive disorders, on the other hand, studies have found that adults, who were cannabis 
users as adolescents, are at an increased risk of being diagnosed with a depressive disorder, with risk being 
higher for females than males254–256,258. Underlining this apparent deleterious effect of adolescent cannabis 
use on adult affective functioning, it has been reported that this type of drug use leads to a significant 
increase in the risk of suicidal ideation and/or suicide attempts, which – again – is greater for females, and 
in proportion to both frequency of use, and age of use onset258. Furthermore, the results of a twin study259 
suggest that at least some of these effects are attributable to genetic vulnerability, and not merely to 
environmental causes. 
Thus, while there seems to be significant evidence to support the assertion that adolescent cannabis use 
induces lasting deleterious effects on affective functioning – especially in the female population – these 
data are inherently limited by their observational nature.  As such, one must complement human data with 
animal pre-clinical research, so as to better understand the relationship between adolescent cannabinoid 
abuse and affective disorders. 
                                                     
b Because the present work focuses on the effects of chronic adolescent cannabinoid exposure on anxiety- and depressive-like 
behaviors, studies on the possible relationship between cannabis use and the development of psychotic disorders will not be 
approached. 
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3.2.2 – Animal Studies of Chronic Adolescent Cannabinoid Abuse 
Unlike human data, animal studies are not susceptible to reverse causality, and are less vulnerable to 
the possible existence of uncontrolled (or uncontrollable) variables that might influence the results – such 
as the potency of cannabis used, the accuracy of subject reports, or other lifestyle choices such as 
concomitant use of other psychoactive substances. Indeed, there is ample animal behavioral data 
supporting the view that the chronic adolescent use of cannabinoids leads to persistent changes in both 
cognitive and affective functioning260. Moreover, these behavioral studies are also accompanied by 
significant evidence of biochemical and electrophysiological changes, as a consequence of adolescent 
treatment, thus giving some evidence of the biological substrates underlying the observed behavioral 
alterations. 
Furthermore, it is worth nothing that, in studies that compare the same drug administration schedule in 
adolescent and adult rats, it is often the case that the changes induced by drug exposure are only present in 
the former group, with the latter showing either no or opposite effects261,262 – again underlining the special 
vulnerability of the adolescent brain to the effects of cannabinoid abuse. Alternatively, this may also 
suggest that, at more advanced ages, there is a decline in ECS functioning, that treatment may be 
offsetting263. 
3.2.2.1 – Cognitive Effects 
The cognitive domain, where the effects of chronic cannabinoid exposure during adolescence have been 
most amply studied, is that of memory. The majority of studies (although exceptions do exist264–268) have 
demonstrated that prolonged administration of cannabinoid receptor agonists (CBRAs), such as THC, 
WIN55,212-2, CP 55,940 or HU-210 (fig. 1.3; table 1.1), induces persistent impairments in recognition 
memory, as indexed by the novel object recognition test (NORT)261,269–282. These impairments are often 
accompanied by spatial memory deficits in the novel object place recognition test (NOPRT)268,269,272,277,281–
283. However this deleterious effect seems to be task-specific, as the majority of studies using both the 
Morris water maze (MWM)265,283–286 – the gold-standard for testing hippocampal-dependent spatial 
memory287 – and the active place avoidance paradigm (APAP)284,288 have found no significant changes in 
this domain of memory, as a consequence of chronic adolescent CBRA exposure. 
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Fig. 1.3 – Molecular structures of the four CBRAs most used in research. All research on the long term effects of chronic adolescent 
cannabinoid exposure has been performed with one of four non-selective CBRAs: THC (a) is a partial agonist with equal affinity for CB1R and 
CB2R, HU-210 (b) is a potent full agonist at both CBRs, with one order magnitude greater selectivity for CB1R, CP 55,940 (c) is a full agonist at 
both CBRs with equal relative affinity for both, and WIN 55,212-2 (d) is a full agonist at both CBRs with slightly greater selectivity for CB2R. 
Regarding working memory, studies using either the Y-maze, the T-maze or the radial maze, reported 
that chronic adolescent CBRA exposure leads to persistent deficits in spatial working memory272,289–291. 
Complementing reports of these deficits, Gomes et al.292 showed that the attentional control of rats 
chronically treated with CBRAs during the adolescent period showed signs of impairment in relation to 
vehicle treated controls. As such, these combined results suggest that chronic adolescent CBRA exposure 
leads to altered adult executive functioning. 
It is of note that, in contrast to what is reported at the levels of affective functioning, the deleterious 
effects of adolescent CBRA exposure on cognitive function are remarkably similar between sexes, with no 
clear trend emerging for sexual dimorphism.  
  
Ki, inhibitory/dissociation constant (measure of drug affinity for a given receptor); EC50, half maximal effective concentration (measure of drug 
potency for a given receptor).  
Table 1.1 – Pharmacological characteristics of the four CBRAs most used in research. 
Drug Efficacy 
CB1R  CB2R  
Ki (nM)293 EC50 (nM)10 Ki  (nM)293 EC50 (nM)10 
∆9-THC 
CB1R/CB2R  
partial agonist 
5.05 – 80.3 9.1 – 530 3.13 – 75.3 41.8 – 1000 
HU-210 
CB1R/CB2R 
 full agonist 
0.06 – 0.73 0.02 – 7.2 0.17 – 0.52 0.37 – 1 
CP 55,940 
CB1R/CB2R 
 full agonist 
0.5 – 5 0.8 – 310 0.69 – 2.8 0.72 – 2.89 
WIN 55,212-2 
CB1R/CB2R 
 full agonist 
1.89 – 123 7.6 – 410 0.28 – 16.2 0.41 – 3 
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3.2.2.2 – Effects on Anxiety-like Behavior 
Contrary to the observed cognitive effects of adolescent CBRA exposure, the results regarding the 
consequences of this type of treatment on adult anxiety-like behavior show more heterogeneity, with some 
contradictory and/or test-specific findings being reported.  
When animals chronically exposed to CBRAs during adolescence are tested in the elevated plus maze 
(EPM) at adulthood, the majority of studies has found no significant treatment effects210,264,265,272,290,294–298. 
However, there are reports of CBRA-treated rats showing either increased299 or decreased levels of anxiety-
like behavior300–302 in this test. While the reason underlying these differences is not clear, it is likely that 
differences regarding animal strains, and dosing/testing schedules are the primary causes.  
Similarly, studies using the open field test (OFT) generally report that animals chronically exposed to 
CBRA treatment during adolescence show no significant behavioral differences from controls in this test 
– i.e., no changes in either anxiety-like and/or locomotor-related behavior210,269,283,294,300,303. Nonetheless, 
there is a limited number of reports describing changes pointing to both increased271,304 or 
decreased296,301,305 anxiety, as well as changes in locomotor behavior278,306. Moreover, unlike in the case of 
the EPM, some of these discrepant results are found in studies employing the exact same strains and 
dosing/testing schedules effects278,294, thus further difficulting the determination of a clear trend in effects. 
While the EPM and the OFT are the most widely used behavioral paradigms to measure anxiety-like 
behavior, they have some significant shortcomings (see chapter 2). However, a small number of studies 
has employed other assays of anxiety-like behavior: while studies with the holeboard test (HBT) find no 
effect of chronic adolescent CBRA exposure on adult anxiety-like behavior271,307, studies using the light-
dark box (LDBT)278,306 and the novelty suppressed feeding tests (NSFT)210, find that CBRA-treated rats 
show increases in anxiety in comparison to vehicle-treated controls. 
Thus, based on these findings, a relatively unclear picture emerges. While the majority of studies do 
not find any effect of adolescent CBRA use on adult anxiety-like behavior, there is a non-insignificant 
amount of studies pointing to the possibility of other effects. As such more data should be obtained to fully 
elucidate the effects of chronic adolescent CBRA exposure. 
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3.2.2.3 – Effects on Mood and Reward Signaling  
While the effects of adolescent CBRA treatment on anxiety-like behavior are somewhat contradictory, 
the same cannot be said for the effects observed on the social behavior of rats. Indeed, it has been 
consistently reported that rats chronically exposed to CBRAs during the adolescent period show persistent 
deficits in social interaction and social motivation at adulthood. In the majority of studies using the social 
interaction test (SIT) CBRA-treated rats choose to spend significantly less time interacting with an 
unknown same-sex partner, than control rats261,262,262,273,274,276,282,308. Likewise, authors using the social 
motivation and social novelty task (SMSNT) have reported decreases in both the interaction with, and 
preference for, novel social partners278,290,306, as a lasting consequence of adolescent CBRA treatment.  
However, these reports can be interpreted in several ways, given that measures of social behavior 
straddle the line between measuring anxiety and reward signaling and/or mood function309: one can 
interpret reduced social interaction and social motivation as being due to either increased anxiety, 
decreased reward value for social stimuli (known to be highly rewarding to rodents310) or even due to a 
combination of both. Indeed, a compelling case can be made for interpreting these deficits as resulting 
from decreases the hedonic value of social behavior, given that they are a) independent of changes anxiety-
like behavior (as SIT results do not correlate to those of other anxiety tests311) and b) often associated with 
changes in other tests, where impaired reward signaling and/or mood functioning276 are found. 
The changes in reward signaling have been demonstrated in several ways: Schneider and Koch279 were 
the first to report that adult rats chronically exposed to WIN55,212-2 during the adolescent period, had 
lower “break points” on a progressive ratio operant task, indicating lower motivation to obtain a reward. 
In line with this, Chadwick et al.312 reported that female rats chronically exposed to CP 55,940 during 
adolescence show persistent decreases in motivation to engage in sexual behavior (which is accompanied 
by other changes in sexual behavior313). However, the most compelling evidence of impaired reward 
signaling, as a result of protracted adolescent CBRA exposure, comes from studies employing the sucrose 
preference (SPT) and palatable food preference tests (PFPT): in most of these studies (but see 
references269,298,312) the CBRA-treated groups show decreased intake of, or preference for, either a sucrose 
solution210,276,294,296 or a palatable food276 when compared to control rats, suggesting that these CBRA-
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treated rats are less sensible to the rewarding properties of these stimuli312 – a result that is generally 
interpreted as being indicative of anhedonia, a key feature of depressive disorders314. 
Further underlining the similarities between the changes induced by chronic adolescent CBRA exposure 
and the features of depressive disorders, rats subjected to manipulations of this sort have been reported to 
show behavioral profiles in the original and modified versions of the forced swim test (FST and mFST, 
respectively) that are associated with depressive-like behavior. Specifically, in most reports (but see 
references268,269) CBRA-treated rats show increased immobility times210,276,280,282,294,308,315, decreased 
swimming times210,276,280,282,308,315 and reduced latency to first immobility210 in comparison to vehicle-
treated controls, suggesting a lasting impairment in stress-coping behavior.  
In sum, there is enough animal behavioral data to support the assertion – suggested by human 
observational data – that chronic adolescent CBRA exposure induces persistent deleterious changes in 
reward signaling and mood that are similar to those found in depressive disorders. 
3.2.2.4 – Biochemical and Morphological Effects 
Given the extensive and lasting impact that chronic adolescent treatment with CBRAs has on both 
cognitive and affective functions, it is reasonable to expect these changes to have biochemical correlates. 
Indeed, numerous studies have confirmed this to be the case, in a myriad of systems and brain regions. 
In the glutamatergic system, changes have been reported to occur primarily in the hippocampus and the 
PFC: At the level of the hippocampus, Rubino et al.316 found that adult male rats treated with escalating 
doses of THC during adolescence, showed diminished NMDAR density at adulthood. However, two 
posterior studies280,317, found this same effect to be observable only in female rats. In addition, other reports 
found reduced levels of mGluR5 318 and increased levels of NMDAR subunit 2B (GluN2B) and AMPAR 
subunits 1 and 2 (GluA1 and GluA2)268, as well as a decrease in the levels of K+-evoked glutamate 
release318. In the PFC, adolescent treatment with CBRAs was found to lead to both decreased levels of 
mGluRs 2 and 3, and reductions in the co-localization of CB1R with vesicular glutamate transporter 1 
(vGluT1) in the medial portions of this region (mPFC)305, as well to as time dependent increases in the 
levels of both NMDAR subunit 2A (GluN2A), GluN2B and GluA1 subunits291. Moreover, in a study 
focusing on the effects of chronic adolescent CBRA exposure on prefrontal gene expression, numerous 
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time-dependent decreases were found in the expression of genes relating to several glutamate receptor 
subunits308. 
Regarding the GABAergic system, a picture emerges that is somewhat the mirror image of the one 
found for the glutamatergic system. Indeed, it has been proposed that chronic adolescent exposure to 
CBRAs disrupts the excitation/inhibition equilibrium in the hippocampus and PFC in opposite manners, 
by tilting this equilibrium towards inhibition in the former region, and towards excitation in the latter317. 
Indeed, in the hippocampus of chronically treated animals, authors have found treatment to lead to 
persistent increases not only in K+-evoked GABA levels, but also in the density of GABA A and B 
receptors (GABAAR and GABABR, respectively), as well as in decreased levels GABA transporter 1 
(GAT-1) RNA 317. Contrastingly, studies focusing on the PFC have found that CBRA treatment leads to 
lasting decreases in the expression of the GABAergic system in this region: Zamberletti et al.281 reported 
decreases in both prefrontal levels and activity of glutamate decarboxylase 67 (GAD67) – the main 
synthetic enzyme for GABA – as well as decreased levels of GABA, as a result of treatment with escalating 
doses of THC. In addition, a pair of key studies278,306 replicated these deficits in GAD67, and found the 
changes in prefrontal GABAergic signaling to be associated with changes in the frequencies and firing 
patterns of both mPFC pyramidal neurons and ventral tegmental area (VTA) DA neurons. Moreover, by 
showing that intra-mPFC administration of a selective GABAAR agonist (muscimol) restores performance 
in tasks relating to object recognition memory, social motivation and anxiety to control levels278, these 
authors conclusively demonstrated that disruption of frontal GABAergic signaling is responsible – either 
directly or through influence on DA signaling – for at least some of the behavioral deficits, induced by 
chronic adolescent CBRA exposure. Finally, similarly to what was observed in the glutamatergic system, 
analysis of prefrontal GABAergic system-related genes, detected time-dependent decreases in the 
expression of several genes coding for both subunits of both GABA receptors, as well as for enzymes 
involved in the synthesis of GABA308. 
The changes reported by Renard et al.278,306, at the level of VTA DA neuron firing, are consistent with 
previous evidence, showing that not only does chronic exposure to CBRAs lead to changes in the activity 
of DA neurons292, but also that it induces other changes in the DAergic system. Indeed, previous studies 
found CBRA treatment to lead to increased NAc density of DA receptor type 1 (D1R)280,319 and D2R280, as 
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well as to a – male specific – increase in prefrontal D2R density280. In the CA1 region of the hippocampus, 
however, treatment led to a decrease in D2R density319. Moreover, treatment also led to female specific 
increases in DA transporter (DAT) levels in the caudate-putamen (CPu)319 and to augmented DA 
metabolism in striatal regions264 (in a study using only male rats), as well as to diminished density VTA 
tyrosine hydroxylase (TH) expressing cells320. In agreement with these changes, other authors have 
reported that animals that underwent chronic adolescent exposure to CBRAs show heightened behavioral 
responses to amphetamine292,321 – suggesting that this CBRA treatment may lead to sensitization of the DA 
system. 
In comparison to the DA system, research on the effects of persistent adolescent exposure to CBRAs 
on other monoaminergic systems has been relatively sparse. This is the case of the NA and 5-HT systems, 
even though both are highly relevant in numerous cognitive and emotional processes. Indeed, to date, only 
a few studies have focused on these systems: Lopez-Rodriguez et al.322 reported a male specific increase 
in serotonin transporter (SERT) expression in parietal cortex fibers, as a consequence of chronic adolescent 
CBRA treatment. In addition, whereas 5-HT type 1A receptor (5-HT1AR) density and mRNA expression 
were not found to be significant altered after treatment323, a significant transient decrease was found in the 
prefrontal expression of the gene encoding for the 5-HT type 2A receptor308 (5-HT2AR). Thus, and given 
the paucity of evidence, little can be asserted about the effects that CBRA treatment has on these systems, 
and how those effects might relate to the behavioral phenotypes observed.  
The opioid system has also been heavily implicated on mood functioning and reward signaling324, and 
studies have demonstrated that chronic adolescent CBRA exposure induces several alterations in this 
system. Specifically, while Ellgren et al.223 found increases in μ-opioid receptor (MOR) function in the 
substantia nigra (SN) and VTA of treated rats, without concomitant changes in MOR density, Biscaia et 
al325 found gender-dependent changes in MOR density in the cingulate cortex, hippocampus, thalamus and 
subcallosal streak of treated rats (with male and female rats showing decreased and increased density, 
respectively). These disparities are likely attributable to differences in drug and treatment schedules used. 
Moreover, using a different drug schedule, Rubino et al.294 found that treatment of adolescent rats led to 
female-exclusive increases in the NAc levels of dynorphin A – a κ-opioid (KOR) agonist peptide, known 
to be involved in the regulation of negative emotions. Finally, two studies have focused on the expression 
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of proenkephalin mRNA, finding contrasting results (again, likely due to highly dissimilar drug treatment 
schedules): whereas Morel et al.326 found decreased expression in both the NAc and the CPu, Tomasiewicz 
et al.327 found the opposite effect for the NAc, without observable changes in CPu expression. As such, 
while there is some compelling evidence of changes to the opioid system, as a consequence of chronic 
adolescent CBRA exposure, the lack of consistency between reports makes it difficult to conclusively 
relate these changes to any of the behavioral changes previously described. 
Given that CBRAs overwhelmingly exert their effects through interactions with the ECS, it is 
reasonable to expect that chronic adolescent CBRA exposure would induce lasting changes in this system. 
Indeed, this seems to be the case at both the receptor, eCB, and degradative enzyme levels. 
Regarding the effects of treatment on cannabinoid receptors, studies have obtained somewhat 
contradictory results, likely as a result of the differences in the technique used: firstly, when receptor 
protein levels have been analyzed through western blot, results have been inconsistent, with some studies 
finding that treatment leads to increases in CB1R protein levels the striatum328 and the hippocampus329, 
while others report no changes in either of these areas330. Moreover, while no effect was found in the 
amygdala of treated mice297, decreases and increases in CB1R and CB2R protein levels, respectively, were 
found in prefrontal tissue of female rats chronically exposed to THC282. On the other hand, when studies 
have used immunohistochemistry, the majority of, but not all331, reports have found treatment to lead to no 
significant alteration in CB1R expression305,312,320,322.  Contrastingly, with a few exceptions223,272,317,326,332, 
studies using radioligand binding assays – a more precise and quantitative measure of receptor levels – 
have found that chronic adolescent CBRA treatment leads to significant widespread decreases in CB1R 
densities280,291,294,315,333,334. Likewise, analyses of CB1R function have shown that adolescent exposure to 
CBRAs results in long-lasting reductions in receptor function – suggesting a decrease in receptor 
sensitivity to ligands280,291,294,329,332, with only a limited number of studies finding different results223,317,326. 
Regarding eCBs, the results reported have been suggestive of both eCB- and region-specific effects. 
While Rubino et al.291 found decreases in PFC AEA levels, Schoch et al.298 reported increased levels of 
this molecule in the NAc (after a 6-hour food deprivation period), and Tomas-Roig et al.303 reported similar 
increases in the hippocampus of CBRA-treated rats. Conversely, the two reports298,303 that have measured 
2-AG levels, found them to not be altered by CBRA treatment.  
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Relatedly, the effects of chronic adolescent CBRA exposure over eCB degradative enzymes, have not 
yet been fully elucidated, with inconsistency in the results of the few studies published so far (likely as a 
result of differences in the rodent species used, in the gender of the animals, and in both the time of 
measurement and the technique used for it). Specifically, while Rubino et al.291 found a persistent decrease 
in FAAH levels, and a transient decrease in the MAGL PFC levels of treated rats – which is accompanied 
by a decrease in the expression of the gene coding for the latter enzyme308 – Lovelace et al.305 found no 
alteration in MAGL levels, in this same region, in mice. Additionally, Gleason et al.318 found the levels of 
both MAGL and FAAH to be increased in the hippocampus of adult male mice chronically exposed to 
WIN 55,212-2 during adolescence. 
Thus, as would be expected, there is ample evidence supporting the notion that chronic adolescent 
CBRA exposure induces lasting alterations in the functioning of the ECS, that may underpin the alterations 
observed when these animals are put through behavioral testing, although more research is clearly needed. 
Related to both cognitive as well as affective functioning, neurogenesis has been consistently shown to 
be impaired by chronic adolescent exposure to CBRAs. Thus, male animals treated with WIN 55,212-2 
were demonstrated to have decreased hippocampal neurogenesis284, while another report showed the 
hippocampal antineurogenic effects of HU-210 to be male-specific321. Moreover, in a recent study using 
only female rats, chronic treatment with THC led to long lasting decreases in the number of dentate gyrus 
(DG) immature neurons, suggesting a deleterious effect of treatment315. 
As is the case with neurogenesis, there is consistent evidence that chronic adolescent CBRA exposure 
induces significant alterations in the morphology of neuronal cells. As such, dendritic length has been 
found to be reduced in both immature315 and mature316 hippocampal neurons, as well as in pyramidal 
neurons located in layers II/III of the PFC335. Similarly, spine density has been shown to be reduced in 
neurons located in the NAc336, the hippocampus316, the amygdala297, and in PFC layers II/III291.  
Given the alterations in both neurogenesis and neuronal morphology, the cognitive deficits observed as 
a consequence of chronic adolescent CBRA exposure, and the known widespread involvement of the ECS 
in plasticity phenomena, it stands to reason that this type of treatment would have correlates at the level of 
neuroplasticity. Indeed, reports have shown chronic treatment with CP 55,940 induces female-specific 
decreases in hippocampal BDNF levels331, while 24-hours after chronic exposure to THC a decrease was 
37 
 
observed in the expression of the gene coding for this neurotrophic factor308. Moreover, alterations have 
been reported in the levels of several proteins known to be key players in the regulation of synaptic 
plasticity, although some significant contradictions, and gender-dependent differences exist: specifically, 
reports have found decreases in post-synaptic density protein 95 (PSD95) levels in the PFC of male rats335 
while, in females, authors have reported this protein to be both transiently increased for a period after 
treatment – being normalized at adulthood291 – as well as decreased, at a posterior adult time-point337. 
Similarly, in the hippocampus of male rats, two reports from the same group have demonstrated both 
increases268 and decreases316 in the levels of this protein (despite using the exact same protocol), while a 
third report from another group found no treatment effect335. Synaptophysin, another protein known to be 
involved in synaptic function and learning processes338, has been shown to be altered in a gender- and 
region-specific manner, whereby it is increased in the hippocampus of male animals268 (but see 
reference335), whereas it is decreased in the PFC of females337. In the same manner, vesicle-associated 
membrane protein 2 (VAMP2), a protein involved in the synaptic vesicle docking and fusion339, has also 
been shown to be decreased in the hippocampus of male animals316. Furthermore, expression of the gene 
coding for activity-regulated cytoskeleton-associated (Arc) protein – thought to play a critical role in 
learning and memory processes340 – has been shown to be transiently decreased 24-hours after chronic 
adolescent CBRA exposure308, and was found to be decreased in a female-specific manner in both the 
hippocampus and PFC of adult animals271. Likewise, phosphorylated cAMP response element-binding 
protein (pCREB), another key player in synaptic plasticity phenomena341, has been shown to be reduced 
in the PFC and hippocampus, and increased in the NAc of female, but not male, adult animals that 
underwent chronic adolescent exposure to THC294. Finally, Renard et al.306 have recently reported that 
chronic adolescent treatment with CBRAs leads to a marked dysregulation and suppression of the 
mammalian/mechanistic target of rapamycin complex 1 (MTORC1) pathway – known to be involved in 
synaptic plasticity and cognitive processing, as well to be altered in numerous neuropsychiatric 
disorders342. 
In addition to alterations at the level of synaptic plasticity, there is some evidence to support the notion 
that chronic adolescent CBRA exposure alters brain metabolic activity, although it is not clear in which 
way. Indeed, despite the fact that Higuera-Matas et al.325 found female-specific increases in metabolic 
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activity in the PFC and septal nuclei, and decreased activity in the DG of CP 55,940-treated rats, there is 
molecular data suggesting that both whole brain pyruvate decarboxylase and NADH dehydrogenase 
expression343, as well as PFC levels of several mitochondrial and glycolytic enzymes337, are reduced by 
treatment.  
In more recent years there has been some interest in the role that neuroinflammation plays in both 
depressive disorders and in cognitive deficits344. Strikingly, it seems to be the case that chronic adolescent 
exposure to THC, may exert some of its effects through the modulation of inflammatory responses, 
whereby, in female animals, this type of treatment led to increases in the prefrontal levels of the pro-
inflammatory agents tumor necrosis factor α (TNFα), inducible nitric oxide enzyme (iNOS) and COX-2, 
concomitantly with increases in both the expression of ionized calcium-binding adapter molecule 1 (Iba1; 
a marker for activated microglial cells), and the number of amoeboid microglia282 – all of which suggest a 
lasting pro-inflammatory effect of THC treatment. Curiously, in another study – where male animals 
underwent similar treatment –  both increases in TNFα and iNOS, as well as decreases in the levels of the 
anti-inflammatory cytokine interleukin-10 (IL-10) were observed in hippocampal (instead of prefrontal) 
tissue, with no changes being observed in either COX-2 or Iba1268. 
Finally, numerous studies have looked into the effects of chronic adolescent CBRA exposure on other 
assorted biochemical targets, such as changes in histone methylation and acetylation levels345, in c-FOS 
reactivity to several different stimuli301,346, in the levels of hippocampal polysialylated-neural cell adhesion 
molecule (PSA-NCAM)265, and of proteins such as 90 kDa heat-shock protein (HSP90) and its chaperone, 
the activator of 90 kDa heat shock protein ATPase homolog 1 (AHA1) enzyme328,330,343, finding this type 
of exposure to lead to significant alterations. 
3.2.2.5 – Electrophysiological Effects 
Given the involvement of the ECS in neuroplasticity phenomena, and both the behavioral and molecular 
evidence pointing to disrupted learning and memory mechanisms, resulting from chronic adolescent 
CBRA exposure, it is unsurprising that there is consistent evidence of alterations in the electrophysiological 
domain. 
At the single neuron level, alterations have been found in both NA, 5-HT, DA, and mPFC pyramidal 
neuron activity: Bambico et al.210 reported CBRA treatment to lead to increased spontaneous and evoked 
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firing of locus coeruleus (LC) NA neurons, and to the opposite effect on dorsal raphe nuclei (dRN) 5-HT 
neuron firing. Concerning the DAergic system, two report have found chronic exposure to CBRAs to lead 
to either no alteration296 or an increase292 in spontaneously active DA neurons (likely due to differences in 
the drug and administration schedule used). Moreover, whereas WIN 55,212-2-296,347, cocaine-347, 
amphetamine- 347 and morphine-evoked347 DA neuron firing rates were demonstrated to be depressed as a 
result of adolescent CBRA treatment, an increase was found both in the number of burst firing DA 
neurons278, as well as in their firing frequencies and number of bursting episodes278,306 – suggesting that 
CBRA treatment induces long-lasting hyperactivity in the DA system306. Similarly, when looking at the 
mPFC, Renard et al.278 found that the pyramidal neurons, of rats chronically exposed to THC as 
adolescents, showed increases in their firing frequencies, as well as in the number of spontaneous burst 
firing episodes, with an increase in the number of burst firing neurons also being observed. 
In recent years, there has been an increase of interest in the layer II/III mPFC synapse, as a potential 
target for the long term effects of chronic adolescent CBRA exposure. In this regard, while Lovelace et 
al.305 found no changes in either short-term presynaptic plasticity or basal synaptic efficiency, they did 
observe a significant impairment of both mGluR2/3 mediated LTD, and eCB-LTD at this site. This latter 
finding has been corroborated by both Rubino et al.291 and Cuccurazzu et al.315. Furthermore, the latter 
authors additionally found DG LTP to be impaired, in both mature and newborn neurons315. Moreover, not 
only was LTP in the hippocampus-PFC pathway (a pathway critical for adequate cognitive functioning) 
found to be impaired as a result of chronic CP 55,940 treatment335, but, in another study283, LTP in the 
ventral subiculum (vSub)-NAc pathway was also found to be transiently diminished, whereas no such 
effect was found in perforant path (PP)-DG pathway LTP. 
Lastly, two studies by Raver et al.275,348 have looked at the effects of chronic adolescent CBRA exposure 
on local field potentials (LFP). Specifically, these authors have reported that chronic adolescent exposure 
induces dose-dependent decreases in the power of gamma (γ), beta (β), alpha (α), and theta (θ) frequencies 
recorded in the mPFC and the somatosensory cortex, as well as significant decreases in LFPs evoked by 
the combination of kainic acid and carbachol. Thus, and given that Renard et al.278, also found mPFC γ 
frequencies to be altered as consequence of treatment, these data suggest that chronic adolescent CBRA 
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exposure induces alterations in the functioning of synchronized neural networks, that may underlie some 
of the behavioral alterations observed in these animals. 
3.3 – Sexual Dimorphism in the Effects of Chronic Adolescent Cannabinoid Abuse 
One peculiar finding in both the human and animal research literature on the effects of chronic 
adolescent CBRA abuse, pertains to the fact that there seems to be a significant effect of gender on the 
severity of drug effects. Indeed, there is evidence that, despite the fact that men are the primary consumers 
of CBRAs349,350, and stand at an increased risk of developing CUD349–351, women show a faster progression 
from first use to problematic use350,352, and experience more severe withdrawal effects350,353–355. Moreover, 
it seems to be the case that women are more vulnerable to both the immediate subjective effects of 
CBRAs350 as well as to the psychiatric consequences of long-term use, especially when it concerns 
depressive and anxiety disorders254–256.  
Because human studies, even experimental ones, suffer from several limitations, animal data provides 
a unique window into the possible gender-dependent effects of CBRAs. Indeed, there is some relevant 
evidence that female animals are more sensitive to the effects of these drugs – showing greater drug-
induced antinociception350, anxiogenesis349,350, and locomotor impairment328,349,350,356,357 – as well as 
responsive to their reinforcing effects349,350,358. Furthermore, there is some suggestion of a greater negative 
effect of chronic adolescent CBRA exposure in females, with regards to affective behavior, and a roughly 
equal effect on cognitive function268,276,282,294,308,315,359. 
There is increasing evidence that this dimorphism may arise from a confluence of several 
factors349,350,359,360. There is some evidence suggesting that the ECS of females may differ from that of 
males360, with differences having been found in the levels of eCBs361, in the density271,280,362, affinity362, 
and function271,280,360 of CB1R (importantly, in some brain regions critically involved in affective 
functioning360). Furthermore, differences have been found in both the recovery of hippocampal CB1R 
expression334 following protracted CBRA administration, as well as in the CB1R desensitization 
response332 to this type of manipulation. In addition, in a recent study, it was demonstrated that 
pharmacological blockade of FAAH led to a marked female-specific suppression of inhibitory synaptic 
transmission, suggesting the existence of gender-specific tonic eCB signaling363. 
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Relatedly, the female ECS shows significant variation across the hormonal cycle, via the action of sex 
steroids such as estrogens and progesterone349, which correlate to fluctuations in eCB levels364, as well as 
in CB1R density, affinity and function362,365, and impact behavioral tests329. Even more interestingly, and 
in line with this, there is evidence supporting the notion that ovarian hormones may alter both cannabinoid 
seeking and taking behaviors366,367. Furthermore, while ovarian hormones seem to potentiate the effects of 
CBRAs, androgens such as testosterone seem to have the opposite effect, reducing the behavioral responses 
to these drugs368,369. 
Finally, there is convincing evidence supporting the idea that there may be gender-specific 
pharmacokinetic differences in cannabinoid metabolism that may, at least partially, underlie the stronger 
effects observed in females349. Specifically, while Tseng et al.370 reported similar levels of THC and its 
metabolites in males and females, these authors found the levels of these compounds to be higher, and 
present for longer periods of time, in the brains of females. On the other hand, Wiley et al.371 found females 
to have higher brain and blood levels of the CB1R-active THC metabolite 11-OH-THC. Interestingly, while 
there is some suggestion that this difference is at least partially independent of hormonal influence, an 
important role for gonadal hormones also seems to exist, such that testosterone led to a decrease in the 
metabolism of THC into 11-OH-THC, while estradiol had the opposite effect368. 
Thus, while there is still much to discover, there is enough evidence to support the assertion that there 
is clear sexual dimorphism in the effects of CBRAs, and that this dimorphism likely stems from both 
organizational (that is, previous to the influence of gonadal hormones) and hormonal differences between 
males and females. Moreover, given that in previous animal studies, the depressive-like effects of chronic 
adolescent CBRA exposure were observed almost exclusively in females268,276,282,294,308,315,359, in the present 
work only female animals were employed. 
4 – HU-210  
Originally synthetized by Mechoulam et al.372, the highly potent non-selective CBRA, HU-210 ((6aR)-
trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-
methanol), is a structural analog of the phytocannabinoid Δ8-tetrahydrocannabinol373. However, despite 
the structural similarity with this natural cannabinoid (which is less potent than THC at inhibiting AC 
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activity and cAMP increases374,374), HU-210 exhibits remarkably high affinity and efficacy at the CB1R, 
being a very potent agonist of this receptor373,375,376. Moreover, while no direct data exists as to the half-
life of HU-210, it has been predicted – based on the data obtained for its NMDAR-targeting enantiomer 
HU-211377 – that this drug may have an exceptionally long half-life. As such, while these characteristics 
have made HU-210 a widely used pharmacological tool for the exploration of the ECS373, they have also 
made it an attractive substance for recreational purposes, with HU-210 having been found in apprehended 
samples of SC products378. Furthermore, while HU-210 shares many pharmacological actions of THC, 
there is data suggesting that it may interact with other receptors not targeted by the latter drug. For example, 
while both HU-210 and THC have been shown to potentiate the activation of glycine receptor α1 and α1β 
subunits379,380, HU-210 has been demonstrated to also inhibit α2 and α3 subunits of that same receptor379, 
as well as to potentiate the activation of the 5-HT2 sub-family of receptors381. 
In the studies that have used HU-210, a pattern of effects similar to those of THC – albeit at a much 
increased potency – has been widely described. As such, HU-210 was shown to dose-dependently decrease 
the levels of a number of hormones (such as plasma growth hormone)373,382, to alter the functioning of the 
HPA axis – by leading to marked increases in corticotropin releasing factor (CRF), corticosterone (CORT) 
and adrenocorticotropic hormone (ACTH) levels373,382 – and to propitiate a decrease in DA levels, as 
suggested by a decreased L-3,4,-dihydroxyphenylacetic acid (DOPAC)/DA ratio373,382. Moreover, at the 
behavioral level, HU-210 has been demonstrated to induce deleterious effects on locomotor activity, as 
indicated by marked hipolocomotion, catalepsy382–384, and a curious repetitive circling behavior385. At the 
level of cognitive function, HU-210 has also been demonstrated have a deleterious impact, as indicated by 
spatial learning impairments386,387. Furthermore, with regard to affective functioning, HU-210 has been 
shown acutely increase anxiety-like behavior in a number of behavioral assays383,387,388, as well as to lead 
to increased vocalization responses to tactile stimulation385,387, increased aggression383, and increased 
grooming (after subchronic administration388). Interestingly, the changes reported in anxiety-like behavior 
seem to be related to the alterations at the in HPA axis functioning, as concomitant injection with a CRF 
receptor antagonist largely abolished them383. In addition, there is some suggestion that HU-210 
administration alters the sexual drive of injected rats – either through its hormonal effects, or through its 
effects on the DAergic system – leading to impaired male sexual behavior, and a decrease in female 
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receptivity behavior389, which suggests the possibility that the drug may interfere with the rewarding 
properties of reproductive activity. 
Despite the reported effects of HU-210, and its common use in cannabinoid research, it is rather curious 
that no study has, thus far, tested the effects of chronic adolescent exposure to this drug on adult affective 
functioning. This is the case even though, the single study focusing on the effects of adolescent exposure 
to HU-210 did report several alterations that are suggestive of a prodepressant-like effect, such as 
decreased hippocampal neurogenesis and increased stress-reactivity321. Moreover, this lack of studies 
becomes even more perplexing when one considers the existence of studies where adult animals 
chronically administered high-doses of HU-210 not only show increased hippocampal neurogenesis213, but 
actual antidepressant-213,390 and anxiolytic-like213 responses to drug treatment, both on the day after the end 
of drug treatment and after a 30-day washout. Furthermore, at least some of these beneficial effects of HU-
210 stem from direct or indirect interactions with non-ECS targets, such as the NA system390. 
Thus, in summary, despite the existence of results suggesting a prodepressant effect of HU-210, there 
is still no conclusive data as to the effects that chronic adolescent exposure to this drug may have on long-
term affective behavioral outcomes. Moreover, the existence of adult data pointing towards the opposite 
effect raises the possibility that HU-210 may either have age-dependent effects, or that it may present 
characteristics that make it distinct from other previously studied CBRAs, and, as such, worth exploring. 
5 – Reasoning, Aim and Organization of the Present Work 
As detailed in the previous sections, the effects of chronic adolescent CBRA exposure have been 
extensively documented in numerous domains and levels of analysis. However, the literature presents a 
significant gap: specifically, the overwhelming majority of studies were performed using either THC, WIN 
55,212-2 or CP 55,940. While these drugs are well characterized, there is some suggestion that their long-
term effects may not be comparable – with differences in pharmacology (table 1.1) being a likely culprit. 
Indeed, while CP 55,940 shares the same relative affinities for CB1R and CB2R as THC, it acts as a full, 
and not partial, agonist at these receptors. Moreover, WIN 55,212-2, also a full agonist at both receptors, 
is more selective for CB2R than CB1R, despite still being classified as a non-selective CBRA.  
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This overreliance on such a small pool of drugs becomes problematic when one considers two aspects: 
on the one hand, there is some evidence that different CBRAs may signal through different G-protein 
subtypes, even though they activate the same receptor391 (i.e., they present biased agonism), such that it 
may be the case that the three drugs used may not be capable of evoking the totality of the possible effects 
of CBR activation. On the other hand, different CBRAs may have different interactions with other, ECS- 
or non-ECS related, receptors293, which may lead to different effects.  
In this regard it is interesting that the highly potent CBRA, HU-210, has yet to be tested with regards 
to its effects after chronic adolescent administration. This is the case even though: a) HU-210 is more 
potent, effective and CB1R selective (despite also being a non-selective CBRA) than the aforementioned 
drugs; b) HU-210 has been found in SC products378, and; c) in the few studies that have used this drug, 
results have suggested it may have a rather peculiar effect profile: with both prodepressant-321, and 
antidepressant-like results having been observed213,390.  
As such, the overarching aims of the present work were to characterize the effects of chronic adolescent 
exposure to HU-210 with regards to: a) anxiety-like behavior; b) depressive-like behavior and; c) 
molecular alterations in the ECS. For this, four experiments were performed, each designed to further 
explore and answer questions derived from the results of the previous experiment.  
Because of the results-driven nature of the present work, each experiment constitutes its own separate 
chapter, with a brief explanation of the rationale behind the experiment and the hypotheses contemplated, 
the description of the methods used to perform the experiment, the results obtained, and a brief discussion 
of their possible interpretation. Finally, so as to provide a more global account of the overall project, the 
last chapter of this work constitutes a general discussion of the results obtained across the four experiments, 
including both possible explanations for them, as well as a number of ways in which to test the resulting 
hypotheses, and further understand the results herein obtained. 
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Chapter 2 – Behavioral Methodologiesc 
The assessment of psychological/psychiatric disorders is, by definition, a difficult endeavor, given the 
intrinsically subjective nature of these pathologies394,395. Since this is a problem even in human research, it 
is not surprising that in animal research this obstacle is even greater: for one, while humans can, with 
varying degrees of accuracy, relate their subjective experiences, animals are incapable doing the same, 
thus eliminating the possibility of assessing several critical and defining features of these disorders – such 
as the feelings of worthlessness and guilt, or suicidal ideation, in major depressive disorder314,396. 
Furthermore, it is highly questionable whether less developed animals, such as rodents, are even capable 
of experiencing such complex psychological statesd.  
Thus, animal research into psychiatric disorders is deeply reliant on behavioral testing as a tool and 
method of validation. Indeed, even researchers that focus on the molecular and biological underpinnings 
of psychiatric disorders, or on the study of causes and/or effects of certain alterations found in humans and 
replicable in animals, will – at some point in their research programs – need to validate their findings and 
conclusions with behavioral data, or have it done for them397. As an example, in the context of the topic of 
the present work, had the reports of decreased neurogenesis (one of the most well established biological 
correlates of depressive disorders398,399), in adult animals who underwent chronic adolescent exposure to 
CBRAs284,315,321 not included behavioral tests, the findings could only be taken as replications of human 
correlational data, and not as evidence of causality397. That is, it is only by employing behavioral testing 
that one can determine whether any biological alteration observed is necessary and/or sufficient for the 
development of a disordered state, and not merely a downstream consequence (or, indeed, an irrelevant 
correlate) of the real cause of that state397. 
Importantly, the deep necessity for behavioral testing carries with it the implicit assumption that the 
tests are actually adequate for the job in question. This proposition, however, is not necessarily true (and 
its truth value varies from test to test), and is contingent on numerous factors, both intrinsic to the test 
                                                     
c This chapter is an adapted version of two review papers392,393 published by the author, during the development of the work here 
presented.  
d It is also for these reasons that animal researchers generally use terms such as depressive-like or anxiety-like, instead of depressive 
or anxious, to describe altered behavior, in animal models of these disorders. 
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itself, such as its validity and reliability, and related to its use, such as the adequate implementation of the 
test and interpretation of the data obtained. 
As such, and given that the current work relies heavily on behavioral testing to achieve its proposed 
aims, a description and critical appraisal will be made, of each of the behavioral tests used herein. 
Critically, the tests described and evaluated here are also some of the most widely used behavioral tests in 
depression and anxiety research. 
However, before any evaluation is made, one must first consider the criteria by which this appraisal is 
commonly done: reliability and validity. The former concept is easily definable, translating the idea that 
outcomes obtained with one test must be reproducible across experiments and experimenters, for data and 
conclusions derived from that data to be valid400. For this reason, the importance of reliability, is rarely (if 
ever) contested. Validity, on the other hand, has been a more contentious topic continued of discussion401. 
However, despite this, most animal researchers still use the framework proposed by Willner402 – who based 
it on a similar framework used for psychological testing in humans – where three types of validity are 
contemplated: 
Face validity translates the degree of phenomenological similarity between the model and the disease 
being modeled402. That is, the face validity of a model is evaluated by whether the model presents 
characteristics observed in the disease, without presenting characteristics that are not observed in that same 
disease. This concern, however, has largely abated in recent years, as researchers have focused less on 
developing models that capture the entire presentation of any given disorder, opting instead to develop 
models of specific disease endophenotypes403,404 (such as the impaired stress-coping behavior that is 
measured by the mFST).  
Construct validity refers to how interpretable and homologous the behavior of the model is, in relation 
to the disorder being modelled, both theoretically and empirically402. Thus, the construct validity of a model 
relates how well its theoretical account (e.g., its assumptions about disease nature, etiology and biological 
underpinnings) as well as the empirical observations obtained with it, match those of the disease402. This 
matching between the model and what is being modelled, will define how interpretable any result obtained 
with the model will be, in relation to the disorder in question. 
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Lastly, predictive validity refers to the capacity of the model to correctly identify the effects of 
manipulations (e.g., antidepressant effects of selective serotonin reuptake inhibitors [SSRIs], or the 
prodepressant effects of chronic stress), without also being vulnerable to false positives or false 
negatives402.  
In addition, a distinction must be made between methods of inducing psychiatric disorder-like 
alterations (commonly called animal models), and behavioral tests (also called screening tests). The former 
are used to study the biology and etiology of psychiatric disorders, as well as the effects that possible 
treatments may have on those disorders405. For this reason, models heavily emphasize construct validity as 
an important attribute400. The methods by which disorder-like alterations can be induced are varied, from 
environmental (e.g., CMS406,407) to genetic manipulations (e.g., animals genetically modified to exhibit a 
given behavior pattern408). Moreover, models can, in and of themselves, include measures by which to 
assess disordered behavior, or be combined with screening tests for that purpose.  
Screening tests, on the other hand, were developed with the primary intent of accurately identifying 
new possible treatments, or to evaluate the impact on some previous manipulation on a specific dimension 
of a given disorder405. These tests do this through the quantification of a specific, well-defined and easily 
measurable, behavioral output, that is evoked by the test situation itself405. That is, whereas models can be 
understood to encompass both the dependent and independent variables being studied, screening tests 
encompass only the former409. Furthermore, given the more practical and applied nature of screening tests, 
they are often evaluated primarily in terms of their reliability and predictive validity396,409. 
1 – Elevated Plus Maze  
The EPM410 is one of the most – if not, indeed, the most – widely used screening tests for the assessment 
of anxiety-like behavior. Indeed, this popularity is likely the product of the fact that, not only has the EPM 
been amply validated to work with both rats and mice, but also that it is reliable, as well as easy to use and 
automate (using video tracking software). In addition, these factors are increased by the fact that the test 
has been widely shown to be sensitive to the effects of previous manipulations on anxiety-like behavior411, 
making it useful not just in pre-clinical pharmaceutical research, but also in basic research settings as well. 
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Like the SIT and OFT, the EPM is classified as an unconditioned test of anxiety, given that it relies on 
natural, unconditioned, responses of the animals to some ethological relevant situation for it to work, 
instead of necessitating the development of a conditioned response to some stimulus412. Indeed, this 
reliance on unconditioned responses has led some researchers to suggest that that tests of unconditioned 
anxiety may be better analogues of human anxiety412. 
In the case of the EPM, the underlying ethological assumption driving the test, is that it triggers a 
conflict between two opposing drives. Specifically, it is assumed that by placing the animals in the EPM 
apparatus – a plus-sign shaped apparatus, that is raised off the ground, where two open arms are 
perpendicular to two arms enclosed by tall walls on three sides (fig. 2.1) – one is placing the animal in a 
situation where its natural aversion to open and/or elevated spaces (i.e., the open arms) conflicts with the 
equally strong drive towards exploration and novelty413,414. From this follows that anxiolytic-like 
manipulations will shift this conflict towards exploration, whereas anxiogenic-like manipulations are 
expected to do the opposite.  
The most widely used EPM protocol consists of a single trial, at the beginning of which the animal is 
placed in the center of the maze, facing an open arm, being left to freely explore the apparatus for 5 
minutes414. Many measures can be derived from this test, but the two most common ones are the percentage 
of time spent, and the total number of entries, in the open arms, which are taken as inverse indexes of 
anxiety-like behavior413,414. Additionally, while some reports derive measures of locomotor activity from 
this test – such as the number of areas entered over the duration of the trial – these are not adequately 
validated, and may not be reliable indexes of this parameter414. 
Despite its widespread popularity, the EPM is also the subject of numerous criticisms, concerning both 
its conceptual underpinnings, and its usefulness for pre-clinical therapeutic research. First, the ethological 
assumption that underlies the EPM – i.e., that it triggers a conflict between opposing drives – is not an 
unarguable one. Indeed, one can easily understand the EPM in terms of preference: animals naturally prefer 
enclosed spaces, and, by putting them in the maze apparatus, one is effectively asking them to choose 
between a non-aversive – and maybe even rewarding – stimulus (i.e., the closed arms) and an aversive one 
(i.e., the open arms)415. This is even more pressing when one considers that there is very little to actually 
explore in the EPM: indeed, in other tests relying on the same assumptions as the EPM, such as the OFT, 
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Fig. 2.1 – Schematic representation of the elevated plus maze. The apparatus consists of four arms: two (dark gray) are enclosed on three sides 
by tall walls (thick black lines), providing a dark space for rodents to hide in, while the other two (light gray) are open. At the beginning of the 
trial the animal is placed in the virtually defined (dashed lines) center zone (dotted), facing an open arm. Time spent in the open arms is interpreted 
as being inversely correlated to anxiety. 
the time spent in aversive zones is increased if these regions contain objects unknown to the animals415–417. 
Moreover, simple avoidance of an aversive stimulus is, in itself, rewarding415,418. Thus, one can ask whether 
there is any conflict at all being evoked by the EPM as, for a conflict to exist, there would have to be a 
possibility of both negative and positive outcomes resulting from either of the options available415. 
However, this is not the case, as there is little to no possible negative consequence from staying in the 
closed arms, while the same is not true for the open arms.  
Similarly, one can reasonably question whether avoidance of aversive stimuli necessarily implies the 
existence of an anxiety response415. Indeed, there are plenty of quotidian situations where this is not the 
case, leading to the possibility that EPM-behavior may be interpreted purely in terms of simple avoidance 
without the necessity of anxiety being considered. 
The remaining significant criticism of the EPM focuses on the fact that it seems to be severely lacking 
in predictive validity, in two ways: firstly, this test has been shown to be incapable of differentiating 
changes in anxiety-like behavior, from changes in locomotor activity (such as those induced by 
amphetamine419), leading to misleading results415. Secondly, the fact that the EPM has been repeatedly 
shown to not detect the therapeutic effects of drugs known to be anxiolytic420,421, not only brings into 
question its adequacy in this regard – and in also detecting anxiogenic manipulations – but also casts doubt 
into the construct validity of the test: that is, if drugs known to alter anxiety in humans, have no measurable 
impact on EPM behavior, one can question whether this test is actually measuring anxiety at all420,421. In 
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this line, it has been suggested that tests such as the EPM may only be measuring one of several possible 
types of anxiety422 – a proposition yet untested. 
2 – Open Field Test  
The OFT is one of the oldest behavioral tests still in use, and its popularity rivals that of the EPM. This 
is likely the case because not only is this test extremely simple to perform and automate, but also because, 
in addition to providing a measure of anxiety-like behavior423,424, it also purports to provide a measure of 
locomotor activity424. Indeed, this last reason makes the OFT an extremely common test in depression 
research, being used to control for possible locomotor alterations, that may bias results from assays such 
as FST or tail suspension test (TST)425. 
Similarly to the EPM, the ethological underpinnings of the OFT relate to the natural aversion of rodents 
towards open, brightly lit, spaces, and the conflict between that aversion and the drive towards 
exploration415,421. A marked difference from the EPM, however, comes from the fact that whereas there is 
an almost complete agreement in the protocol used for that test, the way the OFT is performed varies 
almost from researcher to researcher426,427. Indeed, there is marked variation in terms of the open field 
(OF) apparatus itself (e.g., shape, color, texture423,427), in the environmental conditions in which the test is 
run (e.g., light level, background noise423,427), in trial duration (with some as short as 2 minutes and some 
taking a full hour426,427), in the number of trials performed426,427, and, critically, in both the way the data 
is gathered and in how that data is interpreted. Thus, numerous methods can be used to collect data – from 
highly precise light-beam systems, to video-tracking software, to lines marked on the floor of the apparatus 
– with measurement precision varying accordingly. Additionally, the choice of data gathering system will 
necessarily impact what parameters will be measured, further aggravating the fact that the biggest source 
of heterogeneity in this test concerns the parameters measured and their interpretation. Indeed, numerous 
parameters can be, and have been, derived from the OFT and – critically – the interpretations derived from 
the same parameter also frequently vary from researcher to researcher426,427. The upshot of this is that what 
is considered anxiety-like behavior is entirely dependent on the choice of parameters and of interpretation 
made – resulting in a marked decrease in the reliability of any single result, and in an equally marked 
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increase in the difficulty comparing results obtained by different groups. Indeed, this is – in addition to the 
criticism below – one of the main points of contention regarding the OFT. 
While ambulation/locomotion is the most commonly used parameter427, being interpreted either as a 
measure of rodent exploration428, arousal/emotionality429,430, or locomotor activity423, there are two 
critical problems with it: for one it leads to a situation where one can reach markedly different 
interpretations, based on one single outcome (i.e., depending on whether one chooses to see ambulation as 
indexing exploration or emotionality/arousal, increases in this parameter would imply either anxiolysis or 
anxiogenesis, respectively). On the other hand, when intending to use the OFT as a simultaneous 
assessment of anxiety-like behavior and locomotor activity, one faces a critical limitation: decreases or 
increases in ambulation may be a result of sedation or hyperactivity, respectively, independently of the 
existence of any alteration at the level of anxiety424. Thus, and while an adequate experimental design can 
be helpful in offsetting this, the usefulness of this parameter as a measure of anxiety-like behavior, is 
inherently limited by this vulnerability426. 
In addition to ambulation it also common that researchers will quantify ethological parameters (such as 
the number of grooming episodes), the majority of which lack any appreciable validation427. However, due 
to how commonly used they are, two of these parameters – defecation and rearing – deserve a brief 
mention: defecation has been an OFT measure ever since the inception of the test431, and it has been 
demonstrated to be a reliable index of negative affective states432,433 (i.e., increased defecation is tied to 
negative affect). Rearing, however, is a more controversial measure, despite how common its use is. 
Specifically, while decreases and increases in rearing are commonly interpreted as being indicative of 
increased434 or decreased anxiety-like behavior, respectively, there have been reports of increased rearing 
in situations of increased anxiety435 – thus bringing into question the validity of this measure415.  
Thus, if one aims to use the OFT as a measure of anxiety-like behavior, one has to focus not just on 
how the animal behaves, but also in where it performs that behavior436. Specifically, in more recent years, 
researchers have taken to use an approach whereby the open field is divided (virtually or through line 
markings; fig. 2.2) into peripheral (PZ), intermediate (IZ) and central zones (CZ). As such, based on the 
ethological assumption that CZ will be more anxiogenic, due to its open and exposed nature415,421, the 
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quantification of time spent and/or distance travelled in each of the three zones, provides measures that are 
less vulnerable to being biased. Specifically, increased percentage of total time spent and/or distance 
travelled in PZe or CZ – without concomitant alterations in overall locomotor activity – are interpreted as 
being indicative of increased or decreased anxiety-like behavior, respectively424,437.  
Irrespective of how popular the OFT is, several authors have highlighted a need for caution when using 
the test as a measure of anxiety, since it may not be an adequate analogue of pathological anxiety415,424: as 
is the case with the EPM, numerous drugs known to have beneficial effects in the treatment of anxiety 
disorders have no impact on OFT behavior – indeed, some drugs, such as tricyclic antidepressants (TCAs) 
actually lead to anxiogenic-like alterations in this test – thus casting into doubt both the predictive and 
construct validities of this tests421,424. This has led some authors to propose that the type of anxiety evoked 
by tests such as the EPM and the OFT may be more akin to the “everyday” anxiety present under stressful 
or threatening conditions424,438, rather than pathological anxiety that characterizes anxiety disorders, which 
is likely to have different neurobiological substrates439.  
Finally, there is significant criticism of the OFT as a measure of locomotor activity. Specifically, one 
has to make the important, and often ignored, consideration that, if differences in locomotor activity can 
bias the measurement of anxiety-like behavior, then the opposite must also be true: that is, any given 
 
Fig. 2.2 – Schematic representation of the open field test. The open field is virtually divided (dashed lines) into three zones: the peripheral (PZ; 
dark gray), intermediate (IZ; light gray) and central (CZ; dotted) zones. Increased path length and time spent in the more anxiogenic CZ are taken 
to be inversely correlated to anxiety. Additional measures can be quantified, such as the number of transitions between zones and the average 
speed of the animal. 
                                                     
e It is common for the proclivity of rodents for walking close to the walls of the open field to be described as “wall-walking” or 
“thigmotaxis”. This behavior is similar in nature to that observed in the EPM, whereby rodents prefer darker, less exposed areas. 
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pattern of locomotor activity may be as much affected by the purported anxiogenic nature of the testing 
situation, as by any actual locomotor activity altering effects of the manipulation in study426,440. This is 
even more relevant when the OFT consists of a single, short-duration, session, where anxiety is presumed 
to be at its maximum. Furthermore, there seems to be little to no appreciable correlation between OFT and 
home-cage measurements of locomotor activity441, suggesting that either a) anxiety is exerting an 
unappreciated biasing effect on locomotion in the OFT or; b) the OFT is simply inadequate to assess this 
parameter. Indeed, this has led Stanford to suggest that, despite the heightened logistical requirements, 
locomotor activity can only be reliably assessed through home-cage-derived measures441.   
3 – Social Interaction Test  
The SIT was originally developed by File and Hyde442, with the purpose of using ethological valid 
sources of anxiety (e.g., light intensity) and naturally occurring behaviors (social interaction) to assess 
anxiety-like behavior443,444. Curiously, however, subsequent research found that SIT results do not 
correlate to those of other anxiety tests311, suggesting the possibility that it may be measuring a different 
construct altogether, such as social anxiety. Indeed, there is also a legitimate argument for the SIT as 
straddling the line between the assessment of anxiety and of reward-functioning – given that social 
interaction is a highly rewarding stimulus for rodents310 – which would explain the lack of correlation to 
other tests of anxiety. 
In the original, and most used version of the SIT protocol, animals are individually habituated to the 
testing apparatus (commonly the open field), for 10-minutes in the 2 days preceding the testing. On the 
third day, animals are again placed in the apparatus for the same duration, with the sole difference being 
the presence of a previously unknown social partner, of equal sex, age, and weight (so as to avoid 
confounds relating sexual or dominance drives)442. Thus, the primary measure of interest is the time that 
the test animal chooses to spend in active social interaction – defined as “sniffing, following, grooming, 
kicking, mounting, jumping on, wrestling and boxing with, crawling under/over the partner”442 – based on 
the premise that, when exposed to anxiogenic stimuli, rodents will spend less time interacting with novel 
social partners442. As such, in the SIT, increased anxiety-like behavior is signed by a decrease in the time 
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spent in social interaction (in the absence of concomitant decreases in locomotor activity), whereas the 
opposite is true for decreases in anxiety-like behavior (assuming no concomitant increase in locomotor 
activity)443,444. Furthermore, while it is common that researchers will also quantify passive social 
interaction – defined as the animals “sitting or lying with their bodies in contact, but without interacting 
with each other”443 – as well as a number of other ethological parameters, such as grooming episodes445, 
these measures lack validation and may not be reliable. 
Several criticisms can be leveled at the SIT. First, like the EPM and the OFT, there is an inherent 
vulnerability of test measures to being biased by possible locomotor activity-related alterations444. 
However, one can somewhat try to circumvent this limitation by quantifying locomotor activity in both in 
habituation and test sessions, despite the limitations that this type of assessment may have (see section 2). 
Secondly, the rewarding nature of social interaction may be a point of entry for a further confound, since 
manipulations that impact reward function may conceivably be mistaken for alterations in anxiety309,310. 
However, it seems that this possibility has yet to be tested. Thirdly, there is data suggesting that male and 
female rats may respond differently to this test, with females showing reduced effects of arena familiarity 
on time spent in social interaction446. Finally, as is the case with the EPM and OFT, it seems to be the case 
that the SIT has limited predictive validity, given that numerous anxiolytic drugs do not affect test 
performance415,421,444,447. Moreover, this lack of predictive validity also implies a somewhat questionable 
construct validity – although, in the case of this test, given that there is some question has to what the SIT 
is actually assessing, it is not as pressing a concern. 
4 – Modified Forced Swim Test  
The mFST448 is one of the most used screening tests in depression research. This test was derived from 
the previous – and still commonly used – FST, designed by Porsolt et al449. The popularity of both tests 
derives from their ease of use, the low time and resource investment required to perform them450, as well 
as from the fact that they have been demonstrated to be sensitive to the effects of prodepressant 
manipulations451.  
The FST is based on the observation that rodents, when placed in an uncovered water-filled cylinder, 
from which they cannot escape, will initially try to do so, but will – after a short amount of time – stop 
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trying to actively escape, adopting an immobile behavior, keeping only their head above water450. This 
behavior was originally interpreted as being a form of “behavioral despair”452, similar in nature to the 
learned helplessness phenomenon described by Seligman453. In more recent years, however, this 
interpretation has come to be largely replaced by an understanding of the behavior as representing a shift 
from an active, energy-expensive, coping strategy, to a passive one, in an effort to conserve energy454–456. 
While this interpretation is not as directly related to the conception of the FST as an assay of depressive-
like behavior, as that of behavioral despair, it is nonetheless congruent with the endophenotypic approach 
described in the first section of this chapter. Indeed, altered stress coping is one of the paramount symptoms 
of depressive disorders457, and it may be argued that the FST (and, consequently, the mFST) is a test of 
this particular aspect. Moreover, notwithstanding the interpretation chosen, it is expected that 
antidepressant treatments will decrease immobility – defined as the animals “floating passively in the water 
making only those movements necessary to keep their heads above water”452 –  and that prodepressant 
treatments will increase it450. 
The driving force behind the development of the mFST was a limitation of the original test: specifically, 
the FST was shown to have limited predictive validity in identifying SSRIs396,448,458,459 – the first line of 
treatment for depressive disorders460 – as being antidepressants. This led Detke et al.448, to introduce 
several changes to the protocol, while keeping some aspects in common between the two tests: whereas, 
like the FST, the mFST consists of two sessions (lasting 15 and 5 minutes, respectively) on consecutive 
days450 – so as to allow for the development of stable behavioral patterns in the second swim450 – in the 
mFST water depth was increased from 15-18 to 30 cm, so as to avoid animals from being able to touch the 
bottom of the cylinder and using their tails to stabilize themselves, an alteration that led to decreased levels 
of immobile behavior448. Moreover, whereas in the FST the only behavior quantified was immobility, in 
the mFST a distinction is made between two types of active behavior, allowing for the correct identification 
of SSRIs as antidepressant: climbing and swimming448. The former is defined as the animal making “active 
movements with its forepaws in and out of the water, usually directed against the walls”448, while the latter 
is defined as the animal making “active swimming motions, more than necessary to merely maintain its 
head above water”448 (fig. 2.3). Critically, while immobility is expected to be decreased by all 
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antidepressant treatments, the active behaviors are differentially affected by pharmacological 
manipulations, such that drugs targeting 5-HT activity (such as SSRIs) will increase swimming behavior, 
whereas therapeutic drugs targeting NA signaling will selectively increase climbing behavior461. Finally, 
whereas in the FST scoring is done in a continuous, cumulative manner (i.e., the scorer will count the 
number of seconds spent in immobility during the entirety of the trial), for the mFST a time-sampling 
technique was introduced, whereby scoring is performed in 5 second intervals, with each interval being 
classified in terms of the predominant behavior displayed during that interval448. It should, however, be 
noted, that it is still common462 that the continuous cumulative manner of scoring be used in the mFST. 
The primary criticism made of both the FST and mFST concerns the susceptibility of these assays to 
being biased by alterations at the level of locomotor activity. Indeed, when testing pharmacological 
treatments in these assays, the majority of false positives (e.g., amphetamines) and false negatives (e.g., 
benzodiazepines) result from the locomotor hyper and hypoactivity induced by these drugs, 
respectively425,450,459. Thus, when using the FST/mFST it is imperative that one obtain some measure of 
locomotor activity – something that is commonly done via the OFT. Another concern, less relevant context 
of the present work, focuses on the fact that neither version of the test accurately replicates the temporal 
dynamics of antidepressant treatment effects: whereas, in humans, antidepressant drugs have to be 
chronically administered (2-4 weeks) for effects to be appreciable, in these behavioral assays acute 
administration is enough for effects to be detectable450. However, while this is an important criticism, it 
has been somewhat curtailed by findings that not only is there rapid improvement in some symptoms of  
 
Fig. 2.3 – Schematic representation of the modified forced swim test. Animals are placed into a cylinder filled with water to a depth of 30 
centimeters. During the trial three types of behavior are quantified: climbing, swimming and immobility (see definitions in text), with increased 
immobility being interpreted as being indicative of increased depressive-like behavior.  
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depression, in humans being treated with antidepressants463, but also that the acute effectiveness of drugs 
in these tests is only present when large doses are administered, with lower doses requiring prolonged 
administration450. 
5 – Sucrose Preference Test  
Marked reductions in interest or pleasure, referred to as anhedonia, are one of the key diagnostic criteria 
for depressive disorder314. Thus, tests that can reliably assess the effects of manipulations on this parameter 
are critically important for depression research309. However, testing reward functioning in animals is not 
as easy as testing the response to acute inescapable stress: when testing the effectiveness of antidepressant 
manipulations on reward functioning, researchers have to first induce a deficit in this domain by some 
means464, so that a beneficial effect of treatment may then be detected. Indeed, the SPT was developed in 
the context of such a prodepressant manipulation – the CMS paradigm465,466 – based on the finding that 
animals previously exposed to mild but inescapable stress, would, overtime, develop decreases in both 
intake of, and/or preference for, a sucrose solution (generally 0.5-2%), when given a choice between two 
bottles, one of which contained only tap water406,467. Moreover, in contrast with the immediate effects of 
acute antidepressant administration in the mFST, in the SPT a beneficial treatment effect is only observed 
after chronic treatment – more faithfully replicating the temporal dynamics of antidepressant drug 
treatment. 
However, despite co-originating with the CMS paradigm, the SPT has since been shown to work with 
other methods of inducing deficits in reward functioning. Furthermore, from its development onwards, the 
SPT has become almost as heterogeneous as the OFT, in terms of the ways it is performed. Indeed, there 
is variability with regards to where the test is performed (i.e., home-cage466 vs specific housing294), in the 
moment of application (during466 vs. after the induction protocol294), in its duration (e.g., 1468 to 72 
hours294), in the number of trials (e.g., weekly466 vs. single testing294), in whether testing is performed with 
animals isolated466 or not469, in whether a period of habituation to sucrose exists466 before testing or not294, 
in whether animals undergo food/water deprivation before testing466 or not294, in whether calorie-
containing sucrose294 or calorie-free saccharin470 is used for solutions, in the concentration of the 
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sweetened solutions294,466,471, and in whether one measures absolute intake472, relative preference473 or 
both474. Evidently, as is the case with the OFT, this is a significant point of criticism for this test, as it 
hinders the determination of exactly how valid and reliable the SPT, and any results obtained with it, 
actually are. 
Another possible criticism pertains to the fact that the SPT cannot adequately distinguish if altered 
behavior stems from impaired reward sensitivity (i.e., an inability to feel pleasure) or, alternatively, from 
altered reward valuation (i.e., low relevance attributed to pleasurable stimuli, despite intact reward 
sensitivity)475. Indeed, reward functioning is a multidimensional concept309, that encompasses not just the 
consummatory component tested by the SPT, but also anticipatory, motivational and learning components, 
all likely having different neurobiological substrates, which may be differentially affected475.  
Finally, the face validity of the SPT has also been questioned in two ways: first, notwithstanding the 
relevance given to anhedonia as a diagnostic criterion of depressive disorders, there is data suggesting that 
this symptom is only moderately associated with disorder severity476. On the other hand, when humans 
suffering from depressive disorders have been tested in situations similar to the SPT, they did not show 
decreased preference for the sweet solutions477,478. 
6 – Marble Burying Test  
In recent years the marble burying test (MBT479) has been gradually becoming one of the more widely 
used behavioral tests. This is all the more remarkable, when one considers how much discussion there is 
over the nature of this test, and what it is actually measuring. Nevertheless, it is likely that this rise in the 
adoption of the MBT is the consequence of two factors: for one, the MBT is extremely easy to quickly 
perform in large numbers of animals, in a relatively short amount of time, only requiring cheap and easily 
obtainable materials. Secondly, despite the discussion over the construct in study, the MBT has one of the 
best – if not the best – predictive validities of any screening tests for anxiety targeting drugs. Indeed, 
whereas the EPM or OFT are not sensitive to the anxiolytic effects of antidepressant drugs such as SSRIs 
or TCAs, these effects are reliably detected by the MBT420,421. 
The MBT is a more ethically acceptable480,481 version of the older shock-probe test482. In this latter test 
animals are individually placed in a cage where a small electrified probe is present, that will mildly shock 
59 
 
the animal when it touches it482. This shock is theorized to trigger a natural rodent defensive response, 
whereby the animal will defensively push cage bedding towards the probe, effectively burying it482. Indeed, 
in natural settings, rodents are known to displace soil towards predators entering their burrows481. 
Critically, this burying response is expected to be decreased by anxiolytic drugs, and increased by 
anxiogenic drugs481.  
The MBT does away with the use of a shock-probe (hence being more ethically acceptable481), 
ostensively using novelty as the aversive stimulus,483 instead: in this test, animalsf are individually placed 
in a cage with lightly tamped bedding, on top of which a number of objects – generally glass marbles – are 
evenly distributed481. After the end of the 30-minute trial, animals are removed, and the number of marbles 
buried – that is, with at least two thirds of their volume covered (fig. 2.4) – is counted481. As in the case of 
the shock-probe test, anxiolytic treatment is expected to reduce the number of marbles buried, with 
anxiogenic treatment being expected to have the opposite effect.  
Despite the high predictive validity of the MBT420,421, there is significant discussion over what the test 
is actually measuring481,483–485. The idea that marble burying behavior is the product of novelty-induced 
anxiety, would make the MBT a test of unconditioned anxiety, like the EPM, OFT or the SIT. However, 
there is significant indication that this may not be an accurate interpretation: for one, if novelty were the 
anxiety-inducing stimulus, it would be expected that previous habituation to the marbles would lead to a 
decrease in the number of buried marbles – something that is not observed483,485. Secondly, it would be 
reasonable to expect that, if marbles were an aversive stimulus to animals, they would avoid them if given 
the chance. However, this is not the case, as animals seemingly make no special effort to avoid the marbles, 
even when given ample opportunity to do so483,485. Thirdly, while it would also be expectable that animals 
would only bury stimuli that have aversive properties, the fact is that even stimuli with which animals are 
amply familiarized, and which are completely devoid of aversive properties – such as food pellets – are 
readily buried485,486 (although to a slightly lesser extent485). Finally, it would be expectable that performance 
in this test would correlate to performance in other tests of unconditioned anxiety, however this is not the 
case, as MBT outcomes do not correlate to either EPM, OFT or LDBT scores480,485. 
                                                     
f It should be noted that while the MBT is more commonly performed with mice, there is ample evidence that rats also share this 
type of behavior. Indeed, there is some suggestion that defensive burying behavior is more directed, and deliberate, in rats than it 
is in mice. 
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Fig. 2.4 – Representative pictures of the marble burying test. Animals are individually placed into a cage filled with 24, evenly distributed, 
marbles (a). At the conclusion of the 30-minute trial (b), animals are removed, and the number of marbles buried up to two thirds of their volume 
(dashed circles) is scored. Full circles identify marbles left unburied. 
In combination, this has led some researchers to suggest that the MBT might not be a test of anxiety, 
but that it may, instead, be a test of repetitive/compulsive behavior485 – such as that observed in obsessive-
compulsive disorder (OCD). While this would, prima facie, fit with the observations described above, there 
are some significant problems with this assertion: for one, that it would be normal, and not disordered, 
animals showing this type of pathological behavior481,487, makes little sense. Indeed, whereas anxiety has 
adaptive functions in the wild, it is difficult to come up with an adaptive explanation for this type of 
(seemingly purposeless) behavior, especially when directed at innocuous stimuli with which the animals 
have ample experience. Secondly, there is some evidence that some habituation occurs, if several trials are 
performed on the same day485 – which would not be expected to exist for a compulsive behavior. Moreover, 
if compulsion was the underlying drive for burying behavior, it would be reasonable to assume that, when 
given the choice between an environment containing marbles and one without them, animals would choose 
the former. However, previous studies have shown this to not be the case483,485. In addition, the fact that 
the disposition of the marbles reliably alters how many the animals will bury483, does not fit with the idea 
of a compulsion-driven behavior. Thirdly, that MBT behavior does not correlate to EPM, OFT or LDBT 
performance, while unexpected, should not be seen as indication that this test does not index anxiety: 
indeed, not only does the SIT also not correlate to other tests of unconditioned anxiety311, but also there is 
both the possibility that these other tests may not be measuring pathological anxiety, and/or that there may 
be different dimensions of anxiety, one of which is uniquely detected by the MBT422,424,438. Finally, there 
is a question relating to the fact that, while SSRIs, TCAs and other antidepressant drugs are effective in 
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the treatment of OCD, benzodiazepines are not, but nonetheless reliably decrease marble burying483 – thus 
supporting a view of the MBT as a test of anxiety. 
Given that neither interpretation of the MBT fully fits with the observations obtained with it, a third 
possible understanding of the test has been proposed. Specifically, authors have increasingly supported the 
view that marble burying may be merely an accidental byproduct of another, more adaptive, natural rodent 
behavior – that of digging and burrowing in a new environment481,487–489. Indeed, even in the absence of 
any object, rodents will readily exhibit increased digging activity when placed in cages with new substrate, 
likely as a product of both exploration and a drive towards building a burrow in which to hide487. In line 
with this, and despite there being some dissociation between digging behavior and the number of marbles 
buried485, there is a strong correlation between the two490,491. Furthermore, the fact that the number of 
marbles buried, as well as the way in which that burying is done, is much more affected by the density of 
the bedding substrate491, than by any other factor studied to date, supports this line of reasoning. Thus, 
Njung’e & Handley proposed that marble burying may be better understood as a “correlational model for 
detection of anxiolytics rather than an isomorphic model of anxiety”483. Importantly, however, this 
understanding should be widened to also include anxiety-inducing manipulations, as evidence suggests 
that this test is also sensitive to these492. 
Thus, in conclusion, the MBT is still very poorly understood in with regards to what it is actually 
measuring, with all three interpretations being still commonly used. In the present work, however, the 
MBT will be interpreted in terms of anxiety-like behavior, given that not only it may be a more sensitive 
measure of this parameter than either the EPM or the OFT, but also that the evidence with pharmacological 
manipulations420,421 – which are the type of manipulation used in this work – supports this interpretation of 
the test. 
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Chapter 3 - Experiment 1 
1 – Rationale 
As stated in the introduction, no study to date has adequately tested the long-term effects of chronic 
adolescent HU-210 exposure on affective functioning. Indeed, the single report studying this type of 
exposure to this drug321, found it to lead to gender-dependent changes whereby, increased corticosterone 
responses to stress, as well as decreased hippocampal neurogenesis were found exclusively in male animals 
previously treated with HU-210321. Importantly, while neither of these findings can be directly interpreted 
in terms of depressive-like effects, both are suggestive of a possible deleterious effect of HU-210 on 
affective functioning, as both have been reported as correlates of depressive-like phenotypes399,493–495. 
However, the fact that these effects were not found in female animals is somewhat in contradiction with 
the previous literature, in which depressive-like effects are predominantly found in female 
animals268,269,276,280,282,294,308,315. These contradictory findings, in combination with the fact that studies with 
adult animals have reported chronic exposure to high doses (100 µg/kg) HU-210 as having antidepressant-
like effects in the mFST – both 24 hours390, as well as 30-days after the end of drug exposure213 – raise the 
possibility that this drug may be qualitatively different from other CBRAs, with respect to its long-term 
consequences. 
As such, the present experiment was designed to assess whether chronic adolescent exposure to HU-
210 leads to any alteration at the level of adult affective-related behavior. Finding that adult HU-210-
treated animals present impaired performance, in tests of depressive-like behavior (i.e., mFST and SPT) 
would support the notion that chronic adolescent exposure to CBRAs persistently alters affective 
functioning, as well as that the antidepressant-like effects observed in adult animals chronically treated 
with HU-210 are likely an artefact of different testing ages496. Conversely, finding a beneficial effect of 
HU-210 treatment on adult behavioral performance, in line with the aforementioned adult antidepressant 
effects, would suggest that HU-210 is somehow different from other previously studied CBRAs, with 
regards to its impact on affective functioning. 
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2 – Methods 
2.1 – Animals and Ethical Approval 
Twenty-five female Wistar rats, aged 21 days (PND 21) at the time of arrival, were ordered from 
Charles River Laboratories (Lyon, France) and housed in groups of five, in clear plastic cages filled with 
corn cob shavings as bedding material. Animals were kept on a 12-hour light-dark cycle (lights on from 
6:00 to 18:00), with housing facility temperature (22ºC) and humidity (70%) maintained at stable levels. 
Animals were given ad libitum access to both food and water for the entirety of the stay at the animal 
facility, and were provided several environmental enrichments, such as aspen wood blocks, transparent red 
acrylic rat tunnels and cardboard tubes. A period of at least three days of acclimatization was allowed 
before any experimental procedure was performed, and animals were monitored daily for physical and 
behavioral signs of distress and/or suffering. 
All experiments took place during the light phase of the cycle, and were performed in conformity with 
European Community Guidelines (Directive 2010/63/UE), and with the approval of the Committee for 
Ethics in Animal Research of the Faculty of Medicine of the University of Lisbon, as well as of the 
Portuguese Competent Authority for Animal Welfare. 
2.2 – Drugs  
HU-210 ((6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol; Tocris Bioscience, Bristol, UK) was suspended in dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, St. Louis, MO, USA) resulting in a stock solution at 1mM concentration. Aliquots 
were prepared and stored at -20ºC until the day of use. From this stock solution further dilutions were made 
each day, in 0.9% saline, to reach adequate volume.  
2.3 – Drug Administration 
At the time of arrival animals were randomly assigned to be treated with either HU-210 (n=10), vehicle 
solution (VEH; n=10), or to serve as stimulus animals during the SIT (n=5). 
Drug administration (fig. 3.1) was performed according to a slightly modified version of the protocol 
used by Lee et al.321: Daily intraperitoneal (i.p.) injections of HU-210 were administered five days per 
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week for three weeks, in an escalating dosing schedule (PND 35-39: 25μg/kg; PND 42-46: 50μg/kg;  PND 
49-53: 100μg/kg), at a volume of 1 ml/kg. This administration schedule was designed so as to both reduce 
the likelihood of animals developing tolerance to drug effects (shown to develop more rapidly in younger 
rats497), and to mimic the pattern of increasing use reported by humans498. Intermission periods of two days 
between dosing steps were introduced, to both further diminish the likelihood of tolerance development, 
and mimic the pattern of frequent, voluntary and involuntary periods of sobriety. To minimize animal 
stress and facilitate injection procedures, animals were handled for at least three days before the first 
injection took place. 
 
Fig. 3.1 – Timeline of drug administration. 
2.4 – Animal Body Weight  
Animal body weight was monitored for the entirety of the experiment. During the drug administration 
period (PND 35-53) animals were weighed daily. To avoid excessively disturbing them, animals were 
weighed weekly, for the duration of the washout period (PND 54-79). Finally, during the testing period 
(PND 80-91) animals were weighed at the start of each behavioral testing day. 
To calculate weight changes, the starting body weight of each animal at PND 35 was subtracted to its 
body weight at each time-point294, with the resulting values (expressed in grams) being used to compare 
the effects of treatment across groups, at the various stages of the experiment. 
2.5 – Behavioral Testing 
After drug administration ended (PND 53), animals were given a 27-day drug washout period, during 
which they were only disturbed for weekly weighings, and periodic cage cleanings. To reduce animal 
stress, and its possible confounding effect on behavioral performance, rats were individually handled for 
at least five minutes, on the five days preceding the first test (PND 75-79). Furthermore, to diminish the 
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likelihood of stress induced by one test influencing the results of the following, two-day rest periods were 
introduced wherever possible. A chronogram of behavioral testing procedures is described in fig. 3.2. 
On testing days, animals were allowed to acclimatize to the testing room for at least 30 minutes, with 
light and temperature conditions kept stable throughout the testing period. All testing occurred from 8:00 
to 18:00, and animals were always tested in the same order, alternating between groups every five animals 
(i.e. after all animals in one cage had been tested). 
In the EPM and OFT, animal behavior was recorded and analyzed using the SMART®2.5 video-
tracking software (Panlab, Harvard Apparatus, Barcelona, Spain), with the dorsum of the animals as the 
reference point used for tracking. On the other hand, the SIT and mFST were recorded using a Brio 4K 
Pro camera (Logitech, Lausanne, Switzerland), and the resulting videos were analyzed posteriorly, using 
the Solomon Coder beta version 17.03.22 (András Péter, Milan, Italy) behavior coding software. 
 
Fig. 3.2 – Chronogram of behavioral experiments performed. PND, post-natal day; EPM, elevated plus maze; OFT, open field test; SIT, social 
interaction test; mFST, modified forced swim test; SPT, sucrose preference test; MBT, marble burying test; 
2.5.1 – Elevated Plus Maze  
The day after the end of drug washout (PND 80) animals were tested for anxiety-like behavior in the 
EPM413. The testing apparatus consisted of a plus sign shaped platform, elevated 50 cm above the floor, 
composed by two arms with no walls (open arms; 10 x 50 cm), perpendicular to two arms surrounded by 
walls on three sides (closed arms; 10 x 50 x 30 cm). At the start of the trial animals were placed in the 
intersection between the four arms (center zone), facing an open arm, and were allowed to explore the 
entirety of the maze for 5 minutes. The apparatus was virtually divided into three zones corresponding to 
the open and closed arms, as well as the center zone. After trial conclusion, animals were returned to their 
home cages, and the test apparatus was cleaned with a 30% ethanol solution, to erase olfactory clues. 
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Two measures were derived from this test: time spent in the open arms (expressed as a percentage of 
total trial duration) and the number entries in the open arms, both of which were taken as inverse indexes 
of anxiety-like behavior. 
2.5.2 – Open Field Test  
Two OFT trials were performed, as part of the habituation period for the SIT, with different measures 
being derived from each session. 
The first trial took place on PND 80, after all animals had been exposed to the EPM. Because first 
exposure to the OF is likely to be more anxiogenic and, thus, a less reliable measure of locomotor activity 
(see chapter 2), this session was scored for parameters relating to anxiety. Specifically, permanence time 
and distance traveled in CZ (expressed as percentages of total time, and distance traveled, respectively) 
were taken as inverse indexes of anxiety. 
The second trial took place on PND 81, and was assessed for parameters related to locomotor activity. 
Specifically, average velocity (expressed as cm/s) and total distance traveled (expressed as cm), were taken 
as indexes of this parameter. 
Testing apparatus consisted of an empty square box (60 x 60 x 40 cm), virtually divided into three 
concentric square zones, respectively designated PZ, IZ, and CZ. In both trials animals were individually 
placed into the center of the OF, and allowed to freely explore for 10 minutes, after which they were 
returned to their home cage. The test apparatus was cleaned with a 30% ethanol solution, between each 
animal, to erase olfactory clues. 
2.5.3 – Social Interaction Test  
The SIT444 consists of two phases, spread over three consecutive days. The habituation phase consists 
of two 10-minute sessions, over the first two days, during which animals are allowed to explore the testing 
apparatus (in this case the OF) by themselves. This period coincided with the aforementioned OFT trials, 
and was also performed for the five stimulus animals. The test phase occurred on the third day (PND 82), 
and also had a duration of 10 minutes. However, in the test session, when subjects were placed in the OF, 
another, sex- and weight-matched, rat (the stimulus rat) was already present.  
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The primary measure derived from the SIT is the time spent in active social interaction, being expressed 
as the amount of time (expressed in seconds) that the test rat spent “sniffing, following, grooming, kicking, 
mounting, jumping on, wrestling and boxing with, crawling under/over the partner”444. 
To avoid the possible confounding effects of fatigue, each of the five stimulus animals was never used 
in two consecutive trials and as much as time as possible was given between each trial using each individual 
stimulus rat. 
2.5.4 – Modified Forced Swim Test  
The mFST was performed as previously described276. Briefly, a single 15-minute session was performed 
on PND 85, during which animals were individually placed into a glass cylinder (20 cm diameter), filled 
with water maintained at a temperature of 23-25 ºC, to a depth of 30 cm. After each trial ended, animals 
were removed from the water, dried with a warm towel, and placed under a heating lamp for a period of at 
least 15 minutes. Additionally, to avoid possible confounding effects, resulting from scent clues, water was 
replaced between animals.  
Three behaviors were scored during the duration of the trial: a) climbing, defined as the rat making 
“active movements with it forepaws in and out of water, usually directed against the walls448”; b) 
swimming, defined as the rat making “active swimming motions, more than necessary to merely maintain 
its head above water448”, which included sporadic bouts of diving and; c) immobility, defined as the rat 
making “only the movements necessary to keep its head above water448”. Scoring was done by quantifying 
the total time spent in each behavior (expressed in seconds) during the trial. 
2.5.5 – Sucrose Preference Test  
The SPT was performed as previously described294. Briefly, from PNDs 88 to 91, animals were 
individually housed, and allowed ad libitum access to food, as well as to two drinking bottles: one 
containing tap water, and the other containing a 2% sucrose solution. Bottles were weighed at the start of 
the test, and every 24 hours afterwards, for the duration of the testing period. To avoid preference or 
learning effects, the position of the bottles was changed daily, after weighing.  
Several parameters were derived from this test: for each time-point (24, 48, and 72h) sucrose intake 
(normalized for body weight at the start of the test [PND 88]; expressed in milliliters per gram of body 
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weight) and sucrose preference (expressed as the percentage of sucrose solution consumed relative to total 
fluid intakeg, whereby values over 50% indicate preference for sucrose, and values below 50% indicate 
preference for water) were calculated. Additionally, average daily sucrose intake (expressed in 
milliliters/gram of body weight) and sucrose preferenceh, over the testing period, were also calculated.  
2.5.6 – Marble Burying Test  
The MBT was performed on PND 91, after the final SPT measurements had been obtained. The test 
was performed as previously described499, with some slight modifications: briefly, five full size cages were 
filled with at least 5cm of lightly tamped bedding material, providing a flat surface. Six evenly spaced 
rows, of four light blue ceramic marbles, were placed on top of the bedding, totaling 24 marbles per cage.  
Each animal was placed in a cage, and left undisturbed for 30 minutes. After that time animals were 
removed and returned to their original group-housing conditions. Between trials visible fecal boli were 
removed, bedding was again tamped flat, and marbles were cleaned with a 30% ethanol solution. The 
dependent variable of interest was the number of marbles buried, which was taken as an index of anxiety-
like behavior. Marbles were considered buried if more than two thirds of their volume was covered.  
2.6 – Statistical Analysis 
All comparisons were made between treatment groups, with statistical significance level (α) established 
at .05. Outliers were detected using the method outlined by Tukey500: observations found to be outside of 
the interval defined by the first quartile (Q1) - 1.5 interquartile range (IQR) and the third quartile (Q3) + 
1.5 IQR, for that group, were considered outliers and subsequently removed from analysis. After outlier 
removal, and before any analysis was conducted, data from each group was tested for normality, using the 
Shapiro-Wilk normality test. Where no violations of normality were found (p > .05), data was analyzed 
through two-tailed unpaired Student’s t tests, with the Holm-Sidak correction for multiple comparisons 
when appropriate, with data expressed as means ± standard error of mean (SEM). Where the assumption 
of normality was not met, data were analyzed with Mann-Whitney U test, with data being expressed as 
                                                     
g                    =  
              
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medians and IQR, or range (minimum and maximum values), wherever appropriate. All statistical analyses 
were performed using GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA).  
3 – Results 
3.1 – Animal Body Weight 
To assess the effect of chronic adolescent exposure to CBRAs on body weight, the weight changes were 
measured relative to baseline weight at PND 35. At this initial measurement moment, a significant 
difference in absolute weighr was found between groups, such that HU-210-assigned animals were found 
to weight significantly more than their VEH-assigned counterparts (VEH = 134 ± 2.34, HU-210 = 143 ± 
2.23; t(18) = 2.63, p = .017; fig. 3.3).  
 
Fig. 3.3 – Animal weights at the start of the experiment (PND 35). HU-210-treated animals weighed significantly more than controls. Data are 
expressed as mean ± SEM (n=10); * p < .05, unpaired Student’s t-test. 
On PND 36, and in every time-point during the drug administration period, HU-210-treated animals 
showed statistically significant decreases in weight-gain, in comparison to controls (all p ≤ .001). These 
differences in weight-gain persisted during part of the drug washout period, being significant at PND 59 
(p ≤ .001) and PND 66 (p < .05). However, from PND 73 onwards, the effect of HU-210 treatment ceased 
to be significant, with both groups showing similar weight-gain for the remainder of the experiment (fig. 
3.4). 
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Fig. 3.4 – Change in animal weight relative to PND 35 over the course of the experiment. HU-210 treatment significantly reduced the amount 
of weight animals gained during the drug administration period (PND 35-53), and for 15 days after its end (PND 63). This effect did not, however, 
persist for the remainder of the experiment. Data are expressed as mean ± SEM (n=10); * p < .05, *** p ≤ .001, unpaired Student’s t-test with 
Holm-Sidak correction. 
3.2 – Behavioral Testing 
3.2.1 – Elevated Plus Maze 
To assess the effects of chronic exposure to HU-210 during the adolescent period, on anxiety-like 
behavior, the percentage of time spent in, and the number of entries in the open arms of the EPM were 
compared between groups. No differences were found for either the first (VEH = 25.7 ± 5.29, HU-210 = 
32.5 ± 5.92; t(18) = 0.852, p = .406; fig. 3.5a) or second (VEH = 9.5, range: 4 – 16, HU-210 = 8.5, range: 
0 – 15; U = 48, p = .896; fig. 3.5b) parameters. 
 
Fig. 3.5 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the EPM after a 27-day drug 
washout. The EPM was performed on PND 80 with two measures of anxiety being derived from the 5-minute trial, neither of which showed 
significant differences: percentage of time spent in the open arms (data expressed mean ± SEM [n=10]; unpaired Student’s t-test) (a); and the total 
number of open arm entries (data expressed as median and IQR [n=10]; Mann-Whitney U test) (b).  
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3.2.2 – Open Field Test 
3.2.2.1 – Anxiety-like Behavior  
To complement the measures obtained with the EPM, the first OFT trial was scored for measures 
relating to anxiety-like behavior. In this test HU-210-treated rats showed no statistically significant 
difference from controls, regarding either the percentage of time spent (VEH = 3.18 ± 0.726, HU-210 = 4 
± 0.885; t(18) = 0.716, p = .483), or of distance traveled (VEH = 4.37 ± 0.748, HU-210 = 3.9 ± 0.885; t(18) 
= 0.551, p = .589) in the CZ of the OF (fig. 3.6). 
 
Fig. 3.6 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the OFT after a 27-day drug 
washout. Two measures of anxiety were derived from the first OFT trial (PND 80): percentage of time spent (a), and distance traveled (b) in CZ. 
Neither parameter showed significant differences across groups. Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
3.2.2.2 – Locomotor Activity  
To determine if chronic HU-210 exposure during the adolescent period induced persistent alterations 
in locomotor activity, the second OFT trial was scored for measures relating to this parameter. Specifically, 
no significant differences between groups were found for either average velocity (VEH = 14.2 ± 1.1, HU-
210 = 13.5 ± 0.84; t(17) = 0.542, p = .595; fig. 3.7a), or total distance traveled (VEH = 1588 ± 79.8, HU-
210 = 1454 ± 206; t(18) = 0.609, p = .550; fig. 3.7b) during this trial. 
 
Fig. 3.7 – Chronic adolescent exposure to HU-210 did not persistently alter adult locomotor activity in the OFT after a 27-day drug 
washout. Two measures of locomotor activity were derived from the second OFT trial (PND 81): average velocity (a), and total distance traveled 
(b) during the entire 10-minute trial. Neither parameter showed significant differences across groups. Data are expressed as mean ± SEM (n=9-
10); unpaired Student’s t-test. Reported group sizes exclude significant outliers (see section 2.6). 
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3.2.3 – Social Interaction Test 
Given that previous studies have shown that chronic adolescent exposure to CBRAs induces long-
lasting deficits in social interaction, animals were assessed for performance in the SIT. Comparison of the 
time spent in active social interaction during the test, showed that HU-210-treated rats did not significantly 
differ from VEH-treated animals, in this parameter (VEH = 91.4 ± 7.93, HU-210 = 108 ± 13.8; t(18) = 
1.04, p = .311; fig. 3.8).  
 
Fig. 3.8 – Chronic adolescent exposure to HU-210 did not persistently alter adult social behavior in the SIT after a 27-day drug washout. 
Total time spent in active social interaction was quantified during the 10-minute SIT (PND 82). No difference was found between treatment groups 
Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
3.2.4 – Modified Forced Swim Test 
To assess the possibility that chronic HU-210 treatment might lead to persistent alterations at the level 
of stress-coping behavior, animals were tested in the mFST (fig. 3.9). No differences between groups were 
found in either the time spent swimming (VEH = 165 ± 6.74, HU-210 = 179 ± 13.1; t(15) = 0.903, p = 
.381), or in immobility (VEH = 625 ± 9.75, HU-210 = 630 ± 13.4; t(15) = 0.37, p = .763). However, a 
significant decrease, in the time spent engaging in climbing behavior, was found for HU-210-treated rats, 
in comparison to controls (VEH = 110 ± 5.05, HU-210 = 90.8 ± 6.31; t(15) = 2.32, p = .035). 
 
Fig. 3.9 – Chronic adolescent exposure to HU-210 led to persistent alterations of stress-coping behavior in the mFST after a 27-day drug 
washout. Three parameters were assessed during the 15-minute FST trial (PND 85): climbing, swimming and immobility. While treatment groups 
did not differ, regarding the time spent swimming or in immobility, HU-210-treated animals spent significantly less time climbing than with 
controls. Data are expressed as mean ± SEM (n=8-9); * p < .05, unpaired Student’s t-test. Reported group sizes exclude significant outliers (see 
section 2.6). 
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3.2.5 – Sucrose Preference Test 
To assess the impact of chronic adolescent exposure to HU-210 on adult reward functioning, animals 
were tested in a 3-day version of the SPT. No differences were found between groups regarding sucrose 
intake (fig. 3.10a) at either day 1 (VEH = 0.49 ± 0.09, HU-210 = 0.67 ± 0.06; t(18) = 1.69, p = .109), day 
2 (VEH = 0.49 ± 0.12, HU-210 = 0.62 ± 0.06; t(18) = 1, p = .329) or day 3 (VEH = 0.38 ± 0.09, HU-210 
= 0.51 ± 0.06; t(18) = 1.22, p = .237). Likewise, no differences were found between groups regarding their 
average daily sucrose intake, over the duration of the experiment (VEH = 0.45 ± 0.09, HU-210 = 0.6 ± 
0.05; t(18) = 1.38, p = .183; fig 3.10b). 
 
Fig. 3.10 – Chronic adolescent exposure to HU-210 did not persistently alter sucrose intake after a 27-day drug washout. Sucrose intake 
was assessed daily (a) and was averaged at the end of the testing period (b), with no differences being found between groups for either parameter. 
Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
Similarly, comparison of the relative preference for the sucrose solution over water, found no 
differences between groups at either day 1 (VEH = 94.3 ± 0.98, HU-210 = 95.4 ± 0.36; t(16) = 1.19, p = 
.251; fig. 3.11a), day 2 (VEH = 94.4, range: 78.2 - 97.2, HU-210 = 95.3, range: 93.6 – 97.2; U = 30, p = 
.673; fig. 3.11b), day 3 (VEH = 96.3, range: 87.8 – 98.1, HU-210 = 95.7, range: 90 – 98; U = 33.5, p = 
.589; fig. 3.11c), or over the testing period (VEH = 96.3, range: 89 – 97.6, HU-210 = 95.9, range: 93.5 – 
96.7; U = 34, p = .633; fig. 3.11d). 
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Fig. 3.11 – Chronic adolescent exposure to HU-210 did not persistently alter relative preference for sucrose after a 27-day drug washout. 
Sucrose preference was assessed daily (a-c) and was averaged for the entirety of the testing period (d), with no differences being found between 
groups for either parameter. Data are expressed as either mean ± SEM (a; n=8-10; unpaired Student’s t-test) or median and IQR ranges (b-d; n=8-
10; Mann-Whitney U test). Reported group sizes exclude significant outliers (see section 2.6). 
3.2.6 – Marble Burying Test 
Given that the MBT seems, in certain circumstances (see chapter 2), to be a more sensitive assay of 
anxiety-like behavior, animals were tested in this paradigm, to provide a complementary measure to the 
EPM and the OFT. Analysis of the number of marbles buried during the 30-minute trial showed no 
statistically significant difference between groups (VEH = 15.8 ± 1.43, HU-210 = 16.1 ± 1.46; t(18) = 
0.147, p = .885; fig. 3.12).  
 
Fig. 3.12 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the MBT after a 27-day drug 
washout. The number of marbles buried during the 30-minute MBT trial (PND 91) was quantified. No difference was found between groups 
regarding this measure. Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
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4 – Discussion 
The aim of this experiment was to determine whether chronic adolescent treatment with the highly 
potent, non-selective, CBRA, HU-210, would lead to persistent alterations in anxiety- and depressive-like 
behavior at adulthood. While changes in these domains have been repeatedly reported in the literature, as 
a result of adolescent treatment with other CBRAs, there is a scarcity of data regarding the effects of HU-
210. Moreover, the few studies that have studied the effects of prolonged HU-210 exposure, have done so 
with adult– and not adolescent – animals, and found beneficial effects of treatment213,390. Thus, this is the 
first study explicitly examining the long-term effects of chronic adolescent exposure to this drug, on 
affective functioning. 
Similarly to what has been previously reported for other CBRAs, administration of HU-210 led to a 
significant decrease in weight gain. This decrease was highly significant during the drug administration 
period, and remained detectable for 15 days after the end of that period. While this effect is contrary to the 
widely reported stimulatory effects of CBRAs on food intake in humans501,502, it has long been reported to 
exist in rodents294,300,333,503–505, for reasons not yet entirely clear. Moreover, it should be noted that this effect 
occurred despite the fact that, at the outset of the experiment, the HU-210 assigned group weighed 
significantly more than the VEH-treated group – a difference that is entirely attributable to chance, given 
that animals were randomly assigned to a treatment condition before their first weighing. 
Regarding alterations at the level of anxiety-like behavior, HU-210 treatment did not affect behavior in 
the EPM, with groups showing similar numbers of entries, and percentages of time spent in, the open arms 
of the maze. Likewise, in the first OFT trial, HU-210-treated animals did not significantly differ from 
VEH-treated controls in either the time spent, or the distance travelled, in the CZ of the OF. While in 
accordance with results from other studies with adolescent animals, this lack of anxiogenic effect in the 
OFT is in disagreement with previous work done with HU-210 in adult animals493. This disparity may, 
however, stem from differences between the two studies regarding the age, strain and sex of the animals, 
as well as in the dose used. Additionally, in the MBT, the number of marbles buried did not significantly 
differ as a function of treatment group. Thus, in line with previous animal work with other 
CBRAs210,264,265,271,272,290,294–298, these results suggest that chronic adolescent exposure to increasing doses 
of HU-210 does not alter the expression of anxiety-like behavior at adulthood. 
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Contrarily to what was expected based on previous reports261,262,273,274,276,282,308,506, HU-210-treated 
animals were found to behave similarly to controls in the SIT. That is, whereas chronic adolescent exposure 
to other CBRAs has been found to lead to decreases in adult social interaction, this type of exposure to 
HU-210 does not seem to persistently impact social behavior. 
Regarding the assessment of depressive-like behavior, when animals were tested in the mFST, the 
pattern of results obtained differed from those previously reported210,276,280,282,294,308. Contrarily to what was 
expected, based on previous reports, HU-210 treatment did not significantly decrease the time the animals 
spent either swimming or in immobility. There was, however, a significant decrease in the time animals 
spent engaging in climbing behavior. Importantly, given that no differences between groups were 
observed, in either the average velocity, or the total distance traveled in the second OFT trial, it can be 
argued (but see Stanford et al.426) that the differences in the mFST were not the product of alterations at 
the level of locomotor activity. As such, while there is some suggestion that HU-210 treatment may lead 
to impaired adult stress-coping, this alteration was not accompanied by increased immobility (the primary 
parameter by which depressive-like behavior is identified in the mFST) and, thus, cannot be fully 
interpreted in terms of depressive-like behavior. Moreover, these results are in disagreement with the 
results reported after adult chronic exposure to HU-210213,390, thus providing some support to the notion 
that the timing of exposure to CBRAs is crucial in determining its long-term consequences496. 
Supporting the results obtained with the mFST, HU-210-treated rats tested in the SPT did not 
significantly differ from controls with regards to either their intake of, or their relative preference for, the 
sucrose solution over water, both at each time point and over the entirety of the test. Thus, these results 
suggest that chronic adolescent exposure to HU-210 does not induce persistent deleterious effects on adult 
reward functioning, contrary to what is the case with other CBRAs210,276,294,296.  
As such, the combined results of the mFST and the SPT can be taken as suggesting that, unlike that 
previously reported with other CBRAs, chronic exposure to HU-210 during the adolescent period, does 
not increase adult depressive-like behavior.  
There are several, non-mutually exclusive, possible explanations for the discrepancy between the results 
obtained here, and those previously reported in the literature. The first possibility relates to differences 
regarding both animal strain and experimental protocol. Whereas most studies on the adult effects of 
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chronic adolescent exposure to CBRAs – and indeed all studies using the mFST for this purpose – have 
used Sprague-Dawley rats210,268,269,282,282,294,294,315, in the present experiment the subjects were of the Wistar 
strain. This possible confound is further aggravated by the fact that the experimental protocol used 
introduced several modifications – such as the duration of each dose step and the 2-day periods between 
dose steps – to the protocol used by Lee et al.321, which is itself a modified version of the original (and 
most widely used) protocol, designed by Rubino et al294. In addition, the time course of the present 
experiment was somewhat different, regarding the onset of drug administration, the length of drug washout, 
and the onset of behavioral testing. 
Secondly, there is a possibility that the lack of alterations might not itself be a result of HU-210 
ineffectiveness in triggering them, but that drug effects may have been masked by an inadvertent 
deleterious effect of the vehicle solution. Due to the concentration at which the stock solution was 
suspended (1mM), an inordinate amount of DMSO was injected in both control and HU-210 animals, to 
reach appropriate drug dosages. Indeed, DMSO represented 6, 13 and 26% of the total volume injected 
daily, during the first, second and third drug steps, respectively. Given that prolonged exposure to DMSO 
has been demonstrated to both be toxic at similar concentrations507–509, and to induce behavioral 
alterations510, it might be the case that the performance of VEH-treated rats was negatively impacted by 
this exposure. As such, it may be possible that HU-210 treatment did negatively impact the behavior of 
animals, but that this effect was masked by the equally deleterious effects of toxic levels of DMSO. If this 
were to be the case, it would imply that the few differences found between groups (e.g., the decreased 
climbing in the mFST) likely result from the additive effect of HU-210 over that of DMSO. 
The third possible explanation for these differences relates to the possibility that, notwithstanding the 
problems previously described, HU-210 might be qualitatively different from the previously studied 
CBRAs. Indeed, HU-210 differs from THC by being a full, rather than partial, agonist, and from CP 55,940 
and WIN 55,212-2 by having different relative affinities for CB1R and CB2R. Furthermore, it is also 
possible that these disparate effects may not be mediated by activity at either CBR, and instead result from 
non-specific activity at other receptors.  
As such, and since multiple possible explanations exist for the unexpected outcomes observed, a second 
experiment was designed to control for as many of these confounds as possible.  
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Chapter 4 – Experiment 2 
1 – Rationale 
Given the numerous confounds that may have led to the unexpected results obtained in experiment 1, 
the present experiment was designed in such a way as to minimize as many of those confounds as possible. 
Thus, changes were made regarding the strain of animal used, the number of injections administered to the 
animals, the duration of the drug administration period, and of each dose step, so as to replicate the protocol 
that is most commonly used to study the effects of chronic adolescent CBRA exposure 294. In addition, to 
diminish the possibility that the vehicle solution may have had a deleterious effect on behavioral 
performance, a new stock solution of HU-210 was made, at a more appropriate concentration (see section 
2.3 below), thus reducing the amount of DMSO administered per injection. 
As such, if results show a prodepressant-like effect as a result of HU-210 treatment in these conditions, 
these would both be in line with previous reports210,261,262,273,274,276,278,280,282,294,296,306,308,315,506 and, given that 
similar exposure has been found to be antidepressant in adult animals213,390, would further support the 
notion that the timing of exposure is critical with regards to the consequences of chronic cannabinoid 
use496. Conversely, if results are still found to be discrepant with those previously reported for other 
CBRAs, it would make it more likely that these discrepancies do, in fact, stem from differences in the 
pharmacology of HU-210, and not from experimental confounds. Moreover, should an antidepressant-like 
effect be found, this would – in addition to the previous point – also imply that this differential effect of 
HU-210 vis a vis other CBRAs, is age-independent, having also been found in adult animals. 
2 – Methods 
2.1 – Animals and Ethical Approval 
Twenty-five female Sprague-Dawley rats, aged 21 days (PND 21) at the time of arrival, were ordered 
from Charles River Laboratories (Calco, Italy) and were housed in groups of five, in the same conditions 
as described in experiment 1. A period of at least three days of acclimatization was allowed before any 
experimental procedure was performed, and animals were monitored daily for physical and behavioral 
signs of distress and/or suffering. 
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All experiments took place during the light phase of the cycle, and were performed in conformity with 
European Community Guidelines (Directive 2010/63/UE), and with the approval of the Committee for 
Ethics in Animal Research of the Faculty of Medicine of the University of Lisbon, as well as of the 
Portuguese Competent Authority for Animal Welfare. 
2.2 – Drugs  
HU-210 (Tocris Bioscience, Bristol, UK) was suspended in DMSO (Sigma-Aldrich, St. Louis, MO, 
USA) resulting in a stock solution at 25mM concentration. Aliquots were prepared and stored at -20ºC 
until the day of use. From this stock solution further dilutions were made each day in 0.9% saline, to reach 
adequate volume. 
2.3 – Drug Administration 
At the time of arrival animals were randomly assigned to be treated with either HU-210 (n=10) or 
vehicle solution (VEH; n=10), or to serve as stimulus animals during the SIT (n=5). 
Drug administration (fig. 4.1) was performed according the protocol described by Rubino et al.294: 
Intraperitoneal (i.p.) injections of HU-210 were administered twice-daily for 11 consecutive days, in an 
escalating dosing schedule (PND 35-37: 25μg/kg; PND 38-41: 50μg/kg; PND 42-45: 100μg/kg), at a 
volume of 1 ml/kg. At no point during the administration period did DMSO amount exceed 1% of the total 
injected volume. Injections were administered early in the morning and in the afternoon, with at least 6 
hours between them. To minimize animal stress and facilitate injection procedures, animals were handled 
for at least three days before the first injection took place.  
 
Fig. 4.1 – Timeline of drug administration. 
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2.4 – Animal Body Weight  
Animal body weight was monitored during the entirety of the experiment. During the drug 
administration period (PND 35-45) animals were weighed daily. To avoid excessively disturbing them, 
animals were weighed weekly, for the duration of the washout period (PND 46-75). Finally, during the 
testing period (PND 76-87) animals were weighed at the start of each testing day. 
To calculate weight changes, the starting body weight of each animal at PND 28 was subtracted to its 
body weight at each time-point, with the resulting values (expressed in grams) being used to compare the 
effects of treatment across groups, at the various stages of the experiment. 
2.5 – Behavioral Testing 
After drug administration period ended (PND 45), animals were given a 30-day drug washout period, 
during which they were only disturbed for weekly weighings and periodic cage cleanings. To reduce 
animal stress, and its possible confounding effect on behavioral performance, rats were individually 
handled for at least five minutes, on the five days preceding the first test (PND 71-75). Furthermore, to 
diminish the likelihood of stress induced by one test influencing the results of the following, two-day rest 
periods were introduced wherever possible. A chronogram of behavioral testing procedures is described in 
fig. 4.2. 
Behavioral testing and analysis procedures were in every way similar to those described in experiment 1.  
 
Fig. 4.2 – Chronogram of behavioral experiments performed. PND, post-natal day; EPM, elevated plus maze; OFT, open field test; SIT, social 
interaction test; mFST, forced swim test; SPT, sucrose preference test; MBT, marble burying test; 
2.5.1 – Elevated Plus Maze  
The EPM was performed and scored similarly to that described in experiment 1, with the sole difference 
being that testing occurred on PND 76. 
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2.5.2 – Open Field Test  
The OFT was performed and scored similarly to that described in experiment 1, with the sole difference 
being that the first trial (scored for anxiety-related parameters) took place on PND 76, and the second trial 
(scored for locomotor activity related parameters) occurred on PND 77. 
2.5.3 – Social Interaction Test  
The SIT was performed and scored similarly to that described in experiment 1, with the sole difference 
being that habituation trials (i.e., the OFT) took place on PND 76-77, and the test trial occurred on PND 
78. 
2.5.4 – Modified Forced Swim Test  
The mFST was performed and scored similarly to that described in experiment 1, with the sole 
difference being that testing occurred on PND 81. 
2.5.5 – Sucrose Preference Test  
The SPT was performed and scored similarly to that described in experiment 1, with the sole difference 
being that the testing occurred from PNDs 84 to PND 87. 
2.5.6 – Marble Burying Test  
The MBT was performed and scored similarly to that described in experiment 1, with the sole difference 
being that the testing occurred on PND 87. 
2.6 – Western Blot 
2.6.1 – Animal Sacrifice and Tissue Removal 
On the day following the last behavioral test (PND 88), animals were individually anesthetized with 
isoflurane, until the paw-pinch reflex was no longer present, and then decapitated. 
Brains were quickly removed and dissected in ice-cold artificial cerebral-spinal fluid (aCSF; 124 mM 
NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26mM NaHCO3, 1mM MgSO4, 2mM CaCL2, and 10 mM D-
glucose, pH 7.4) previously oxygenated with 95% O2 and 5% CO2. Three regions of interest were isolated 
82 
 
in each animal: the hippocampus, striatum and PFC. After isolation, tissue samples were immediately 
frozen in liquid nitrogen and stored at -80 ºC, until the moment of tissue processing. 
2.6.2 – Sample Preparation and Protein Quantification 
Whole tissue homogenates were prepared from the samples. For this, samples were homogenized 
through sonication, in Radio Immunoprecipitation Assay (RIPA) lysis buffer (1% Nonidet® P40 Substitute 
[NP40], 5 mM ethylenediamine tetraacetic acid [EDTA], 0.1% sodium dodecyl sulfate [SDS], 1% Triton 
X-100, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5), containing one cOmplete™ Mini protease inhibitor 
cocktail tablet (Roche, Penzberg, Germany) for each 10 ml, and the phosphatase inhibitors 10mM NaF and 
5mM Na3VO4. Samples were then centrifuged at 16000g for 10 minutes at 4ºC, after which the supernatant 
was collected.  
Sample protein quantification was performed through the Lowry assay, using the DC™ Protein Assay 
kit (Bio-Rad Laboratories, CA, USA), with bovine serum albumin (BSA) as the standard. Absorbance was 
read at 750 nm, using an Infinite M200 multimode microplate reader (Tecan, Männedorf, Switzerland). 
After quantification, samples were prepared for Western Blot, by adding 6x sample buffer (36% glycerol, 
12% SDS, 0.015% bromophenol blue, 720 mM dithiothreitol, 420 mM Tris pH 6.8) and denaturing them 
(10 min, 95ºC), and were then stored at -20ºC until the day of use. 
Proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 
in running buffer (0.1% SDS, 192 mM glycine, 25 mM Tris pH 8.3), at constant voltage (80-120 V), using 
12% acrylamide/bis-acrylamide resolving gels (0.1% SDS, 0.1% ammonium persulfate [APS], 0.04% 
N,N,N',N'-tetramethylethane-1,2-diamine [TEMED], 375 mM Tris pH 8.8), and 5% acrylamide/bis-
acrylamide stacking gels (0.1% SDS, 0.1% APS, 0.1% TEMED, 125 mM Tris pH 6.8), with 1.5 mm 
thickness. NZYColour Protein Marker II (NZYTech, Lisbon, Portugal) was used as a protein molecular 
weight marker. Proteins were transferred to polyvinylidene difluoride (PVDF; GE Healthcare, 
Buckinghamshire, UK) membranes, previously soaked in methanol, in transfer buffer (10% methanol, 192 
mM glycine, 25 mM Tris pH 8.3), at constant amperage (350 mA, 90 min). After transfer, membranes 
were first soaked in Ponceau S solution (0.1% Ponceau S, 5% acetic acid) to confirm transference efficacy, 
and were then blocked with 3% BSA in Tris buffered saline with Tween® 20 (TBS-T; 200 nM Tris base, 
1.5 M NaCl, 0.1% Tween® 20, pH 7.6) for 1 hour at room temperature (RT). Membranes were washed 
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with TBS-T (3 x 5 min), before incubation with primary antibodies (overnight at 4ºC), and again before 
incubation with secondary antibodies (1 hour at RT). All primary (table 4.1) and secondary antibodies 
(table 4.2) were prepared in the blocking solution. Between incubations with different primary antibodies, 
membranes were placed in a stripping solution (200 mM glycine, 0.1% SDS, 1% Tween® 20, 50% acetic 
acid glacial, pH 2.2) for 25 minutes at RT, and washed with TBS-T (3 x 5 min) to remove the previous 
antibodies.  
After incubation with secondary antibodies, membranes were revealed with Western Lightning ECL 
ProTM (PerkinElmer, MA, USA), and immunorreactivity was visualized using a Chemidoc XRS+ system 
(Bio-Rad Laboratories, CA, USA) with Image LabTM software (Bio-Rad Laboratories, CA, USA). Band 
intensities were quantified via digital densitometry, through ImageJ 1.52a software (National Institutes of 
Health, Bethesda, MD, USA), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band intensities 
as a loading control. Data were normalized for the VEH-treated group, and are expressed as protein levels 
(% of VEH). 
2.7 – Statistical Analysis 
Statistical analysis was in every way similar to that described in experiment 1. All data are expressed 
as means ± SEM, or as medians and IQR, or range (minimum and maximum values, wherever appropriate), 
depending on whether parametric or non-parametric tests were used, respectively. All statistical analyses 
were performed using GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA).  
Table 4.1 – Primary antibodies used for Western Blot. 
Antibody Dilution Supplier Reference (RRID) 
Guinea pig polyclonal anti-CB1R 1:500 
Frontier Institute Co. Ltd 
(Hokkaido, Japan) 
CB1-GP-Af530 
(AB_2571593) 
Mouse monoclonal anti-GAPDH 1:5000 
Ambion®  
(CA, USA) 
AM4300 
(AB_437392) 
Table 4.2 – Secondary antibodies used for Western Blot. 
Antibody Dilution Supplier Reference (RRID) 
Goat polyclonal anti-guinea pig IgG-HRP 1:10000 
Santa Cruz Biotechnology 
(TX, USA) 
sc-2438 
(AB_650492) 
Goat polyclonal anti-mouse IgG-HRP 1:10000 
Bio-Rad Laboratories 
(CA, USA ) 
172-1011 
(AB_11125936) 
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3 – Results 
3.1 – Animal Body Weight 
Baseline animal body weight, measured on PND 28, was found to not be significantly different between 
treatment conditions (VEH = 89.7 ± 3.25, HU-210 = 96.1 ± 2.85; t(18) = 1.48, p = .156). Moreover, change 
in weight, relative to PND 28, on the first day of injections (PND 35) was also found to not differ between 
groups. However, after the first day of injections, and for the duration of the drug administration period 
(PND 36-45), a highly significant (p ≤ .01, PNDs 36, 41 and 42; p ≤ .001 PNDs 37-40 and 43-45) difference 
in weight change was found between groups, whereby HU-210-treated animals gained significantly less 
weight than the VEH-treated group (fig. 4.3). This effect persisted for the next 15 days, being detectable 
at PND 53 (p ≤ .001) and PND 60 (p ≤ .01), after which it ceased to be significant, remaining so for the 
rest of the experiment.  
 
Fig. 4.3 – Change in animal weight relative to PND 28 over the course of the experiment. HU-210 treatment significantly reduced the amount 
of weight animals gained during the drug administration period (PNDs 36-45), and for 15 days after its end (PND 60). This effect did not, however, 
persist for the remainder of the experiment. Data are expressed as mean ± SEM (n=10); ** p ≤ .01, *** p ≤ .001, unpaired Student’s t-test with 
Holm-Sidak correction. 
3.2 – Behavioral Testing 
3.2.1 – Elevated Plus Maze  
To determine whether chronic adolescent HU-210 exposure – following the protocol described by 
Rubino et al.294 – impacted adult anxiety-like behavior, both the percentage of time spent, and the number 
of entries, in the open arms of the EPM were compared across groups. As was the case in the first 
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experiment, the HU-210 group did not significantly differ from VEH-treated controls in either the first 
(VEH = 42.5 ± 5.06, HU-210 = 39.1 ± 5.26; t(17) = 0.463, p = .650; fig. 4.4a) or second parameters (VEH 
= 10.8 ± 0.48, HU-210 = 9.13 ± 0.69; t(12) = 1.89, p = .084; fig. 4.4b).  
 
Fig. 4.4 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the EPM after a 30-day drug 
washout. The EPM was performed on PND 76 with two measures of anxiety being derived from the 5-minute trial, neither of which showed 
significant differences: percentage of time spent in the open arms (a), and the total number of open arm entries (b). Data are expressed as means 
± SEM (n=6-10); unpaired Student’s t-test. Reported group sizes exclude significant outliers (see section 2.7). 
3.2.2 – Open Field Test 
3.2.2.1 – Anxiety-like Behavior  
Similarly to what was done on the first experiment, the first OFT trial was assessed for parameters 
relating to anxiety-like behavior. Specifically, as had been found in experiment 1, no differences between 
groups were found, regarding either the percentage of time spent (VEH = 7.58 ± 1.32, HU-210 = 6.58 ± 
0.851; t(18) = 0.642, p = .529), or distance traveled (VEH = 8.31 ± 1.08, HU-210 = 8.93 ± 0.92; t(18) = 
0.436, p = .668) in the OFT CZ (fig. 4.5).  
 
Fig. 4.5 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the OFT after a 30-day drug 
washout. Two measures of anxiety were derived from the first OFT trial (PND 76): percentage of time spent (a), and distance traveled (b) in CZ. 
Neither parameter showed significant differences across groups. Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
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3.2.2.2 – Locomotor Activity  
To determine if the differences between the experimental protocols used in the first and second 
experiments reflected themselves on the locomotor activity of the animals, the second OFT trial was scored 
for measures relating to this parameter. Specifically, no changes were found in either average velocity 
(VEH = 14.9 ± 0.81, HU-210 = 14 ± 0.75; t(18) = 0.864, p = .399; fig. 4.6a) or total distance traveled (VEH 
= 1752 ± 77.2, HU-210 = 1748 ± 118; t(18) = 0.027, p = .979; fig. 4.6b), over the 10-minute trial, as a 
function of treatment.  
 
Fig. 4.6 – Chronic adolescent exposure to HU-210 did not persistently alter adult locomotor activity in the OFT after a 30-day drug 
washout. Two measures of locomotor activity were derived from the second OFT trial (PND 77): average velocity (a), and total distance traveled 
(b) during the duration of the 10-minute trial. Neither parameter showed significant differences across groups. Data are expressed as mean ± SEM 
(n=10); unpaired Student’s t-test. 
3.2.3 – Social Interaction Test 
Since previous studies using the protocol described by Rubino et al.294, have found that chronic 
adolescent exposure to CBRAs induces deficits in SIT performance261,262,273,274,276,282,308,506, and these 
deficits were not found in experiment 1, animals in this experiment were also tested in this assay. 
Contrary to previous studies, and in accordance with the outcomes observed in experiment 1, HU-210-
treated animals behaved similarly to controls, with no significant differences in social interaction time 
being found (VEH = 106 ± 7.43, HU-210 = 122 ± 9.62; t(18) = 1.28, p = .217; fig. 4.7).  
. 
Fig. 4.7 – Chronic adolescent exposure to HU-210 did not persistently alter adult social behavior in the SIT after a 30-day drug washout. 
Total time spent in active social interaction was quantified during the 10-minute SIT (PND 78). No difference was found between treatment 
groups. Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
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3.2.4 – Modified Forced Swim Test 
In the first experiment some alterations were found that suggested impairments at the level of stress-
coping/depressive-like behavior. However, the classical sign of depressive-like behavior in the mFST – 
increases in the time spent in immobility448 – was not observed. Thus, in the present experiment the mFST 
was also performed, with the intent of trying to determine if the mixed results previously obtained derived 
from the confounds identified in experiment 1. 
Surprisingly, no differences were found between treatment groups (fig. 4.8), regarding either the time 
the animals spent climbing (VEH = 104 ± 9.49, HU-210 = 100 ± 10.9; t(17) = 0.266, p = .793), swimming 
(VEH = 162 ± 6.67, HU-210 = 142 ± 17.5; t(17) = 1.08, p = .297), or in immobility (VEH = 634 ± 11.8, 
HU-210 = 658 ± 17; t(17) = 1.14, p = .27). 
 
Fig. 4.8 – Chronic adolescent exposure to HU-210 did not persistently alter stress-coping behavior in the mFST after a 30-day drug 
washout. Three parameters were assessed during the 15-minute FST trial (PND 81): climbing, swimming and immobility. Treatment groups did 
not differ regarding the time spent any of these behaviors. Data are expressed as mean ± SEM (n=9-10); unpaired Student’s t-test. Reported group 
sizes exclude significant outliers (see section 2.7). 
3.2.5 – Sucrose Preference Test 
Because no alterations were found in SPT behavior in the first experiment, despite previous studies of 
chronic adolescent CBRA exposure having found them210,276,294,296, the test was again performed in the 
present experiment. 
Similar to the results obtained in experiment 1, comparisons of sucrose intake between groups (fig. 
4.9a), found no group differences for days 1 (VEH = 0.36 ± 0.06, HU-210 = 0.32 ± 0.05; t(18) = 0.542, p 
= .595), 2 (VEH = 0.25 ± 0.04, HU-210 = 0.23 ± 0.05; t(18) = 0.359, p = .724) or 3 (VEH = 0.27 ± 0.05, 
HU-210 = 0.24 ± 0.05; t(18) = 0.358, p = .725). Furthermore, the average daily sucrose intake over the 
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duration of the experiment was also not significantly different between groups (VEH = 0.29 ± 0.05, HU-
210 = 0.26 ± 0.05; t(18) = 0.447, p = .660; fig. 4.9b). 
 
Fig. 4.9 – Chronic adolescent exposure to HU-210 did not persistently alter sucrose intake after a 30-day drug washout. Sucrose intake was 
assessed daily (a) and was averaged at the end of the testing period (b), with no differences being found between groups for either parameter. Data 
are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
Likewise, comparison of the preference for the sucrose solution over water at each time point (fig. 
4.10a), also found no differences between groups for either the first (VEH = 90.6, range: 80 – 95.7, HU-
210 = 90.3, range: 73.7 – 95.3; U = 44.5, p = .699), second (VEH = 90.1, range: 74.4 – 92.9, HU-210 = 
86.1, range: 23.5 – 97.2; U = 39, p = .661) or third days (VEH = 88.1, range: 67.5 – 92.4, HU-210 = 87.2, 
range: 78.1 – 93.4; U = 35, p = .942). Additionally, the averaged preference over the duration of the 
experiment (VEH = 89.9, range: 78.3 – 93.2, HU-210 = 87.3, range: 45.7 – 93.8; U = 36, p = .497; fig. 
4.10b) also did not significantly differ across groups.   
 
Fig. 4.10 – Chronic adolescent exposure to HU-210 did not persistently alter relative preference for sucrose after a 30-day drug washout. 
Sucrose preference was assessed daily (a) and was averaged for the entirety of the testing period (b), with no differences being found between 
groups for either parameter. Data are expressed as medians and IQR (n=8-10); Mann-Whitney U test. Reported group sizes exclude significant 
outliers (see section 2.7). 
3.2.6 – Marble Burying Test 
As was the case in the first experiment, the MBT was also performed in this group of animals, as a 
novel measure of the effect of chronic adolescent CBRA exposure, on adult anxiety-like behavior. 
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Similarly to the results previously obtained, the number of marbles buried did not significantly differ 
between groups (VEH = 15.4 ± 1.34, HU-210 = 13.5 ± 1.39; t(18) = 0.982, p = .339; fig. 4.11), in line with 
the behavioral outcomes observed in both the EPM and the first OFT trial. 
 
Fig. 4.11 – Chronic adolescent exposure to HU-210 did not persistently alter adult anxiety-like behavior in the MBT after a 30-day drug 
washout. The number of marbles buried during the 30-minute MBT trial (PND 87) was quantified. No difference was found between groups 
regarding this measure. Data are expressed as mean ± SEM (n=10); unpaired Student’s t-test. 
3.3 – Western Blot 
To assess the possible alterations that chronic adolescent exposure to HU-210 may induce on the 
expression of CB1R, the protein levels of these receptors were quantified, in three brain regions known to 
be involved in affective functioning. 
Congruently with the lack of behavioral alterations, no changes in CB1R protein levels were found in 
either the hippocampus (VEH = 100 ± 23.7, HU-210 = 84.5 ± 14.8; t(8) = 0.582, p = .579; fig. 4.12a), the 
striatum (VEH = 100 ± 29.7, HU-210 = 71.7 ± 6.74; t(8) = 0.929, p = .380; fig. 4.12b), or the PFC (VEH 
= 100 ± 27.8, HU-210 = 110 ± 19.6; t(8) = 0.3, p = .772; fig. 4.12c) of HU-210-treated rats.  
   
Fig. 4.12 – Chronic adolescent exposure to HU-210 did not persistently alter CB1R protein levels, in regions involved in affective 
functioning, after a 30-day drug washout. The levels of CB1R protein were quantified through Western Blot. No differences were found in either 
the hippocampus (a), the striatum (b) or the PFC (c) in the HU-210-treated group. Data are expressed as mean ± SEM (n=4-5); unpaired Student’s 
t-test. Reported group sizes exclude significant outliers (see section 2.7). 
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4 – Discussion 
Given that the pattern of results obtained in experiment 1 was markedly different from that previously 
described210,261,262,273,274,276,278,280,282,294,296,306,308,315,506, and that these differences may have stemmed from 
experimental confounds –  such as the possible deleterious effects of high volumes of DMSO – the present 
experiment was designed with the intent of minimizing as many of those confounds as possible. Moreover, 
to further increase the comparability of results, drug administration was performed in accordance with the 
most widely described experimental protocol in this literature294. It is, thus, surprising, that the results 
obtained in these conditions are not only at even greater odds, with what had been described for other 
CBRAs210,261,262,273,274,276,278,280,282,294,296,306,308,315,506, than those obtained in the first experiment, but also with 
those reported for adult HU-210 exposure213,390.  
As in experiment 1, HU-210 treatment led to a marked decrease of weight-gain during the 
administration period. Moreover, replicating those results, this effect persisted for 15 days after HU-210 
administration ended, but it ceased to be noticeable at the following time-points. The fact that not only did 
this effect manifest in both experiments, but did so in the exact same timeframes, strongly suggests that it 
is, indeed, a product of HU-210 activity and not an artifact of experimental confounds. 
Regarding anxiety-like behavior, the results obtained are in accordance with both those of the first 
experiment, and those of the previous literature in adolescent animals. That is, chronic adolescent HU-210 
exposure did not alter the performance of the animals in either the EPM, the OFT, or the MBT. Moreover, 
whereas the first two tests had been previously used in this literature, the MBT had yet not been performed. 
As such, while the results from this test in the first experiment could have stemmed from the 
aforementioned experimental confounds, the results we present here – by being free of those 
methodological concerns – represent a novel finding in this field. Additionally, the fact that, as in 
experiment 1, but unlike in previous adult work with this drug493, decreases in the time spent in the CZ of 
the OF were not found, may be explained either by differences in age, strain and sex of the animals, as 
well as in the doses used. 
In alignment with the results from experiment 1, but in stark contrast with those of the literature, no 
effects were found at the level of social interaction behavior, as indexed by the SIT, after chronic adolescent 
exposure to HU-210. Whereas these results could have been attributed to experimental confounds in the 
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first experiment, in the present case this is not a likely explanation, thus showing a clear difference between 
HU-210 and other CBRAs. 
Similarly, analysis of the mFST data revealed no differences in the performance of HU-210-treated 
animals. This result differs from that of the first experiment, where a significant decrease in climbing 
behavior was found. Moreover it is also in contrast with the previous literature where increases in 
immobility and decreases in swimming behavior are generally detected276,280,282,308,315. Thus, it seems to be 
the case that chronic adolescent exposure to HU-210 does not lead to lasting deficits at the level of stress-
coping behavior. Furthermore, these results are also at odds with those reported for chronic adult HU-210 
exposure, where antidepressant-like effects were found213,390. While this discrepancy may stem from a 
difference in the drug dosages used – indeed, Jiang et al.213 exclusively administered the highest dose used 
in the present experiment (100 µg/kg) – it may also be indicative of the well-established age-dependent 
differences in long-term CBRA exposure effects496. However, there is a possibility that mFST performance 
may have been contaminated by behavioral instability during the trial. Indeed, despite the fact that most of 
the previous studies on the affective impact of chronic adolescent exposure to HU-210 only perform one 
15-minute mFST session276,280,282,308,315, it is advised that, when doing this test with rats, two sessions be 
performed – with only the second session, lasting 5 minutes, being recorded and scored – so as to obtain 
more stable patterns of behavior450. 
Notwithstanding this caveat, and in accordance with the unaltered behavior in the mFST, SPT 
performance was also unchanged as a result of treatment. These results, while in line with those of 
previously obtained in experiment 1, are at odds with those of the literature, where chronic adolescent 
CBRA exposure has been shown to lead to impairments in reward functioning, as indexed by this 
test210,276,294,296. As such, the combined results of the mFST and SPT, can be interpreted as meaning that – 
at least when following the most widely used experimental protocol – chronic adolescent exposure to HU-
210 does not lead to lasting increases in adult depressive-like behavior, in contrast with adolescent 
exposure to other CBRAs, such as THC.  
Congruently with the lack of behavioral effects, western blotting revealed no differences in the levels 
of CB1R protein in either the hippocampus, the striatum or PFC of HU-210-treated animals. While these 
results are in agreement with two other studies using the same technique328,330, two caveats must be made: 
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for one, studies using western blotting have also found chronic adolescent CBRA exposure to lead to 
increases in hippocampal329, striatal328, or prefrontal282 CB1R protein levels. Secondly, while the lack of 
differences observed here is in accordance with the results obtained by most studies using 
immunohistochemistry/fluorescence techniques305,312,320,322, it must be noted that a large number of reports 
employing radioligand binding assays – a much more reliable and precise methodology for the 
quantification of receptor levels – found chronic adolescent CBRA treatment to lead to significant 
decreases in CB1R density280,282,291,294,333,334. One possible reason for this difference may be that, while 
radioligand assays commonly use only the membranar fraction of the tissue homogenate, here this was not 
done: thus, it may have been the case that chronic adolescent exposure to HU-210 did lead to a decrease 
in the number of membrane bound receptors through internalization, but that this was not detected, as these 
internalized receptors would still be detectable in the whole-tissue homogenate.  
Overall, the results obtained in this experiment are highly surprising, given both the structural 
similarity, increased potency, efficacy and affinity for CB1R, of HU-210 in comparison to THC373,375,511. 
This is even more the case, when taking into account that these finding differ not only from the literature 
with other drugs, but, indeed, from those obtained in experiment 1. That is, whereas a decrease in climbing 
behavior was found in experiment 1, no alteration was observed in any mFST parameter in the present 
experiment. On the one hand, the latter disparities can largely be attributed to differences in the 
experimental protocol and animal strain used, as well as to the possible deleterious effects of high quantities 
of DMSO. On the other hand, given that the only detectable difference, between the present study and 
those previously published, concerns the drug used, the most likely explanation for these discrepant results 
is that HU-210 may be qualitatively different from other CBRAs. If this were the case, this qualitative 
difference may stem from differences in affinity, potency and/or efficacy for CBRs373,375,511, from 
differences in the intracellular signaling mechanisms triggered by CBR activation376,391, from 
pharmacokinetic differences, or from non-specific interactions with other pharmacological targets293. 
Confirmation of these differences would be an important finding for studies employing CBRAs, given that 
it is fairly commonplace that researchers will look at results obtained with different drugs as being 
comparable, when it might actually be the case that they present specific characteristics that not only 
prevent that comparison, but actually lead to the formation of erroneous assumptions about drug effects. 
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This is even more relevant when considering the high degree of structural similarity between HU-210 and 
THC: that is, if two highly similar drugs lead to such different results, it is not unreasonable to expect that 
this would be even more the case for structurally dissimilar drugs, such as WIN 55,212-2 or CP 55,940. 
Notwithstanding the specific mechanistic differences of HU-210 vis a vis other CBRAs, a question 
remains as to how those differences manifest themselves, to lead to the lack of alterations observed. 
Specifically, two options present themselves as the most likely: for one HU-210 may have no long-term 
effects because whatever changes it is capable of inducing, then revert to normality during the washout 
period. Alternatively, this lack of effects may indicate that – despite HU-210 having a demonstrable impact 
on adult stress-coping behavior – adolescent animals are partially or completely resistant to the affective 
effects of HU-210.  
To disentangle these two possibilities, and given that adult studies have shown HU-210 treatment to 
also be antidepressant immediately after the end of the administration period, a third experiment was 
designed, where the mFST was performed on the day following the end of the drug administration period. 
Furthermore, to control for the possible confounding effect of behavioral instability in the first mFST 
session, the full two-session protocol was used. 
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Chapter 5 – Experiment 3 
1 – Rationale 
In the previous experiment, chronic adolescent exposure to increasing doses of HU-210, was found to 
have no lasting behavioral effects, in contrast with what has been described for both adolescent exposure 
to other CBRAs210,261,262,273,274,276,278,280,282,294,296,306,308,506, and adult exposure to HU-210213,390. That is, the 
results of experiment 2 suggest that not only is HU-210 different from other CBRAs in its long-term effects, 
but also that – as is the case for these other drugs496 – these effects are age-dependent. Both of these aspects 
present interesting lines of inquiry, and the present experiment was designed in such a way as to allow 
their simultaneous exploration. 
To this end, a new batch of animals was treated with the exact same administration protocol used in 
experiment 2, but – instead of allowing them to washout from the drugs – was tested for alterations in the 
stress-coping dimension of depressive-like behavior (i.e., in the mFST), on the two days immediately 
following the last drug exposure.  
On the one hand, by replicating, in adolescent animals, previous work done with adults exposed to HU-
210390, the results of this experiment allow for further exploration of the role that age of exposure plays in 
the long-term consequences of drug treatment. On the other hand, by testing adolescent animals 
immediately after drug exposure ceased, this experiment helps to elucidate how the putative 
pharmacological differences, between HU-210 and other CBRAs may lead to the lack of adult effects 
observed in experiment 2. Furthermore, by using the full 2-session mFST protocol, the present experiment 
additionally allows for the determination of the role that behavioral instability during the first mFST 
session450 may have played, in the outcomes observed in this test, in experiments 1 and 2. 
As such, several different sets of hypothesis exist for this experiment. First, when considering the 
apparent differences between HU-210 and other CBRAs, finding altered mFST behavior in the present 
experiment would support the notion that HU-210 is capable of inducing behavioral alterations, but that 
these cease to be detectable after a period of abstinence. Conversely, finding no such effects, even in the 
immediate aftermath of drug administration, would support the notion that – in contrast to what is the case 
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for other CBRAs – adolescent animals are less vulnerable to HU-210-induced behavioral 
alterations260,496,512,513. 
Secondly, when considering the role that age may play in the effects of prolonged HU-210 exposure, if 
animals are found to behave similarly to that described by Morrish et al.390 in adult rats (i.e., antidepressant-
like behavior), this would suggest that – at least in the immediate – HU-210 affects behavior in an age-
independent manner. By contrast, finding a different outcome, such as no behavioral alteration or an 
increase in depressive-like behavior, would suggest that prolonged exposure to HU-210 leads to different 
outcomes, depending on the age at which takes place, as is the case for other CBRAs496. 
Finally, if behavioral instability in the first mFST session is capable of biasing results, then it would be 
expected that, here, performance in the first and second test sessions would be noticeably different. On the 
contrary, if performance is found to be similar, this would imply that behavioral instability likely had a 
limited (if at all relevant) effect on mFST outcomes reported not just in experiments 1 and 2, but also in 
previous studies. 
2 – Methods 
2.1 – Animals and Ethical Approval 
Twenty female Sprague-Dawley rats, aged 21 days (PND 21) at the time of arrival, were ordered from 
Charles River Laboratories (Calco, Italy) and were housed in groups of five, in the same conditions as 
described in experiment 2. A period of at least three days of acclimatization was allowed before any 
experimental procedure was performed, and animals were monitored daily for physical and behavioral 
signs of distress and/or suffering. 
All experiments took place during the light phase of the cycle, and were performed in conformity with 
European Community Guidelines (Directive 2010/63/UE), and with the approval of the Committee for 
Ethics in Animal Research of the Faculty of Medicine of the University of Lisbon, as well as of the 
Portuguese Competent Authority for Animal Welfare. 
2.2 – Drugs  
The same HU-210 stock solution at 25mM concentration used in experiment 2 was used here. From 
this stock solution further dilutions were made each day, in 0.9% saline, to reach adequate volume.  
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2.3 – Drug Administration 
At the time of arrival animals were randomly assigned to be treated with either HU-210 (n=10) or 
vehicle solution (VEH; n=10). 
Drug administration (fig. 5.1) was performed in every way similarly to that described for experiment 2. 
 
Fig. 5.1 – Chronogram of drug administration and behavioral testing. mFST, modified forced swim; OFT, open field test. 
2.4 – Animal Body Weight  
Animal body weight was monitored during the entirety of the experiment, with animals being weighed 
daily for the full period of drug administration and behavioral testing (PND 35-47). 
To calculate weight changes, the starting weight of each animal (PND 28) was subtracted to its weight 
at each time-point, with the resulting values (expressed in grams) being used to compare the effects of 
treatment on weight-gain across groups. 
2.5 – Behavioral Testing 
The day after drug administration period ended (PND 46), animals were subjected to behavioral testing, 
so as to assess the immediate effects of chronic adolescent HU-210 exposure. Because any effect that might 
exist was judged likely to disappear over time, only two tests were used: the OFT, as a measure of 
locomotor activity and anxiety-like behavior, and the mFST, with the full two session protocol (fig. 5.1). 
The mFST was chosen because it is the most widely used animal behavioral test of depressive-like 
behavior, whereas the OFT was chosen to control for possible locomotor alterations that could bias the 
results of the former test. 
 To reduce animal stress and its possible confounding effect on behavioral performance, rats were 
individually handled for at least five minutes, on the five days preceding the first test (PND 41-45), after 
morning injections. 
Behavioral testing and analysis procedures were in every way similar to those described in experiment 1.  
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2.5.1 - Open Field Test  
Unlike in the previous experiments, only a single 10-minute OFT trial was performed, taking place on 
PND 46. This trial was scored for parameters relating to both anxiety and locomotor activity. Specifically, 
for the assessment of anxiety, permanence time and distance traveled in CZ (expressed as percentages of 
total time, and distance travelled, respectively) were taken as inverse indexes of anxiety. For the assessment 
of locomotor activity, average velocity (expressed as cm/s) and total distance traveled (expressed as cm), 
were taken as indexes of this parameter. 
2.5.2 – Modified Forced Swim Test  
The mFST was performed as described for experiments 1 and 2, with the difference that a second 5-
minute session was also performed, 24 hours after the first 15-minute trial. Both sessions were recorded 
and scored for the parameters previously described. The first session was performed on PND 46, 
immediately after the end of the OFT, and the second session was performed on PND 47. 
2.6 – Western Blot 
2.6.1 – Animal Sacrifice and Tissue Removal 
On the day following the last behavioral test (PND 48), animals were individually anesthetized with 
isoflurane, until the paw-pinch reflex was no longer detectable and were then decapitated.  
The process of brain removal and dissection, as well as the regions isolated, and the way samples were 
stored, were in every way similar to that described in experiment 2. 
2.6.2 – Sample Preparation and Protein Quantification 
Sample preparation, protein quantification and western blotting procedures were in every way similar 
to those described in experiment 2.  
2.7 – Statistical Analysis 
Statistical analysis was in every way similar to that described in experiments 1 and 2. Additionally, to 
assess the degree of correlation between behavior in the first and second mFST sessions, Pearson 
correlation (r) coefficients were obtained.  
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All data are expressed as means ± SEM, or as medians and IQR, or range (minimum and maximum 
values, wherever appropriate), depending on whether parametric or non-parametric tests were used, 
respectively. All statistical analyses were performed using GraphPad Prism 7 software (GraphPad 
Software, San Diego, CA, USA).  
3 – Results 
3.1 – Animal Body Weight 
Animal body weight was measured at PND 28, at which point no difference was found between animals 
assigned to be treated with vehicle solution and those assigned to HU-210 treatment (VEH = 124 ± 1.42, 
HU-210 = 125 ± 1.26; t(18) = 0.528, p = .604). On the first day of the drug administration period (PND 
35) there was no significant difference between treatment groups, regarding weight-gain relative to PND 
28. However, 24 hours after the first injection (PND 36), and for the remainder of the experiment, the HU-
210-treated animals showed highly significant decreases (all p ≤ .01) in weight gain in comparison to VEH-
treated controls (fig. 5.2). 
 
Fig. 5.2 – Change in animal weight relative to PND 28 over the course of the experiment. HU-210 treatment significantly reduced the amount 
of weight animals gained during the entirety of the experiment. Data are expressed as mean ± SEM (n=10); ** p ≤ .01, *** p ≤ .001, unpaired 
Student’s t-test with Holm-Sidak correction. 
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3.2 – Behavioral Testing 
3.2.1 – Open Field Test 
Given that only one OFT session was performed, animals were simultaneously assessed for anxiety- 
and locomotor activity-related parameters. Regarding the former (fig 5.3a), no differences were found 
between groups in either the time spent (VEH = 5.48 ± 0.69, HU = 5.16 ± 0.79; t(18) = 0.32, p = .753), or 
distance traveled (VEH = 7.13 ± 0.6, HU-210 = 7.77 ± 0.57; t(18) = 0.776, p = .448) in the CZ. Similarly, 
when assessing the average velocity of the animals during the trial, no differences were found (VEH = 
22.3 ± 1.13, HU-210 = 22.9 ± 1.03; t(18) = 0.395, p = .697; fig. 5.3b). However, a tendency was observed 
in the total distance traveled during the 10-minute trial, whereby HU-210-treated rats showed a slight, 
statistically non-significant, decrease in this parameter (VEH = 3931 ± 165, HU-210 = 3523 ± 107; t(17) 
= 2.02, p = .059; fig. 5.3c). 
 
Fig. 5.3 – Chronic adolescent exposure to HU-210 did not alter anxiety-like behavior or locomotor activity in the OFT 24-hours after the 
last drug administration. Two measures of anxiety (a) were derived from the OFT: percentage of time spent and distance traveled in CZ, neither 
of which showed significant differences across groups. Likewise, average velocity (b) and total distance traveled (c) during the entirety of the trial 
did not differ between groups, despite a tendency towards a difference in the latter parameter. Data are expressed as mean ± SEM (n=9-10); 
unpaired Student’s t-test. Reported group sizes exclude significant outliers (see section 2.7). 
3.2.2 – Modified Forced Swim Test 
The first mFST session, lasting 15-minutes (fig. 5.4a), was performed on PND 46, immediately after 
the end of the OFT. Analysis revealed statistically significant differences between groups, whereby HU-
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210-treated animals spent more time climbing (VEH = 104 ± 8.87, HU-210 = 264 ± 22.5; t(17) = 6.34, p 
≤ .001), and less time immobile (VEH = 553 ± 17.3, HU-210 = 423 ± 26; t(17) = 4.08, p ≤ .001), than their 
VEH-treated counterparts, with no differences in terms of swimming behavior (VEH = 256 ± 10.2, HU-
210 = 213 ± 19.8; t(17) = 1.85, p = .082). 
To confirm that these results did not stem from instability in behavioral patterns, in the first mFST 
session, a second, 5-minute session (fig. 5.4b) was performed on the next day (PND 47). Here, the results 
were essentially the same: HU-210-treated animals spent significantly more time climbing (VEH = 51.2 ± 
6.97, HU-210 = 144 ± 19.7; t(17) = 4.24, p ≤ .001), and significantly less time immobile (VEH = 165 ± 
12.8, HU-210 = 104 ± 17.8; t(18) = 2.81, p = .012), than VEH-treated controls, without showing differences 
in the time spent swimming (VEH = 66.1 ± 4.72, HU-210 = 52.8 ± 7.7; t(17) = 1.43, p = .17). 
Additionally, as a way to further determine whether performance in the first mFST session was the 
product of behavioral instability, a correlational analysis was performed for each of the behaviors, in both 
sessions, for each animal. This analysis revealed strong (r = 0.60 – 0.79) to very strong (r = 0.80 – 1) 
significant correlations, between the levels of climbing (r = 0.872, n = 19, p ≤ .001), swimming (r = 0.608, 
n = 18, p = .007) and immobility (r = 0.786, n = 19, p ≤ .001) in the first and second sessions. 
 
Fig. 5.4 – Chronic adolescent exposure to HU-210 altered stress-coping behavior in the mFST 24-hours after the last drug administration. 
Three parameters were assessed during the 15-minute (a) and 5-minute (b) mFST sessions: climbing, swimming and immobility. In both sessions 
HU-210-treated animals presented increased levels of climbing behavior and concomitantly decreased levels of immobility, in relation to controls. 
Data are expressed as mean ± SEM (n=9-10); * p < .05, *** p ≤ .001; unpaired Student’s t-test. Reported group sizes exclude significant outliers 
(see section 2.7). 
3.3 – Western Blot 
To investigate whether the immediate behavioral alterations resulting from HU-210 treatment were 
paralleled at the level of CB1R expression, Western Blots were performed for the same three brain regions 
already analyzed in experiment 2. 
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No changes were found in the levels of CB1R protein in either the striatum (VEH = 100 ± 8.03, HU-
210 = 84.8 ± 14.2; t(7) = 0.864, p = .416; fig. 5.5b) or the PFC (VEH = 100 ± 21.8, HU-210 = 103 ± 3.33; 
t(7) = 0.14, p = .892; fig. 5.5c) of HU-210-treated animals. However, a marked and significant decrease 
was found, in the levels of this receptor, in the hippocampal tissue obtained from animals treated with HU-
210 (VEH = 100 ± 3.63, HU-210 = 54.7 ± 5.61; t(8) = 6.78, p ≤ .001; fig. 5.5a). 
    
Fig. 5.5 – Chronic adolescent exposure to HU-210 selectively altered the levels of CB1R protein, in regions involved in affective functioning, 
24-hours after the last drug administration. The levels of CB1R protein were quantified through Western Blot. Significant decreases were found 
in the hippocampus (a), but not in the striatum (b) or the PFC (c), of the HU-210-treated group. Data are expressed as mean ± SEM (n=4-5); *** 
p ≤ .001, unpaired Student’s t-test. Reported group sizes exclude significant outliers (see section 2.7). 
4 – Discussion 
The present experiment was designed with two purposes: for one, to allow the determination of whether 
hypothesized differences in the pharmacology of HU-210, in relation to other CBRAs, lead it to either 
causing effects that revert to normality after a washout period, or make it so that this drug does not 
behaviorally impact adolescent animals. Secondly, to further elucidate the role that age at the moment of 
exposure plays in the effects of this HU-210.  
As was the case in both the previous experiments, HU-210 treatment induced highly significant 
decreases in the amount of weight the animals gained over the course of the experiment, further cementing 
the notion that reductions in weight-gain are a clear phenotype of HU-210 exposure. 
Because only a single OFT session was performed, behavior in that session had to be analyzed for 
measures relating to both anxiety-like behavior and locomotor activity. While this is not ideal (see chapter 
2), no changes were found in either locomotor activity-related parameter, with only a tendency for a 
decrease in the total distance traveled by the HU-210-treated animals – suggesting a possible 
hipolocomotive effect of treatment. Nevertheless, because this tendency did not reach statistical 
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significance, the results suggest that 24-hours after the last HU-210 injection, animals did not present 
treatment-induced locomotor alterations. Furthermore, groups did not significantly differ in either of the 
anxiety-related measures, thus suggesting that even when tested immediately after the end of drug 
administration, chronic adolescent HU-210 does not impact anxiety-like behavior in this test, in contrast to 
what has been previously observed in adult animals493.  
However, in contrast to that tendency towards decreased locomotor activity, but in line with previous 
work with this drug in adult animals213,390, performance in the mFST revealed a marked antidepressant 
effect of treatment, in both sessions, characterized by highly significant increases in climbing behavior, 
and equally highly significant decreases in the time spent in immobility. While it could be argued that this 
performance was an artifact of withdrawal-induced behavioral alterations, it is unlikely that this is the case 
given both the likely long half-life of HU-210377 and the fact that Morrish et al.390, found no difference in 
the performance of animals undergoing withdrawal in comparison to a drug-maintained group. 
Furthermore, even in animals undergoing rapid rimonabant-precipitated withdrawal, mFST performance 
was not indicative of depressive-like behavior, but was instead brought to control levels390. Thus, results 
seemingly suggest two things: for one, it seems that HU-210 is indeed capable of inducing behavioral 
alterations in adolescent animals, and, as such, the lack of adult behavioral alterations found in experiment 
2 is likely the product of these alterations having been normalized during washout. Secondly, it seems that 
HU-210 differs from other CBRAs, not just in that it does not induce long-term effects (at least at the doses 
used here), but also in the fact that the immediate effects that it does induce are not age-dependent496. 
These behavioral results must, however, be taken cautiously, as they were also accompanied by a 
concomitant decrease in hippocampal protein levels of CB1R, in line with previous reports294,333,334. Indeed, 
these receptors are  known to be down- and upregulated, by chronic stress regimens198i, and chronic 
antidepressant treatment514, respectively. Moreover, unlike it has been previously reported in several 
studies with other CBRAs using female animals291,294,333, no changes were observed in the levels of either 
striatal or prefrontal CB1R. However, while these disparities may be further indication of differences 
                                                     
i It should be noted that when female animals are exposed to chronic stress paradigms an increase in CB1R density is found in 
hippocampal tissue201. While this is apparently in contradiction with the results observed here, it the fact that a potent CBRA is 
used in the present work may explain this difference. 
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between HU-210 and other CBRAs, or stem from the dissimilar techniques employed, it must also be noted 
that some studies have also found no differences in these regions after adolescent CBRA treatment332,334. 
Finally, finding strong significant correlations between behavior in the first and second mFST sessions, 
suggests that, while behavioral instability may be present to some extent in the first session, it is not enough 
to substantially bias the behavioral outcomes observed in both the first two experiments, as well as in the 
literature. That is, while behavioral instability may have had some impact on the discrepant results 
observed in experiment 2, it is unlikely that those results were a full artifact of it. 
While in accordance with the work previously published using adult rats, the present results are still 
somewhat counterintuitive, given the known pro-depressant actions of prolonged exposure to other 
CBRAs. This is especially more relevant when the sole measure of locomotor activity used was the OFT 
– whose reliability in measuring this parameter is, at best, controversial393,426. Indeed, from observation 
and manipulation of HU-210-treated animals in this experiment, it was quite evident that treatment induced 
marked alterations. Specifically, much in line with previous reports, animals were noticeably hyperactive, 
reactive and aggressive383,385,387. As such, and in line with the – as of yet untested by anyone – suggestion 
laid out by Morrish et al.390, a fourth experiment was designed to assess another facet of depressive-like 
behavior, using a test that is independent of locomotor activity. 
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Chapter 6 – Experiment 4 
1 – Rationale 
While the results obtained in experiment 3 are in line with previous reports with adult animals 
chronically exposed to HU-210390, it is still unexpected that prolonged exposure to a highly potent CBRA 
would lead to such a marked antidepressant-like effect – especially in adolescent animals496. Moreover, 
given that the sole measure of locomotor activity used in experiment 3 was the OFT – a test whose 
reliability for measurement of locomotor activity has come into question393,426 – a possibility remains that 
the mFST results may have somehow be an artifact of locomotor effects of treatment. Indeed, in the 
discussion of their work, Morrish et al. suggest that complementary tests of depressive-like behavior should 
be performed, in order to further confirm these results390. This suggestion has not, however, yet been 
pursued in any published research. 
As such, the present experiment was performed with the intent of exploring the immediate effects of 
chronic adolescent exposure to HU-210, on another dimension of affective functioning – that of reward 
functioning – through the use of the SPT, a test that is independent of locomotor activity. Additionally, to 
further complement the results obtained with the OFT, and construct a clearer picture of how this treatment 
impacts anxiety-like behavior, animals were also tested in the EPM. 
2 – Methods 
2.1 – Animals and Ethical Approval 
Twenty female Sprague-Dawley rats, aged 21 days (PND 21) at the time of arrival, were ordered from 
Charles River Laboratories (Calco, Italy) and were housed in groups of five, in the same conditions as 
described in experiment 1. A period of at least three days of acclimatization was allowed before any 
experimental procedure was performed, and animals were monitored daily for physical and behavioral 
signs of distress and/or suffering. 
All experiments took place during the light phase of the cycle, and were performed in conformity with 
European Community Guidelines (Directive 2010/63/UE), and with the approval of the Committee for 
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Ethics in Animal Research of the Faculty of Medicine of the University of Lisbon, as well as of the 
Portuguese Competent Authority for Animal Welfare. 
2.2 – Drugs  
The same HU-210 stock solution at 25mM concentration used in experiment 2 was used here. From 
this stock solution further dilutions were made each day, in 0.9% saline, to reach adequate volume.   
2.3 – Drug Administration 
At the time of arrival animals were randomly assigned to be treated with either HU-210 (n=10) or 
vehicle solution (VEH; n=10). 
Drug administration (fig. 6.1) was performed in every way similarly to that described for experiments 
2 and 3. 
 
Fig. 6.1 – Chronogram of drug administration and behavioral testing. EPM, elevated plus maze; SPT, sucrose preference test. 
2.4 – Animal Body Weight  
Animal body weight was monitored during the entirety of the experiment, with animals being weighed 
daily for the full period of drug administration and behavioral testing (PND 35-49). 
To calculate weight changes, the starting body weight of each animal (PND 28) was subtracted to its 
body weight at each time-point, with the resulting values (expressed in grams) being used to compare the 
effects of treatment across groups. 
2.5 - Behavioral Testing 
The day after drug administration period ended (PND 46), animals were subjected to behavioral testing, 
so as to further assess the immediate effects of chronic HU-210 exposure during adolescence. Two tests 
were performed: the EPM, as a measure of anxiety-like behavior and locomotor activity, and the SPT to 
assess reward functioning (fig. 6.1). To reduce animal stress, and its possible confounding effect on 
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behavioral performance, rats were individually handled for at least five minutes, on the five days preceding 
the first test (PND 41-45), after morning injections. 
Behavioral testing and analysis procedures were in every way similar to those described in experiment 1.  
2.5.1 – Elevated Plus Maze  
The EPM was performed and scored similarly to that described in experiments 1 and 2, with the sole 
difference being that testing occurred on PND 46. Furthermore, the total number of zone changes during 
the 5-minute trial, was derived from this test, as a measure of locomotor activity. 
2.5.2 – Sucrose Preference Test  
The SPT was performed and scored similarly to that described in experiments 1 and 2, with the sole 
difference being that the testing occurred from PND 46 to PND 49. 
2.6 – Statistical Analysis 
Statistical analysis was in every way similar to that described in experiments 1, 2 and 3. All data are 
expressed as means ± SEM, or as medians and IQR, or range (minimum and maximum values, wherever 
appropriate), depending on whether parametric or non-parametric tests were used, respectively. All 
statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, San Diego, 
CA, USA).  
3 – Results 
3.1 – Animal Body Weight 
Similarly to what was done on experiments 2 and 3, animals were weighed on PND 28, with no 
difference being observed between groups (VEH = 97.4 ± 1.96, HU-210 = 97.6 ± 1.56; t(18) = 0.8, p = 
.937). When changes in weight from this baseline were assessed, no effect was detectable on the first day 
of drug administration (PND 35). However, on the second day of treatment, a difference emerged, whereby 
HU-210-treated animals gained significantly less weight than their VEH-treated counterparts (fig. 6.2). 
This effect remained significant for the remainder of the experiment (all comparisons at least p < .05). 
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Fig. 6.2 – Change in animal weight relative to PND 28 over the course of the experiment. HU-210 treatment significantly reduced the amount 
of weight animals gained during the entirety of the experiment. Data are expressed as mean ± SEM (n=10); * p < .05, ** p ≤ .01, *** p ≤ .001, 
unpaired Student’s t-test with Holm-Sidak correction. 
3.2 – Behavioral Testing 
3.2.1 – Elevated Plus Maze  
To expand on the immediate effects of chronic adolescent exposure to HU-210, on anxiety-related 
behavior, the EPM was performed the day after drug administration ceased.  
Analysis of the anxiety-related parameters showed that HU-210-treated animals did not significantly 
differ from controls regarding either the percentage of time spent (VEH = 32.2 ± 3.62, HU-210 = 40.3 ± 
5.06; t(16) = 1.35, p = .196; fig. 6.3a), or in the number of entries in the open arms (VEH = 11.3 ± 1.41, 
HU-210 = 13.5 ± 0.73; t(16) = 1.28, p = .219; fig. 6.3b). Furthermore, because EPM performance may be 
biased by locomotor alterations, the total number of zone changes was taken as an index of locomotor 
activity, with no differences between groups being detected regarding this parameter (VEH = 44.9 ± 2.16, 
HU-210 = 50 ± 2.38; t(15) = 1.6, p = .131; fig. 6.3c). 
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Fig. 6.3 – Chronic adolescent exposure to HU-210 did not alter anxiety-like behavior in the EPM 24-hours after the last drug 
administration. The EPM was performed on PND 46 with two measures of anxiety being derived from the 5-minute trial, neither of which showed 
significant differences: percentage of time spent in the open arms (a), and the total number of open arm entries (b). Additionally, the total number 
of zone changes was used as an index of locomotor activity (c), with no differences being found for this parameter. Data are expressed as means 
± SEM (n=8-10); unpaired Student’s t-test. Reported group sizes exclude significant outliers (see section 2.6). 
3.2.2 – Sucrose Preference Test  
To assess if, like stress-coping, reward functioning (another facet of affective functioning), is also 
altered immediately after the end of chronic adolescent HU-210 exposure, the SPT was performed from 
PND 46 to PND 49. 
Analysis of sucrose intake revealed a marked effect of HU-210 treatment, whereby HU-210-treated 
animals consumed significantly less sucrose solution than the VEH-treated animals in both the first (VEH 
= 0.29 ± 0.04, HU-210 = 0.15 ± 0.23; t(17) = 3.14, p = .006), second (VEH = 0.39 ± 0.07, HU-210 = 0.13 
± 0.03; t(17) = 3.72, p = .002) and third (VEH = 0.64 ± 0.15, HU-210 = 0.17 ± 0.02; t(17) = 2.91, p = .01) 
days of the test (fig 6.4a). Moreover, this difference also extended to the average daily intake over the 
duration of the SPT (VEH = 0.5 ± 0.1, HU-210 = 0.16 ± 0.03; t(18) = 3.25, p = .004; fig. 6.4b). 
Likewise, analysis of relative preference revealed a similar effect: HU-210-treated rats showed 
markedly inferior sucrose preference in comparison to controls at both the first (VEH = 85.4 ± 2.39, HU-
210 = 59.7 ± 7.07; t(17) = 3.29, p = .004), second (VEH = 82.1 ± 2.59, HU-210 = 44 ± 6.14; t(17) = 5.49, 
p ≤ .001) and third (VEH = 84.9 ± 2.36, HU-210 = 53.4 ± 5.64; t(17) = 4.95, p ≤ .001) measurement 
moments (fig 6.4c). Thus, at all time-points HU-210-treated animals met the criteria for being anhedonic 
(i.e., preference < 60%). Furthermore, average preference over the duration of the test was also found to 
be significantly different between groups, with HU-210-treated rats showing diminished preference for 
sucrose (VEH = 84.4 ± 2.41, HU-210 = 52.4 ± 5.15; t(17) = 5.43, p ≤ .001; fig 6.4d). 
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Fig. 6.4 – Chronic adolescent exposure to HU-210 altered sucrose intake and preference 24 to 96 hours after the last drug administration. 
Sucrose intake was assessed daily (a) and was averaged at the end of the testing period (b), with HU-210-treated animals presenting marked 
decreases in both parameters. Similarly, sucrose preference was severely decreased in both daily assessments (c), and when averaged over the 
entirety of the test (d). Data are expressed as mean ± SEM (n=9-10); ** p ≤ .01, *** p ≤ .001, unpaired Student’s t-test. Reported group sizes 
exclude significant outliers (see section 2.6). 
4 – Discussion 
The present experiment was designed to further elucidate and expand the surprising results obtained in 
experiment 3, by testing a new batch of animals in two other tests of anxiety-like (EPM) and depressive-
like (SPT) behavior, immediately after the end of prolonged HU-210 administration. The results obtained 
were, however, highly unexpected. 
As it was found in the first three experiments, in the present experiment, HU-210 treatment was also 
found to lead to decreased weight-gain. This decrease was significant on the day following first drug 
injections, and remained so for the duration of the experiment.  
Regarding the EPM, no differences between groups were found in either anxiety-like behavior or 
locomotor activity, in line with the results obtained for the OFT in experiment 3. Thus, these results further 
support the assertion that, even though HU-210 is capable of inducing marked effects on affective 
functioning, these are restricted to depressive-like behavior, without affecting anxiety-like behavior.  
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In surprising contrast to the antidepressant-like effect observed in the mFST in both experiment 3 and 
adult studies213,390, in the present experiment HU-210-treated rats presented a marked depressive-like 
phenotype in the SPT: in comparison with VEH-treated controls, the HU-210 group showed highly 
significant decreases in both sucrose intake and preference, at all time-points, as well as when considering 
the average of the three-day period, indicating a strong anhedonic effect of treatment. 
An explanation for these, apparently contradictory, results is not immediately self-evident, but two 
possibilities stand out as the most likely: on the one hand it is possible that chronic HU-210 – at least in 
adolescent animals – induces opposite effects on different aspects of affective functioning. On the other 
hand, it may be the case that either the results obtained here, or in experiment 3, are false positives. If the 
results presented in this experiment were to be false positives, a likely source of this outcome would be the 
effects of cannabinoid-withdrawal. However, this seems unlikely, given that if this were to be the case one 
would expect a progressive change in SPT parameter, as withdrawal symptoms evolved (i.e., improved or 
worsened) over the three-day period – something that was not observed in HU-210-treated animals (fig 
6.4). Thus, it seems more likely that, if a false positive does exist, it would be the results from the mFST 
in experiment 3. Indeed, in that experiment, molecular analysis was more congruent with a prodepressant-
like effect198, than with an antidepressant-like effect514. Moreover, not only is the mFST susceptible to 
being biased by alterations of locomotor activity450,461, but it has also been shown that this test may provide 
inconsistent results when it comes to manipulations of the ECS. Specifically, despite its known 
prodepressant effect in humans31,202, the CB1R antagonist/inverse agonist rimonabant has been 
inconsistently been identified as prodepressant in this test – with some studies even suggesting that it might 
have antidepressant effects515,516.  
Considering the results of all the experiments thus far presented, numerous questions remain as to why 
and how HU-210 induces the unexpected and contradictory behavioral outcomes observed, an issue 
discussed in detail in the next section. 
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Chapter 7 – General Discussion, Future Perspectives, and Conclusions 
The lasting effects of chronic adolescent exposure to CBRAs on adult affective functioning have been 
amply characterized. However, the overwhelming majority of the research done so far has relied on a small 
pool of drugs, leaving open the possibility that the effects observed are only a part of the full spectrum of 
possible outcomes. The present work, by focusing on a drug not yet tested with regards to this dimension 
of its possible effects, aimed to help begin filling that gap. Interestingly, the results obtained suggest that 
the overreliance on a select group of CBRAs may not be desirable, given that the outcomes observed here 
were markedly different from those expected at the outset, based on previous studies. 
The present chapter constitutes a brief overview of the results obtained across the 4 experiments 
performed, and includes a number of possible explanations for them. Furthermore, in the final section of 
this chapter, a discussion will be made with regard to future work, that should be performed to test the 
veracity of the proposed explanations. 
1 – General Discussion 
1.1 – Body Weight Changes 
 The most consistent result obtained, across the four experiments here performed, relates to the effects 
of HU-210 on the changes in body weight. Specifically, in all four experiments, animals showed highly 
significant decreases in weight gain, relative to an original measurement (PND 35 in experiment 1, and 
PND 28 in experiments 2-4), which were already evident on the day following first administration. This 
was the case even though no such differences were observed in the first day of drug administration. 
Moreover, this was also observed in experiment 1, despite the fact that – by chance – the HU-210-assigned 
group weighed significantly more at the experiment outset. Furthermore, in all experiments, this decrease 
in weight gain persisted (and remained highly significant) for the entirety of the drug administration period, 
and – in the case of the first two experiments – lasted for 15 days after the last injection.  
 At first glance this result would seem to be in marked contradiction with both the anecdotally reported 
orexigenic effects of cannabis, as well as the published reports testing the veracity of these anecdotal 
reports501,502. However, it should be noted that, in human users, cannabis use has been linked to a decrease 
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in body mass index517. Moreover, decreased food intake, body weight and weight gain have been 
consistently reported in rodent studies ever since the 1970s503,518,519. Indeed, a study by Giuliani et al.520, 
also found chronic HU-210 exposure to lead to significant lasting decreases in body weight and food intake. 
Several explanations have been proposed for this orexigenic effect of CBRAs. For one, it is possible 
that the locomotion-impairing effects of these drugs may make animals less able to reach food, thus 
decreasing food intake294. This, however, seems unlikely given that not only does tolerance to the 
locomotor effects of CBRAs develop fairly rapidly384,388, but also that, in the first two experiments, the 
decreased weight gain persisted for an extended period after drug administration, where it is improbable 
that significant drug concentrations would still remain in the organism of the animals.  
Secondly, there is the possibility that CBRAs selectively alter feeding behavior, such that they bias the 
animals towards a specific type of food, in detriment of others. Indeed, it has been shown that acute CBRA 
administration selectively increases intake of high fat or sweetened foods, without altering standard rat 
chow intake521. Since the animals used here were fed a standard diet, this may possibly explain, or 
contribute to, the decreases in weight gain.  
Thirdly, there is a possibility that CBRAs may work to modulate the rewarding properties of food, 
through their interactions with the opioid522 and/or DA systems523. In line with this hypothesis, alterations 
have been found in both of these systems in animals chronically exposed to CBRAs as 
adolescents223,264,278,280,292,294,306,319,320,325–327, and alterations in the intake of palatable foods and/or sucrose 
solutions have been reported210,276,294. While these decreases in the intake of palatable/sweet foods are in 
disagreement with the previously proposed explanation (i.e., a preference for sweetened foods), this 
hypothesis would fit with the findings of markedly decreased sucrose solution/preference found in 
experiment 4. Moreover, this explanation would also be consistent with the lack of effects found, in the 
SPT, in the first two experiments. In other words, as weight gain is normalized after 15 days without drug 
exposure, so may the reward and motivation circuitry of HU-210 exposed rats. Accordingly, Bellocchio et 
al.524, showed that CBRAs have a biphasic effect on feeding behavior, with low doses leading to 
hiperphagia and moderate to high doses to hypophagia, and that this effect is contingent on whether 
glutamatergic or GABAergic ventral striatal neurons are inhibited by CB1R activation, respectively. Were 
this hypothesis to hold true, a question would still remain as to why a less potent and less effective CBRA, 
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such as THC, led to lasting DAergic alterations – such as those reported by Renard et al.278,306 – while HU-
210, apparently, had no such effect. 
Another possible explanation is that chronic CBRA exposure may lead to downregulation and/or 
desensitization of hypothalamic CB1R. Indeed, this brain region is well-known to be involved in the 
regulation of numerous homeostatic processes525, including feeding526, and there is an amply described 
interaction between hypothalamic ECS and orexic signaling527. As such, it has been proposed that 
hypothalamic CB1R downregulation may disrupt the capacity of the ECS to effectively stimulate 
orexigenic signaling528. This would, in essence, represent a functionally similar effect to that of the CB1R 
antagonist/inverse agonist rimonabant, which is known to be anorexigenic. Importantly, this hypothesis is 
not mutually exclusive with that postulating a role for the mesolimbic reward system, since it leaves open 
the possibility of a concomitant pro-amotivational effect of CBRAs. Critically, however, it is unlikely that, 
in short time-scales, the anorexigenic effects of HU-210 would be caused by hypothalamic CB1R 
downregulation, since these effect are observable within 24-hours of treatment – when downregulation is 
unlikely to have yet occurred. It may, nonetheless, be the case that, in the earlier stages of drug 
administration, it is the acute hypolocomotor effect of HU-210 that induces the decreases in weight gain, 
whereas, at later time-points, this anorexigenic effect results from hypothalamic CB1R downregulation. 
Finally, the effect of CBRAs on hypothalamic signaling are also key part of another possible 
explanation for the pattern of decreased weight gain observed here. Specifically, it has been proposed that 
HU-210 may induce these changes by altering adequate HPA axis functioning520. Indeed, HU-210 is known 
to lead to marked increases in the secretion of CORT, ACTH and CRF373,520, which are known to negatively 
modulate food intake529–531. Moreover, the effects of prolonged increases in stress-hormones are known to 
be persistent532–534, which may explain the persistence of significantly decreased weight gain in the 15 days 
following drug administration.  
1.2 – Anxiety-like Behavior, Social Anxiety-like Behavior, and Locomotor Activity 
Despite the fact that, in epidemiological studies, adults who used cannabis as adolescents are found to 
be at an increased risk of developing anxiety disorders (especially if they are females254,255), in the present 
work no such effect was found. Indeed, independently of whether animals were tested immediately after 
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drug administration ended, or after a washout period, no evidence of altered performance was observed in 
either the EPM, the OFT or the MBT. Nonetheless, despite this contradiction with human data, these results 
were not entirely unexpected, given that, although some animal studies do find chronic adolescent CBRA 
exposure to lead to lasting alterations in anxiety-like behavior271,289,295,296,299–301,304,305, the majority of 
studies have not found such effects.  
The reasons for this lack of effect are not entirely clear. Indeed, when CBRAs are acutely administered 
to rodents, they commonly alter anxiety-like behavior in a biphasic manner, such that low doses have an 
anxiolytic effect, whereas high doses lead to anxiogenic effects535. Moreover, in one study using adult 
rats493, chronic exposure to the highest dose of HU-210 used here (100 µg/kg) led to decreased time spent 
in the OFT CZ – suggesting a anxiogenic effect of drug exposure – when testing was performed on the day 
following last drug administration. Critically, however, these same animals showed no evidence of altered 
performance in the EPM493. Contrastingly, using a similar drug administration schedule, Jiang et al.213 
found an anxiolytic effect in the NSFT,  after a 30-day washout. 
Several explanations may be posed for this virtual lack of effects upon anxiety-like behavior: for one, 
it may be the case that adolescent animals are less vulnerable to the anxiety-modulating effects of CBRAs, 
than adults. Indeed, Carvalho et al.336 reported an age-related difference in the aversive properties of sub-
chronic high-dose WIN 55,212-2 administration, such that adolescent animals were shown to be less 
sensitive to these effects, than adults. Given that aversive stimuli reliably alter performance in tests of 
anxiety-like behavior536–538, this may explain the discrepancy between results found here and those 
obtained with the same drug in adult animals. This explanation is further supported by the fact that there 
is significant difference, between adult and adolescent animals, with respect to how fast such tolerance 
develops497. Thus, it is conceivable that the adult animals in work the wok of Hill and Gorzalka493 had not 
yet developed full tolerance to the anxiogenic effects of high-dose HU-210, whereas the animals in the 
present experiment may have done so. Indeed, this may have happened despite our best efforts to preclude 
that from happening, through the use of an escalating dosing schedule. A limitation of this explanation, 
however, lies in that it leaves unanswered the question of why similar exposure to HU-210 led, in the study 
by Jiang et al. 213, to an anxiolytic-like effect, after a 30-day washout period. 
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Alternatively, it may be that we (and previous groups) have found no effects on anxiety-like behavior 
not because chronic adolescent CBRA exposure does not induce such alterations, but because the 
assessment of anxiety-like behavior is not adequate. That is, because the behavioral tests employed here 
have limited predictive validity420,421,424 (see chapter 2), it may be that they are unable to detect alterations 
in anxiety-like behavior, induced by adolescent CBRA treatment. Indeed, while the EPM and OFT have 
been widely used, these tests seem grossly inadequate in the detection of pharmacological manipulations 
of anxiety, and some researchers have even questioned whether these assays can be considered to be 
modelling pathological anxiety415,424,438,539. Thus, the discrepancy between epidemiological data and animal 
behavioral data may stem from this limitation in the testing used in animal research.  
The above explanation suffers, however, from two problems: firstly, while the EPM and OFT have the 
aforementioned limitation in detecting pharmacological manipulations of anxiety-like behavior, this has 
not – thus far – been the case for the MBT420,421. However, no alterations were found in this test either, 
leading to one of two conclusions: either the MBT is also inadequate to detect this type of manipulation, 
or chronic adolescent CBRA exposure does not lead to long-term alterations of anxiety-like behavior in 
animals, despite doing so in humans254,255. Irrespective of which of these conclusions may turn out to be 
correct, it must be noted that the use of the MBT in this work, is – to the best of our knowledge – the first 
time that this test has been used in cannabinoid research. As such, this represents a truly novel finding. 
Secondly, a question remains as to why some studies, using the EPM and the OFT as measures of anxiety-
like behavior, do find some persistent alterations271,289,295,296,299–301,304,305, whereas here (and in most other 
studies) no such differences are found. While no ready explanation can be suggested for this discrepancy, 
a careful consideration must be made as to a possible reason for it: of the few studies that have found adult 
anxiety-like behavior to be either increased or decreased as a consequence of adolescent CBRA exposure, 
none have used the same combination of animal strain and gender used here271,289,295,296,299–301,304,305. Indeed, 
no study using Sprague-Dawley rats has found anxiety to be altered as a consequence of chronic adolescent 
CBRA exposure, and of the few that have used Wistar rats (such as those used in experiment 1), all but 
two271,300 have exclusively used males299,301,304. Furthermore, given that this is the first study testing the 
effects of adolescent HU-210 exposure on anxiety-like behavior, there is a possibility that the disparity 
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between the results presented here, and those of the few studies where alterations were found in this 
parameter, stems from the difference in drug used. 
While the differences in general anxiety-like behavior are largely in agreement with the previous 
literature, the lack of observable effect in social interaction is not. Indeed, decreased social interaction has 
been one of the most consistently reported consequences of chronic adolescent CBRA exposure, having 
been observed in studies using both Wistar and Sprague-Dawley rats, as well as with several 
CBRAs261,262,273,274,276,282,308,506. However, here, in both experiments 1 and 2, no such effect was found. 
Importantly, with the exception of the works by Zamberletti et al.268,280, the two other works where no 
alterations were found in adult social behavior, used mice318, or rats from a different strain264.  
Given the known widespread involvement of the ECS in the regulation of social behavior540,541, this 
lack of effect is difficult to explain. The most obvious explanation is that, as seems to be the case with 
depressive-like behavior, any alteration that may have been induced by chronic adolescent exposure to 
HU-210, was normalized during the washout period. Indeed, even at the molecular level, alterations 
induced by treatment were found to be absent, when rats were given a 30-day drug washout (i.e., 
hippocampal CB1R protein levels were found to be reduced soon after the end of drug exposure, but to not 
be altered at adulthood). Moreover, if one were to give primacy to the reward-component of the SIT310, 
then this result would also fit with the lack of alterations in the SPT.  
This suggestion, however, would depend on the notion that HU-210 has pharmacological properties 
that are not shared by other CBRAs. This notion still requires confirmation, despite being suggested by 
other results herein reported, as well as by previous molecular pharmacology work293. For example, it could 
be the case that, given the interactions between HU-210 and glycine receptor subunits (not shared with 
THC379,380), HU-210 has less impact on the social dimension of anxiety, than other CBRAs. Indeed, in line 
with this drugs targeting the glycine receptor have been shown to modulate anxiety-like behavior542.  
Another possibility is that the testing conditions in which the SIT was performed may have precluded 
the detection of any effects on anxiety. Specifically, while in the present work animals were familiarized 
with the arena over two 10-minute sessions443,444, with light kept at a constant intermediate level, there is 
evidence that the anxiety levels induced by this test may be contingent on factors such as familiarity with 
the testing apparatus, or light levels443,444. Thus, a possibility exists that inadvertent differences between 
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the environment in which the tests were performed in the experiments here described, and those in which 
other groups performed their tests, explain the differences in outcome. 
Finally, it must be noted that in none of the experiments was the spontaneous locomotor activity of HU-
210-treated rats found to be altered. This result should, however, not be taken at face value. As discussed 
in chapter 2, OFT measures of locomotor activity are likely not reliable indexes of this parameter426, and 
the use of EPM-derived measures (experiment 4) is even less so414. This lack of locomotor alterations was 
not, however, completely unexpected, as CBRA induced changes in locomotor activity seem to be 
relatively restricted to cases of acute administration382–384, or during the initial stages of chronic exposure, 
with tolerance developing fairly rapidly357 (but see278,306). Thus, irrespective of the necessity of taking into 
account the questionable reliability of measures obtained with the OFT, and in the absence of any adequate 
substitute for these measures, the results obtained here suggest that chronic adolescent HU-210 exposure 
does not alter spontaneous locomotor activity in either the short-, or the long-term, after stopping 
administration. In light of this, any changes observed in other tests, must be considered to be relatively 
unaffected by biases stemming from alterations at the level of locomotor activity. 
1.3 – Depressive-like Behavior 
Alterations at the level of depressive-like behavior have been consistently reported in the literature 
concerning the long-term effects of chronic adolescent CBRA exposure210,276,280,282,294,308,315. Indeed, most 
studies find that this type of exposure leads to lasting deficits in this dimension of affective functioning, 
and that these deficits are more pronounced in female than male animals359 – in line with the findings of 
human epidemiological data254–256,258. In the current work, however, the results obtained are in stark 
disagreement with that previously reported with other CBRAs.  
Specifically, while the first experiment indicated a tendency for impaired stress-coping behavior, this 
finding was not replicated in the second experiment, despite the fact that, in this latter experiment, animals 
were exposed to a greater absolute amount of HU-210. While it is possible that this difference stems from 
differences in the duration of administration (and not the dose administered), or in the timing of behavioral 
testing, a more likely culprit is the possible deleterious effect of the solvent used as a drug vehicle. Indeed, 
as discussed previously, DMSO does have neurotoxic effects507–510, that may have been more pronounced 
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due to the age of the animals at the time of administration. Notwithstanding, it must be noted that, even in 
these conditions, in experiment 1, no alterations were found at the level of reward functioning. Moreover, 
this was the same outcome observed in experiment 2. Thus, it seems that chronic adolescent HU-210 
exposure does not induce long-lasting alterations at the level of depressive-like behavior.  
This finding was entirely unexpected, given the previous literature, and the much increased potency, 
affinity and efficacy of HU-210, in relation to previously studied CBRAs. To further understand these 
findings, experiment 3 was performed to assess whether this lack of long-term effects was the result of 
HU-210 being unable to modulate affective behavior or, alternatively, a result of normalization of any 
previous effect, during the washout period. Curiously, when animals were tested immediately after 
stopping administration, a marked antidepressant-like effect was found – as indicated by greatly increased 
climbing time, and equally greatly decreased immobility time in the mFST. These findings were in line 
with previous studies in adult rats213,390, but required confirmation (i.e., experiment 4) for several reasons: 
for one, the effects of CBRAs are known to be age-dependent496 (and generally more negative in 
adolescents). Secondly, western blotting revealed a change in hippocampal CB1R protein levels that was 
similar to that observed in CMS-exposed rats198. Thirdly, despite no alteration having been found in the 
OFT, personal observation/manipulation of the animals suggested the presence of strong behavioral 
alterations. Specifically, in line with previous reports383,385,387, HU-210 treated animals were remarkably 
more reactive, aggressive and behaviorally hyperactive. Thus, experiment 4 was performed to provide a 
locomotor activity-independent measure of depressive-like behavior, in the form of the SPT. Notably, in 
this final experiment, results were entirely contrasting with those of experiment 3, with animals showing 
markedly impaired reward functioning, as indicated by decreased sucrose intake and preference.  
As such, in combination, the results of experiments 2-4 suggest that HU-210 is indeed capable of 
strongly modulating the expression of depressive-like behaviors, but that these effects are relatively short-
lived. Such a result, while positive for the field of cannabinoid-based therapeutics, does, however, require 
further consideration, since no explanation for it is immediately apparent. The most obvious explanation 
is that HU-210 differs from other CBRAs with regards to either its interaction with the ECS, or with other 
non-ECS targets. In terms of the former, it may be that the greater relative affinity of HU-210 for CB1R 
over CB2R, may be underpinning this differential effect. Alternatively, it may also be that HU-210 has a 
119 
 
unique profile of biased agonism, leading to the activation of a group of G-protein subtypes distinct from 
other CBRAs391, triggering specific signaling pathways. If, however, the latter possibility holds true, and 
the source of the disparate outcomes observed lies in non-ECS interactions, there is a great number of 
possible targets to be considered293. Indeed, to the best of our knowledge, no large scale receptor binding 
profile has been performed, to determine to what other receptors HU-210 binds. This is even more 
interesting when one considers that a simple mirroring of this molecule leads to markedly different 
pharmacodynamics: indeed, not only does HU-211, the enantiomer of HU-210, not interact with the ECS, 
but it is actually a NMDAR antagonist, with known anticonvulsant and neuroprotective effects543,544.  
Similarly, with regards to the contrasting results of experiments 3 and 4, an explanation is also not self-
evident. One possibility deserving future study entails the consideration of the actions that CBRAs have 
on both the NA and HPA axis systems. Specifically, the increased mFST climbing observed in experiment 
3, and in previous adult work390, suggest an involvement of the NA system – given that increases in this 
behavior are known to result from treatment with NA targeting antidepressant drugs448,461. Moreover, in 
some of the aforementioned work, this effect was shown to be attenuated or abolished by administration 
of α1 and β adrenergic receptor antagonists, respectively390. Critically, however, increased NA levels do 
not necessarily imply an antidepressant response. In fact, increased levels of this neurotransmitter have 
been found to not only mediate (at least in part) the aversive effects of CBRAs336,545–547, but also to be 
increased in the cerebral spinal fluid (CSF) and excretions of human depressive patients548. Furthermore, 
it has been demonstrated that NA signaling contributes to the effects of CBRAs on HPA axis functioning549. 
Specifically, administration of α1 and β adrenergic receptor antagonists, to adult rats chronically exposed 
to high dose HU-210, was shown to attenuate the abnormally high corticosterone response to restraint 
stress549. In addition, CBRAs themselves modulate the HPA axis550–553, leading to increases in the levels 
of stress hormones373,382 – that underlie many of the negative effects of acute CBRA administration383. 
Conversely, the HPA axis itself reciprocally influences the release of NA554–556. Thus, it may be the case 
that chronic HU-210 exposure led to a vicious circle: initial HU-210 administration increases both HPA 
and NA activity210, which further potentiate one another. These increases would be maintained by 
continuous drug exposure which, due to the aversive effects of high dose CBRAs336,545,546, is itself stressful 
to animals.  
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Relatedly, given that the hippocampus – especially its most ventral portions557, and the vSub in 
particular558 – is heavily involved in the modulation of HPA axis activity, a role for this structure could 
also be postulated. Specifically, HU-210-induced alterations in hippocampal functioning (as suggested by 
decreased hippocampal CB1R protein levels) could have led to a further aggravation of the hypothesized 
vicious circle. Importantly, it must be noted that, while commonly associated with negative regulation of 
the HPA axis, disrupted vSub functioning has also been implicated in the potentiation of the response of 
this system to specific types of stress558–561, such as exposure to novel spaces, or forced restraint – both of 
which share some similarities to the mFST testing situation. 
Dovetailing into this, the effects of disrupted HPA axis functioning on reward functioning have been 
fairly well described. Indeed, both environmental562–564 and pharmacological565,566 manipulations known to 
induce dysfunction in HPA axis functioning have been described to induce depressive-like alterations in 
the SPT, such as the ones observed in experiment 4. Furthermore, the hippocampus (especially its ventral 
portion) is known to have an important modulatory role over the mesolimbic reward system557. Thus, the 
alterations observed in hippocampal CB1R protein levels, may also suggest a role for dysfunctional 
hippocampal activity, in the adequate regulation of reward functioning. In addition, an increase in NA 
levels could further add to this deleterious effect of HU-210 on SPT performance, given that NA is known 
to have appetite-suppressive properties during stress exposure567,568, which could also account for the 
effects of HU-210 on weight-gain. 
In combination, these data can be taken as the basis for an explanation of why results in experiment 3 
suggest a markedly antidepressant-like effect, whereas results in experiment 4 suggest the exact opposite: 
that is, increased climbing in the former experiment may be a misleading effect of an actual prodepressant 
impact of HU-210 exposure. Specifically, the NA-release stimulatory effects of HU-210, in combination 
with its potentiating effects over HPA axis activity, and the interplay between the NA and HPA axis 
systems, may have led to exaggerated behavioral reactivity in the mFST testing situation. Indeed, such 
behavioral reactivity was readily observable during animal manipulation, and could conceivably be 
misidentified as an antidepressant-like effect, as would be the case for amphetamine-treated hyperactive 
animals425. Conversely, when animals were exposed to a testing situation where behavioral reactivity had 
little possibility of biasing results (i.e., the SPT, in experiment 4) the actual, prodepressant-like, effect of 
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chronic adolescent HU-210 exposure, became readily detectable. Critically, it is unlikely that the 
observations made here are manifestations of cannabinoid withdrawal, given that Morrish et al.390 showed 
the altered mFST behavior to not be different between HU-210-maintained and HU-210-withdrawn rats, 
with differences only being evident in the group where rapid withdrawal was propitiated by administration 
of a CB1R antagonist. Interestingly, despite being counter to the way the mFST is typically interpreted, the 
findings herein reported would actually be fairly similar to human cases of depressive disorder, where 
individuals present increases in restlessness and agitation, as well as in irritability, while also presenting 
anhedonic symptoms314. 
This explanation suffers, however, from two important limitations: for one, it leaves open the question 
of why this mechanism did not have a measurable impact on anxiety-like behavior, if it was in fact the 
cause of the alterations observed at the level of depressive-like behavior. Indeed, alterations in both HPA 
axis564,569,570 and NA system functioning569,571 have been reported to alter performance in tests of anxiety, 
but no such alterations were found in either experiment 3 or 4. One possibility is that alterations anxiety-
like behavior habituate quickly, disappearing after a few days of repeated administration. Secondly, this 
hypothesis does not propose a ready answer for why these effects, if existing, were not maintained after 
washout (experiment 2). While it is possible that a return to baseline would happen after sufficient washout 
time, it seems unlikely that such an effect would leave no lasting traces, especially when administration 
occurs during such a critical neurodevelopmental period as adolescence. This latter point, however, should 
be qualified by the fact that, in the only previous study of chronic adolescent HU-210 exposure321, females 
were found to not have lasting alterations in stress reactivity, whereas an increase in this parameter was 
found in males. Given that, in the present work, female rats were used, this may help explain why we found 
no lasting alterations. Nonetheless, it must be noted that our findings are still in contradiction with the 
reports suggesting both rodent and human females to be more susceptible to the deleterious effects of 
chronic adolescent CBRA exposure. 
Another putative explanation for the contrasting results of experiments 3 and 4, focuses on the role of 
the lateral habenula (LHb) in depressive-like behavior572. Specifically, this brain region is known for 
having a strong modulatory influence over reward circuitry, and for being involved in the emission of 
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aversive and avoidance responses to stressful stimuli572. In line with this, the LHb has been found to be 
overactivated in animal models of depression573,574, and in humans suffering from depressive disorders575.  
Critically, the ECS has been shown to have a key role in the regulation of LHb activity576, and 
manipulations of habenular ECS functioning have been demonstrated to lead to alterations in stress-coping 
behavior516. Specifically, direct LHb microinfusion of CB1R antagonist/inverse agonist rimonabant or non-
selective CBRA WIN 55,212-2 have been shown to lead to increases in active or passive stress-coping 
strategies, respectively. Moreover, a recent study from our lab54, where adult mice were chronically 
exposed to WIN 55,212-2, found both habenular metabolism and functional connectivity with other brain 
regions (including those of the mesolimbic reward circuitry) to be altered as a result of treatment.  
Thus, it may be the case that chronic adolescent exposure to HU-210 led to a dysregulation of adequate 
habenular functioning, by disrupting the ECS functioning in this region. One possible mechanism for this 
would be predicated on a downregulation and/or desensitization of CB1R, leading to altered LHb 
excitability, which would modulate both reward and stress-coping circuitry. Regarding reward functioning, 
HU-210 exposure would increase LHb excitatory output over the inhibitory interneurons modulating the 
VTA, by impairing ECS functioning. This increased inhibitory tone over DA signaling would then lead to 
decreased sucrose preference/intake due to impaired reward functioning. Regarding stress-coping 
behavior, the downregulation and/or desensitization of lateral habenular CB1R would translate itself into 
an effect functionally equivalent to that observed after rimonabant LHb microinfusion. Curiously, in the 
work of Berger et al.516, a gender-dependent difference was found in this region, such that acute rimonabant 
microinfusion led to similar antidepressant-like effects in both genders, but acute microinfusion of WIN 
55,212-2 led to prodepressant-like effects only in male rats. This could contribute to explain why, in 
experiment 2, no differences were found in the mFST. 
Importantly, this explanation does not necessarily preclude the former one, as both stress hormones577 
and NA578,579 have been shown to have powerful modulatory influences over LHb functioning. Indeed, the 
LHb receives direct excitatory input from the paraventricular nucleus (PVN) of the hypothalamus572, a 
region known to be both the main locus of CRF synthesis and release, and strongly modulated by the 
ECS551. Furthermore, CRF has been shown to markedly increase LHb excitability through the modulation 
of eCB signaling, opening up the possibility for an interaction between HU-210-induced increases in CRF 
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and LHb ECS dysfunction577. In addition, NA is known to be released in the LHb, such that increased NA 
levels lead to increases in anxiety-like behaviors578. 
Like the previous explanation, this hypothesis has two limitations: for one, it does not adequately 
explain why no alterations were observed at the level of anxiety-like behavior. While habituation may 
happen more rapidly for this dimension of affective functioning, than it does for either stress-coping or 
reward functioning, this is nonetheless a question deserving further study. Secondly, this hypothesis does 
not propose a clear explanation for why alterations did not persist into adulthood after HU-210 
administration, when that is the case for other CBRAs.  
A third possible explanation, for the contradictory results of experiments 3 and 4, is that it might indeed 
be the case that HU-210 simply induces opposing effects on different dimensions of affective functioning. 
While this is somewhat counterintuitive, and no mechanistic explanation can be readily postulated for it, 
it is possible that HU-210 treatment may positively modulate some aspects of stress-coping behavior, while 
negatively modulating reward functioning which, despite having some overlap, are likely underpinned by 
different brain circuitry.  
2 – Future Perspectives 
The overarching aim of the present work was to characterize the effects of chronic adolescent exposure 
to HU-210 on both anxiety and depression related behavioral outcomes, as well as on one of the key 
molecular components of the ECS, the CB1R. To this end four experiments were performed, such that the 
results of one experiment informed the design and hypothesis of the succeeding ones, in an effort to create 
a full and comprehensive account of what was observed at each step. 
In summary, data points to the possibility that HU-210 may be a pharmacologically unique CBRA. 
Indeed, despite its much increased potency, efficacy and affinity for CBRs (and in special for CB1R) in 
comparison to previously studied CBRAs, treatment with HU-210 had no apparent long-term effects on 
any of the outcomes assessed. Thus, as the current work stands, the overall derivable conclusion is that, 
contrasting with other CBRAs, chronic adolescent exposure to HU-210 does not induce lasting deleterious 
effects on either anxiety- or depressive-like behaviors. Moreover, when testing was performed in close 
proximity to the end of the drug administration period, the pattern of results obtained was entirely self-
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contradictory, with both antidepressant- and prodepressant-like responses being observed in two different 
tests of depressive-like behavior. As such, it seems HU-210 is not incapable of altering affective 
functioning in adolescent animals, but that whatever alterations it does induce are largely abated, if enough 
time is allowed for. This finding, if confirmed, would bode well for the future of cannabinoid-based 
therapeutics.  
The results obtained in the present work leave open a plethora of questions and experiments to be 
performed. For one, the overall picture obtained from this work suggests that HU-210 has pharmacological 
properties that set it apart from other CBRAs, leading to its differing effects on long-term affective 
behavioral changes. This finding may have critical implications for the cannabinoid-related literature, since 
it suggests a need for caution when drawing conclusions based on data obtained with different cannabinoid-
related drugs. The present work also points towards an even more evident flaw in the literature: that 
researchers, ostensively testing the same hypothesis (in this case long-term affective behavioral alterations 
induced by chronic adolescent exposure to CBRAs) will use numerous different administration and testing 
protocols – and variations on those protocols – to do so. Indeed, this lack of methodological homogeneity, 
while sometimes needed, may be masking differences in actual drug effects. Thus, one interesting future 
avenue of work will be the comparative study of the most commonly used non-selective CBRAs, with 
regard to their long-term effects. In line with this, we are already designing a set of experiments where 
different groups of animals will be administered equipotent doses of different CBRAs (i.e., THC, HU-210, 
WIN 55,212-2 and CP 55,940), using a protocol similar to that used in experiment 2. Testing will be 
performed using the same test battery used here, after a 30-day washout period. Moreover, to complement 
these results, molecular analyses and ex-vivo electrophysiological recordings, as well as behavioral tests 
of cognitive function, will also be performed. The combined results of this set of experiments will, then, 
allow for a more solid conclusion of whether there are indeed differences between HU-210 and other 
CBRAs, that underlie their long-term effects upon affective behavior.  
As stated before, these differences, should they actually exist, may result from either ECS or non-ECS 
interactions. As a starting point to disentangle these possibilities, one important step would be the 
identification of the role that CB1R has in the long-term effects of HU-210. This is, at first glance, a 
technically easy task to perform, as one could simply co-administer HU-210 with a selective CB1R 
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antagonist, to determine how this modulates the outcomes observed. However, when focusing on affective 
behavior, this is not as simple as it appears, given that there is ample evidence that CB1R antagonists are 
themselves prodepressant515, and may, thus, bias the results. One possible workaround this problem would 
entail the use of newer generation CB1R neutral antagonists, instead of the commonly used CB1R 
antagonists – such as rimonabant or AM251– which may actually be inverse agonists580–582. While novel 
drugs, such as NESS0327583 and AM4113584,585, do not share this characteristic, and may not have an 
impact on affective functioning, this possibility has yet to be adequately studied. Likewise, it would be 
interesting to study the downstream effects of CB1R activation by HU-210. Specifically, given that there 
is evidence of biased agonism occurring with other CBRAs391, it would be critical to determine exactly 
what G-protein subtypes are activated as a result of CB1R binding HU-210.  
To assess the off-target actions of HU-210, large scale receptor binding assays would be the most 
obvious and effective tool for the task. This, although resource- and technically-intensive, would narrow 
down the list of possible targets to be further investigated as possible sources for the differences between 
the actions of HU-210 and other CBRAs.  
Paralleling this line of study, other avenues for further research are also interesting pursuits. For one, 
given the contradictory nature of the behavioral findings observed when testing was performed soon after 
the end of drug administration, additional behavioral tests should be performed to further assess anxiety- 
and depressive-like behaviors. In this regard, an experiment could be performed where animals are tested 
in both the SIT and the MBT, soon after the last HU-210 administration. Similarly, other tests not used 
here, such as the intracranial self-stimulation paradigm, or the LDBT, could also be performed in similar 
time-frames, so as to provide further measures of these behaviors. Moreover, given that HU-210 may be 
inducing locomotor alterations not detected by the OFT, homecage activity recordings would be 
indispensable in future works. Furthermore, given that, in the present work, the short-term effects of HU-
210 exposure on the mFST and SPT were never tested in the same series of animals, it would be interesting 
to do so, so as to preclude the possibility of the contrasting results observed stemming from differences in 
the tested animals. 
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In addition, given that western blotting is not a quantitative technique for the assessment of receptor 
levels, radioligand binding studies could also be performed to determine if/how CB1R density (at both 
adolescence and adulthood) is altered by adolescent exposure to HU-210. 
Relatedly, given that the effects of chronic adolescent exposure to HU-210 were observed in the short-, 
but not in the long-term, and that the effects of treatment on weight gain are normalized 15 days after the 
last administration, it would be interesting to test whether the behavioral alterations observed show similar 
progression. Thus, testing could be performed after a 10-day washout, allowing for the full battery of 
behavioral tests to be performed. Results from this experiment would further help determine if the lack of 
lasting effects observed here is, in fact, related to a washout of drug action.  
Similarly, given that prodepressant- and antidepressant-like responses are known to be associated with 
decreased398,399 and increased hippocampal neurogenesis586, respectively, this should also be assessed, in 
relation to the results obtained in experiments 3 and 4. This work is already underway, such that animals 
were injected with 5-bromo-2'-deoxyuridine (BrdU), a synthetic analog of thymidine, allowing for the 
immunohistochemical evaluation of whether adolescent treatment with HU-210 leads to alterations at the 
level of both neural stem cell proliferation, as well as at the level of their differentiation into neuronal cells. 
As such, finding an antineurogenic effect would support the idea that the behavioral results of experiment 
3 are misleading – and that adolescent HU-210 leads to a prodepressant-like effect – whereas finding the 
opposite effect would lend credence to the results of experiment 3, suggesting HU-210 treatment to be 
antidepressant-like.  
As one of the hypothesized mechanisms behind the contrasting results observed when animals were 
tested immediately after the end of drug administration, concerns the interaction between the HPA axis 
and the NA system, numerous experiments can be performed to test this hypothesis. For one, the protein 
levels of both glucocorticoid and adrenergic receptors could be assessed in several regions of interest, such 
as the hippocampus, the PFC and the hypothalamus. Likewise, the levels of circulating NA and stress 
hormones could be assessed in blood and/or CSF samples of animals, across time and drug administration, 
to determine how continued drug exposure affects these parameters. In addition, pharmacological studies 
could be carried out to test some assumptions: for example, glucocorticoid receptor antagonists could be 
administered concomitantly with HU-210, to determine if the contradictory results observed in 
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experiments 3 and 4 would remain similar, or were somehow modified – thus allowing for a better 
understanding of the role that HPA axis activity may have on the behavioral phenotype observed here. 
Finally, given that one of the proposed explanations for the contradictory findings in experiments 3 and 
4, involves the role of the ECS in the LHb in the control of affective behavior, this line of investigation 
would also be an interesting one to follow. As a first step, immunohistochemistry could be used to assess 
the expression of several key ECS components in this region, namely of CB1R and CB2R, degradative 
enzymes FAAH and MAGL, as well as of the eCBs AEA and 2-AG. Alterations in these ECS components 
would provide guidance for further studies into the role that the lateral habenular ECS may play in affective 
behavior, and in the alterations observed here. Moreover, since previous evidence suggests that both stress 
hormones and NA have modulatory effects over LHb excitability, the effects of HU-210 exposure on the 
habenular expression of elements of these systems (such as glucocorticoid and adrenergic receptors) could 
be assessed by similar methodology, as a first step in understanding what – if any – role they play in the 
effects herein observed. 
3 – Conclusions 
The present work suggests three primary conclusions. First, results show a clear difference between 
HU-210 and other CBRAs, with regards to its long-term effects on affective behavior, suggesting some 
pharmacological differences not yet described. Secondly, that no long-term effects were observed after a 
period of chronic adolescent administration, suggests that HU-210 may prove to be an interesting candidate 
for future therapeutic research. Moreover, that differences between drugs of the same class can lead to such 
marked differences in outcomes, suggests that this should be a topic of investigation, for the future 
development of cannabinoid-based therapeutics. Finally, the contrasting results obtained in the latter two 
experiments suggest that, similar to what is observed in human research, different dimensions of 
depressive-like behavior exist in preclinical animal models. As such, this underscores both the need for the 
use of behavioral testing, that captures as many of those dimensions as possible, so as to provide a more 
complete picture of the effects of any given manipulation, and the notion that – even in those ideal 
conditions – preclinical testing may not fully reproduce or mimic the findings observed in humans.  
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